UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
AMENDMENT NO. 2
TO
FORM 10
GENERAL FORM FOR REGISTRATION OF SECURITIES
Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934
Celsius Holdings, Inc.
(Exact name of registrant as specified in its charter)
2424 North Federal Highway, Suite 208 | ||
Boca Raton, Florida | 33431 | |
(Address of Principal Executive Offices) | (Zip Code) |
Registrant’s telephone number, including area code: (561) 276-2239
Securities to be registered under Section 12(b) of the Act:
Title of each class | Name of exchange on which each class is to | |
To be so registered | be registered | |
None | Not applicable |
Securities to be registered under Section 12(g) of the Act:
Common Stock, $0.001 par value
(Title of Class)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ | Accelerated filer ¨ | |
Non-accelerated filer ¨ (Do not check if smaller reporting company) | Smaller reporting company x |
TABLE OF CONTENTS
Page | ||
Item 1. | Business | 3 |
Item 1A. | Risk Factors | 8 |
Item 2. | Financial Information | 15 |
Item 3. | Properties | 17 |
Item 4. | Security Ownership of Certain Beneficial Owners and Management | 18 |
Item 5. | Directors and Executive Officers | 19 |
Item 6. | Executive Compensation | 23 |
Item 7. | Certain Relationships and Related Transactions, and Director Independence | 25 |
Item 8. | Legal Proceedings | 25 |
Item 9. | Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters | 26 |
Item 10. | Recent Sales of Unregistered Securities | 27 |
Item 11. | Description of Registrant’s Securities to be Registered | 28 |
Item 12. | Indemnification of Directors and Officers | 29 |
Item 13. | Financial Statements and Supplementary Data | 30 |
Item 14. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure | 30 |
Item 15. | Financial Statements and Exhibits | 30 |
2 |
When used in this Registration Statement, unless otherwise indicated, the terms “ the Company ,” “ Celsius ,” “ we ,” “us” and “ our ” refers to Celsius Holdings, Inc. and its subsidiaries.
NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Registration Statement contains forward-looking statements that reflect our current views about future events. We use the words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. These risks and other factors include described in “ Item 1A. Risk Factors ,” “ Item 2. Financial Information ” and elsewhere in this Registration Statement.
Item 1. | Business |
Overview
We are engaged in the development, marketing, sale and distribution of “ functional ” calorie-burning fitness beverages under the Celsius® brand name. According to multiple clinical studies we funded, a single serving of Celsius® burns 100 to 140 calories by increasing a consumer’s resting metabolism an average of 12% and providing sustained energy for up to a three-hour period. Our exercise focused studies show Celsius delivers additional benefits when consumed prior to exercise. The studies shows benefits such as increase in fat burn, increase in lean muscle mass and increased endurance.
We seek to combine nutritional science with mainstream beverages by using our proprietary thermogenic (calorie-burning) MetaPlus® formulation, while fostering the goal of healthier everyday refreshment by being as natural as possible without the artificial preservatives often found in many energy drinks and sodas. Celsius® has no artificial preservatives, aspartame or high fructose corn syrup and is very low in sodium. Celsius® uses good-for-you ingredients and supplements such as green tea (EGCG), ginger, calcium, chromium, B vitamins and vitamin C. The main Celsius line of products are sweetened with sucralose, a sugar-derived sweetener that is found in Splenda®, which makes our beverages low-calorie and suitable for consumers whose sugar intake is restricted.
We have undertaken significant marketing efforts aimed at building brand awareness, including a wide variety of marketing vehicles such as television, radio, digital, social media, sponsorships, and magazine advertising. We also undertake various promotions at the retail level such as coupons and other discounts in addition to in-store sampling.
We do not directly manufacture our beverages, but instead outsource the manufacturing process to established third-party co-packers. We do, however, provide our co-packers with flavors, ingredient blends, cans and other raw materials for our beverages purchased by us from various suppliers.
Corporate History
We were incorporated in Nevada on April 26, 2005 under the name “ Vector Ventures, Inc .” and originally we engaged in mineral exploration. Such business was unsuccessful. On January 26, 2007, we acquired the Celsius® beverage business of Elite FX, Inc., a Florida corporation engaged in the development of “functional” beverages since 2004 in a reverse merger, and subsequently changed our name to Celsius Holdings, Inc. In addition, on March 28, 2007, the Company established Celsius Netshipments, Inc. a Florida corporation as a wholly-owned subsidiary of the Company.
The Company is an emerging growth company under the Jumpstart Our Business Startups Act of 2012 (the “ Jobs Act ”) and as such, may elect to comply with certain reduced public company reporting requirements for future filings.
Our Products
Celsius® calorie-burning beverages were first introduced to the marketplace in 2005.
According to multiple clinical studies we funded, a single serving (12 ounce can) of Celsius® burns 100 to 140 calories by increasing a consumer’s metabolism an average of 12% for up to a three-hour period. In addition, these studies have indicated that drinking a single serving of Celsius ® prior to exercising may improve cardiovascular health and fitness and enhance the loss of fat and gain of muscle from exercise.
3 |
We seek to combine nutritional science with mainstream beverages by using our proprietary thermogenic (calorie-burning) MetaPlus® formulation, while fostering the goal of healthier everyday refreshment by being as natural as possible without the artificial preservatives often found in many energy drinks or sodas. Celsius® has no chemical preservatives, aspartame or high fructose corn syrup and is very low in sodium. Celsius® uses good-for-you ingredients and supplements such as green tea (EGCG), ginger, calcium, chromium, B vitamins and vitamin C. Celsius is sweetened with sucralose, a sugar-derived sweetener that is found in Splenda®, which makes our beverages low-calorie and suitable for consumers whose sugar intake is restricted. Each 12 ounce can of Celsius® contains 200 milligrams of caffeine which is comparable to one 12 ounce cup of coffee from the leading coffeehouse.
We currently offer Celsius® in seven flavors: orange, wild berry, cola, grape, and watermelon (which are carbonated), and non-carbonated green tea raspberry/acai, and green tea/peach mango. Our beverages are sold in 12 ounce cans, and we have recently begun to market the active ingredients in powdered form in individual On-The-Go packets as well as multiple serving canisters.
Celsius® is packaged in a distinctive twelve ounce sleek can that uses vivid colors in abstract patterns to create a strong on-shelf impact. The cans are sold as singles or in four-packs.
We target a niche in the functional beverage segment of the beverage industry consisting of consumers seeking calorie-burning beverages to help them manage their weight and enhance their exercise regimen. Our target consumers are generally individuals that exercise two to five times a week and are concerned about their health.
Clinical Studies
It is our belief that clinical studies substantiating product claims will become more important as more and more beverages are marketed with health claims. Celsius® was one of the first functional beverages to be launched along with a clinical study. Celsius® is also one of very few functional beverages that has clinical research on the actual product itself. Some beverage companies that do mention studies backing their claims are actually referencing independent studies conducted on one or more of the ingredients in the product. We believe that it is important and will become more important to have studies on the actual product.
We have funded seven U.S. based clinical studies for Celsius®. Each was conducted by a research organization and each studied the total Celsius® formula. The first study was conducted by the Ohio Research Group of Exercise Science & Sports Nutrition. The remaining studies were conducted by the Applied Biochemistry & Molecular Physiology Laboratory of the University of Oklahoma. We funded all of the studies and provided Celsius® beverage for the studies. However, none of our directors, executive officers or principal shareholders is in any way affiliated with either of the two research organizations which conducted the studies.
The first study was conducted in 2005 by the Ohio Research Group of Exercise Science & Sports Nutrition www.ohioresearchgroup.com . The Ohio Research Group of Exercise Science & Sports Nutrition is a multidisciplinary clinical research team dedicated to exploring the relationship between exercise, nutrition, dietary supplements and health. This placebo-controlled, double-blind cross-over study compared the effects of Celsius® and the placebo on metabolic rate. Twenty-two participants were randomly assigned to ingest a twelve ounce serving of Celsius® and on a separate day a serving of twelve ounces of Diet Coke ® . All subjects completed both trials using a randomized, counterbalanced design. Randomized means that subjects were selected for each group randomly to ensure that the different treatments were statistically equivalent. Counterbalancing means that individuals in one group drank the placebo on the first day and drank Celsius® on the second day. The other group did the opposite. Counterbalancing is a design method that is used to control “order effects.” In other words this was done to make sure that the order that subjects were served does not impact the results and analysis.
Metabolic rate (via indirect calorimetry, measurements taken from breaths into and out of calorimeter) and substrate oxidation (via respiratory exchange ratios) were measured at baseline (pre-ingestion) and for ten minutes at the end of each hour for three hours post-ingestion. The results showed an average increase of metabolism of twelve percent over the three hour period, compared to a statistically insignificant change for the control group. Metabolic rate, or metabolism, is the rate at which the body expends energy. This is also referred to as the “caloric burn rate.” Indirect calorimetry calculates heat that living organisms produce from their production of carbon dioxide. It is called “indirect” because the caloric burn rate is calculated from a measurement of oxygen uptake. Direct calorimetry would involve the subject being placed inside the calorimeter for the measurement to determine the heat being produced. Respiratory Exchange Ratio is the ratio oxygen taken in a breath compared to the carbon dioxide breathed out in one breath or exchange. Measuring this ratio can be used for estimating which substrate (fuel such as carbohydrate or fat) is being metabolized or ‘oxidized’ to supply the body with energy.
4 |
The second study was conducted by the Applied Biochemistry & Molecular Physiology Laboratory of University of Oklahoma in 2007. This blinded, placebo-controlled study was conducted on a total of 60 men and women of normal weight. An equal number of participants were separated into two groups to compare one serving (a single 12 ounce can) of Celsius to a placebo of the same amount. According to the study, those subjects consuming Celsius burned significantly more calories versus those consuming the placebo, over a three-hour period. The study confirmed that over the three-hour period, subjects consuming a single serving of Celsius® burned 65% more calories than those consuming the placebo beverage and burned an average of more than 100 to 140 calories compared to the placebo. These results were statistically significant.
The third study, conducted by the Applied Biochemistry & Molecular Physiology Laboratory of University of Oklahoma in 2007, extended our second study with the same group of 60 individuals and protocol for 28 days and showed the same statistical significance of increased calorie burn (minimal attenuation). While the University of Oklahoma study did extend for 28 days, more testing would be needed for long term analysis of the Celsius® calorie-burning effects. Also, although these studies were on relatively small numbers of subjects, they have statistically significant results. Additional studies on a larger number and wider range of body compositions can be considered to further the analysis.
Our fourth study, conducted by the Applied Biochemistry & Molecular Physiology Laboratory of University of Oklahoma in 2009, combined Celsius® use with exercise. This ten-week placebo-controlled, randomized and blinded study was conducted on a total of 37 subjects. Participants were randomly assigned into one of two groups: Group 1 consumed one serving of Celsius® per day, and Group 2 consumed one serving of an identically flavored and labeled placebo beverage. Both groups participated in ten weeks of combined aerobic and weight training, following the American College of Sports Medicine guidelines of training for previously sedentary adults. The results showed that consuming a single serving of Celsius® prior to exercising may enhance the positive adaptations of exercise on body composition, cardio-respiratory fitness and endurance performance. According to the preliminary findings, subjects consuming a single serving of Celsius® lost significantly more fat mass and gained significantly more muscle mass than those subjects consuming the placebo — a 93.75% greater loss in fat and 50% greater gain in muscle mass, respectively. The study also confirmed that subjects consuming Celsius® significantly improved measures of cardio-respiratory fitness and the ability to delay the onset of fatigue when exercising to exhaustion.
Our fifth study was conducted by the Applied Biochemistry & Molecular Physiology Laboratory of University of Oklahoma in 2009. This ten-week placebo-controlled, randomized and blinded study was conducted on a total of 27 previously sedentary overweight and obese female subjects. Participants were randomly assigned into groups that consumed identically tasting treatment beverages with exercise or without exercise. All participants consumed one drink, either placebo or Celsius, per day for 10 weeks. The exercise groups participated in ten weeks of combined aerobic and weight training, following the American College of Sports Medicine guidelines of training for previously sedentary adults. No changes were made to their diet. The results showed that consuming a single serving of Celsius® prior to exercising may improve cardiovascular health and fitness and enhance the positive adaptations of exercise on body composition. According to the preliminary findings, subjects consuming a single serving of Celsius® lost significantly more fat mass and gained significantly more muscle mass when compared to exercise alone — a 46% greater loss in fat, 27% greater gain in muscle mass, respectively. The study also confirmed that subjects consuming Celsius® significantly improved measures of cardio-respiratory fitness — 35% greater endurance performance with significant improvements to lipid profiles — total cholesterol decreases of 5 to 13% and bad LDL cholesterol 12 to 18%. Exercise alone had no effect on blood lipid levels.
Our sixth study was conducted by the Applied Biochemistry & Molecular Physiology Laboratory of University of Oklahoma in 2009. This ten-week placebo-controlled, randomized and blinded study was conducted on a total of 37 previously sedentary male subjects. Participants were randomly assigned into groups that consumed identically tasting treatment beverages with exercise or without exercise. All participants consumed one drink, either placebo or Celsius, per day for 10 weeks. The exercise groups participated in ten weeks of combined aerobic and weight training, following the American College of Sports Medicine guidelines of training for previously sedentary adults. No changes were made to their diet. The results showed that consuming a single serving of Celsius® prior to exercising may improve cardiovascular health and fitness and enhance the positive adaptations of exercise on body composition. Significantly greater decreases in fat mass and percentage body fat and increases in VO 2 were observed in the subjects that consumed Celsius before exercise versus those that consumed the placebo before exercise. Mood was not affected. Clinical markers for hepatic, renal, cardiovascular and immune function, as determined by pre and post blood work revealed no adverse effects.
5 |
Our seventh study was conducted by Miami Research Institute in 2010 and demonstrated the efficacy and safety of the powders and the shots. This study allows the Company to make the same structure/function claims as the ready to drink beverages.
Manufacture and Supply of Our Products
Our beverages are produced by established third party beverage co-packers. A co-packer is a manufacturing plant that provides the service of filling bottles or cans for the brand owner. We believe one benefit of using co-packers is that we do not have to invest in the production facility and can focus our resources on brand development, sales and marketing. It also allows us produce in multiple locations strategically placed throughout the country. We purchase most of the ingredients and all packaging materials. The co-pack facility assembles our products and charges us a fee by the case. The shelf life of Celsius® is specified as 15 to 18 months.
Substantially all of the raw materials used in the preparation, bottling and packaging of our products are purchased by us or by our co-packers in accordance with our specifications. Generally, we obtain the ingredients used in our products from domestic suppliers and some ingredients have several reliable suppliers. The ingredients in Celsius® include green tea (EGCG), ginger (from the root), caffeine, B vitamins, vitamin C, taurine, guarana, chromium, calcium, glucuronolactone, sucralose, natural flavors and natural colorings. Celsius® is labeled with a supplements facts panel. We have no major supply contracts with any of our suppliers. We single-source all our ingredients for purchasing efficiency; however, we have identified a second source for our critical ingredients and there are many suppliers of flavors, colorings and sucralose. In case of a supply restriction or interruption from any of the flavor and coloring suppliers, we would have to test and qualify other suppliers that may disrupt our production schedules.
Packaging materials, except for our distinctive sleek aluminum cans, are easily available from multiple sources in the United States; however, due to efficiencies we utilize single source vendor relationships.
We believe that our co-packing arrangement and supply sources are adequate for our present needs.
Distribution
Celsius® is sold across many retail segments. They include supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants. We also sell to health clubs, spas, gyms, the military, e-commerce websites and a limited number of international markets.
We distribute our products through a hybrid of direct-store delivery (DSD) distributors and as well as sales direct to retailers (DTR).
Sales of our products to one customer, a foreign distributor of our products accounted for 48.3% of our revenues for the year ended December 31, 2015, and 31.4% of our revenues for the six months ended June 30, 2016. In addition, for the six months ended June 30, 2016, a domestic distributor accounted for 12.3% of our revenues. Accordingly, if sales to either of these customers were to significantly decline or cease entirely, our business, results of operations and financial condition may be significantly harmed.
Seasonality of Sales
As is typical in the beverage industry, sales of our beverages are seasonal, with the highest sales volumes generally occurring in the second and third fiscal quarters, which correspond to the warmer months of the year in our major markets.
6 |
Competition
We believe that we are one of the few calorie-burning fitness beverages whose effectiveness is supported by clinical studies, which gives us a unique position in the beverage market. However, our products do compete broadly with all categories of consumer beverages. The beverage market is highly competitive, and includes international, national, regional and local producers and distributors, most of whom have greater financial, management and other resources than us. Our direct competitors in the functional beverage market include, but are not limited to The Coca-Cola Company, Dr. Pepper Snapple Group, PepsiCo, Inc., Nestlé, Waters North America, Inc., Hansen Natural Corp., and Red Bull.
Proprietary Rights
We have registered the Celsius® and MetaPlus® trademarks with the United States Patent and Trademark Office, as well as a number of additional trademarks.
We have and will continue to take appropriate measures, such as entering into confidentiality agreements with our contract packers and ingredient suppliers, to maintain the secrecy and proprietary nature of our MetaPlus® formulation and product formulas.
We maintain our MetaPlus® formulation and product formulas as trade secrets. We believe that trade secrecy is a preferable method of protection for our formulas as patenting them might require their disclosure. Other than a company that is our outsourced production manager, no single member of the raw material supply chain or our co-packers has access to the complete formula.
We consider our trademarks and trade secrets to be of considerable value and importance to our business. No successful challenges to our registered trademarks have arisen and we have no reason to believe that any such challenges will arise in the future.
Government Regulation
The production, distribution and sale of our products in the United States is subject to the Federal Food, Drug and Cosmetic Act , the Dietary Supplement Health and Education Act of 1994 , the Occupational Safety and Health Act , various environmental statutes and various other federal, state and local statutes and regulations applicable to the production, transportation, sale, safety, advertising, labeling and ingredients of such products. California law requires that a specific warning appear on any product that contains a component listed by California as having been found to cause cancer or birth defects. The law exposes all food and beverage producers to the possibility of having to provide warnings on their products because the law recognizes no generally applicable quantitative thresholds below which a warning is not required. Consequently, even trace amounts of listed components can expose affected products to the prospect of warning labels. Products containing listed substances that occur naturally in the product or that are contributed to the product solely by a municipal water supply are generally exempt from the warning requirement. While none of our products are required to display warnings under this law, we cannot predict whether an important component of any of our products might be added to the California list in the future. We also are unable to predict whether or to what extent a warning under this law would have an impact on costs or sales of our products.
Measures have been enacted in various localities and states that require that a deposit be charged for certain non-refillable beverage containers. The precise requirements imposed by these measures vary. Other deposit, recycling or product stewardship proposals have been introduced in certain states and localities and in Congress, and we anticipate that similar legislation or regulations may be proposed in the future at the local, state and federal levels, both in the United States and elsewhere.
Our facilities in the United States are subject to federal, state and local environmental laws and regulations. Compliance with these provisions has not had, and we do not expect such compliance to have, any material adverse effect upon our business, financial condition and results of operations.
7 |
Employees
As of the date of this Registration Statement, the Company employs 38 persons, including its executive officers.
Item 1A. | Risk Factors |
Our business faces certain risks. The risks described below may not be the only risks we face. Additional risks that we do not yet know of, or that we currently think as immaterial, may also impair our business. If any of the events anticipated by the risks described below or elsewhere in this report occur, our results of operations and financial conditions could be adversely affected.
Risk Factors Relating to Our Business
We have a history of losses and we may experience additional losses in the futures.
The Company has a history of losses, including net losses of $3,831,329 and $ 381,877 for the six months ended June 30 2016 and 2015, respectively and $2,570,297 and $2,160,972 for the years ended December 31, 2015 and 2014, respectively. Our future operating results will depend on many factors, both in and out of our control, including the ability to increase and sustain demand for and acceptance of our products, the level of our competition, and our ability to attract and maintain key management and key employees. Accordingly, there can be no assurance that we can attain consistent profitability.
We rely on third party co-packers to manufacture our products. If we are unable to maintain good relationships with our co-packers and/or their ability to manufacture our products becomes constrained or unavailable to us, our business could suffer.
We do not directly manufacture our products, but instead outsource such manufacturing to established third party co-packers. These third party co-packers may not be able to fulfill our demand as it arises, could begin to charge rates that make using their services cost inefficient or may simply not be able to or willing to provide their services to us on a timely basis or at all. In the event of any disruption or delay, whether caused by a rift in our relationship or the inability of our co-packers to manufacture our products as required, we would need to secure the services of alternative co-packers. We may be unable to procure alternative packing facilities at commercially reasonable rates and/or within a reasonably short time period and any such transition could be costly. In such case, our business, financial condition and results of operations would be adversely affected.
We rely on distributors to distribute our products in the DSD sales channel. If we are unable to secure such distributors and/or we are unable to maintain good relationships with our existing distributors, our business could suffer.
We distribute Celsius® in the DSD sales channel by entering into agreements with direct-to-store delivery distributors having established sales, marketing and distribution organizations. Many of our distributors are affiliated with and manufacture and/or distribute other beverage products. In many cases, such products compete directly with our products. The marketing efforts of our distributors are important for our success. If Celsius® proves to be less attractive to our distributors and/or if we fail to attract distributors, and/or our distributors do not market and promote our products with greater focus in preference to the products of our competitors, our business, financial condition and results of operations could be adversely affected.
Our customers are material to our success. If we are unable to maintain good relationships with our existing customers, our business could suffer.
Unilateral decisions could be taken by our distributors, grocery chains, convenience chains, drug stores, nutrition stores, mass merchants, club warehouses and other customers to discontinue carrying all or any of our products that they are carrying at any time, which could cause our business to suffer.
8 |
Two of our customers account for a significant portion of our revenues. If sales to either of those customers were to significantly decline or cease , our business could be significantly harmed .
Sales of our products to one customer, a foreign distributor of our products accounted for 48.3% of our revenues for the year ended December 31, 2015, and 31.4% of our revenues for the six months ended June 30, 2016. In addition, for the six months ended June 30, 2016, a domestic distributor accounted for 12.3% of our revenues. Accordingly, if sales to either of these customers were to significantly decline or cease entirely, our business, results of operations and financial condition may be significantly harmed.
Increases in cost or shortages of raw materials or increases in costs of co-packing could harm our business .
The principal raw materials used by us are flavors and ingredient blends as well as aluminum cans, the prices of which are subject to fluctuations. We are uncertain whether the prices of any of the above or any other raw materials or ingredients we utilize will rise in the future and whether we will be able to pass any of such increases on to our customers. We do not use hedging agreements or alternative instruments to manage the risks associated with securing sufficient ingredients or raw materials. In addition, some of these raw materials, such as our distinctive sleek 12 ounce can, are available from a single or a limited number of suppliers. As alternative sources of supply may not be available, any interruption in the supply of such raw materials might materially harm us.
Our failure to accurately estimate demand for our products could adversely affect our business and financial results.
We may not correctly estimate demand for our products. If we materially underestimate demand for our products and are unable to secure sufficient ingredients or raw materials, we might not be able to satisfy demand on a short-term basis, in which case our business, financial condition and results of operations could be adversely affected.
We depend upon our trademarks and proprietary rights, and any failure to protect our intellectual property rights or any claims that we are infringing upon the rights of others may adversely affect our competitive position.
Our success depends, in large part, on our ability to protect our current and future brands and products and to defend our intellectual property rights. We cannot be sure that trademarks will be issued with respect to any future trademark applications or that our competitors will not challenge, invalidate or circumvent any existing or future trademarks issued to, or licensed by, us.
Our products are manufactured using our proprietary blends of ingredients. These blends are created by third-party suppliers to our specifications and then supplied to our co-packers. Although all of the third parties in our supply and manufacture chain execute confidentiality agreements, there can be no assurance that our trade secrets, including our proprietary ingredient blends will not become known to competitors.
We believe that our competitors, many of whom are more established and have greater financial and personnel resources than we do, may be able to replicate or reverse engineer our processes, brands, flavors, or our products in a manner that could circumvent our protective safeguards. Therefore, we cannot give you any assurance that our confidential business information will remain proprietary. Any such loss of confidentiality could diminish or eliminate any competitive advantage provided by our proprietary information.
We may incur material losses as a result of product recall and product liability .
We may be liable if the consumption of any of our products causes injury, illness or death. We also may be required to recall some of our products if they become contaminated or are damaged or mislabeled. A significant product liability judgment against us, or a widespread product recall, could have a material adverse effect on our business, financial condition and results of operations. The amount of the insurance we carry is limited, and that insurance is subject to certain exclusions and may or may not be adequate.
Our lack of product diversification and inability to timely introduce new or alternative products could cause us to cease operations.
Our business is centered on Celsius®. The risks associated with focusing on a limited product line are substantial. If consumers do not accept our products or if there is a general decline in market demand for, or any significant decrease in, the consumption of functional beverages, we are not financially or operationally capable of introducing alternative products within a short time frame. As a result, such lack of acceptance or market demand decline could cause us to cease operations.
9 |
We are dependent on our key executives and employees and the loss of any of their services could materially adversely affect us which may have a material adverse effect on our Company.
Our future success will depend substantially upon the abilities of, and personal relationships developed by a limited number of key executives and employees, including Gerry David, our Chief Executive Officer and John Fieldly, our Chief Financial Officer. The loss of the services of Mr. David, Mr. Fieldly or any other key employee could materially adversely affect our business and our prospects for the future. We do not have key person insurance on the lives of such individuals and the loss of any of their services could materially adversely affect us.
We are dependent on our ability to attract and retain qualified technical, sales and managerial personnel .
Our future success depends in part on our continuing ability to attract and retain highly qualified technical, sales and managerial personnel. Competition for such personnel in the beverage industry is intense and we may not be able to retain our key managerial, sales and technical employees or attract and retain additional highly qualified technical, sales and managerial personnel in the future. Any inability to attract and retain the necessary technical, sales and managerial personnel could materially adversely affect us.
The FDA has not passed on the efficacy of our products or the accuracy of any claim we make related to our products.
Although six independent clinical studies have been conducted relating to the calorie-burning and related effects of our products, the results of these studies have not been submitted to or reviewed by the FDA. Further, the FDA has not passed on the efficacy of any of our products nor has it reviewed or passed on any claims we make related to our products, including the claim that our products aid consumers in burning calories or enhancing their metabolism.
Risk Factors Relating to Our Industry
We are subject to significant competition in the beverage industry .
The beverage industry is highly competitive. The principal areas of competition are pricing, packaging, distribution channel penetration, development of new products and flavors and marketing campaigns. Our products compete with a wide range of drinks produced by a relatively large number of manufacturers, most of which have substantially greater financial, marketing and distribution resources and name recognition than we do.
Important factors affecting our ability to compete successfully include the taste and flavor of our products, trade and consumer promotions, rapid and effective development of new, unique cutting edge products, attractive and different packaging, branded product advertising and pricing. Our products compete with all liquid refreshments and with products of much larger and substantially better financed competitors, including the products of numerous nationally and internationally known producers, such as The Coca Cola Company, Dr. Pepper Snapple Group, PepsiCo, Inc., Nestle, Waters North America, Inc., Hansen Natural Corp. and Red Bull. We also compete with companies that are smaller or primarily local in operation. Our products also compete with private label brands such as those carried by supermarket chains, convenience store chains, drug store chains, mass merchants and club warehouses.
There can be no assurance that we will compete successfully in the functional beverage industry. The failure to do so would materially adversely affect our business, financial condition and results of operations.
We compete in an industry that is brand-conscious, so brand name recognition and acceptance of our products are critical to our success and significant marketing and advertising could be needed to achieve and sustain brand recognition.
Our business is substantially dependent upon awareness and market acceptance of our products and brands by our targeted consumers. Our business depends on acceptance by our independent distributors of our brand as one that has the potential to provide incremental sales growth rather than reduce distributors’ existing beverage sales. The development of brand awareness and market acceptance is likely to require significant marketing and advertising expenditures. There can be no assurance that Celsius® will achieve and maintain satisfactory levels of acceptance by independent distributors and retail consumers. Any failure of Celsius® brand to maintain or increase acceptance or market penetration would likely have a material adverse effect on business, financial condition and results of operations.
10 |
Our sales are affected by seasonality.
As is typical in the beverage industry, our sales are seasonal. Our highest sales volumes generally occur in the second and third quarters, which correspond to the warmer months of the year in our major markets. Consumer demand for our products is also affected by weather conditions. Cool, wet spring or summer weather could result in decreased sales of our beverages and could have an adverse effect on our results of operations.
Our business is subject to many regulations and noncompliance is costly .
The production, marketing and sale of our beverage products are subject to the rules and regulations of various federal, state and local health agencies. If a regulatory authority finds that a current or future product or production run is not in compliance with any of these regulations, we may be fined, or production may be stopped, thus adversely affecting our business, financial condition and results of operations. Similarly, any adverse publicity associated with any noncompliance may damage our reputation and our ability to successfully market our products. Furthermore, the rules and regulations are subject to change from time to time and while we closely monitor developments in this area, we have no way of anticipating whether changes in these rules and regulations will impact our business adversely. Additional or revised regulatory requirements, whether labeling, environmental, tax or otherwise, could have an adverse effect on our business, financial condition and results of operations.
Risk Factors Relating to our Status as a Fully Reporting Public Company
Upon effectiveness of this registration statement, we will become subject to the periodic reporting requirements of the Securities Exchange Act of 1934 (the “Exchange Act”) that will require us to incur audit fees and legal fees in connection with the preparation of such reports. These additional costs could reduce or eliminate our ability to earn a profit.
Following effectiveness of this registration statement, we will be required to file periodic reports with the Securities and Exchange Commission (the “ SEC ”) pursuant to the Exchange Act and the rules and regulations promulgated thereunder. In order to comply with these requirements, our independent registered public accounting firm will have to review our financial statements on a quarterly basis and audit our financial statements on an annual basis. Moreover, our legal counsel will have to review and assist in the preparation of such reports. The costs charged by these professionals for such services cannot be accurately predicted at this time because factors such as the number and type of transactions that we engage in and the complexity of our reports cannot be determined at this time and will have a major effect on the amount of time to be spent by our auditors and attorneys. However, the incurrence of such costs will obviously be an expense to our operations and thus have a negative effect on our ability to meet our overhead requirements and earn a profit. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock, if a market ever develops, could drop significantly.
Our internal controls may be inadequate, which could cause our financial reporting to be unreliable and lead to misinformation being disseminated to the public .
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Rule 13a-15(f) under the Exchange Act, internal control over financial reporting is a process designed by, or under the supervision of, the principal executive and principal financial officers and effected by the board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
• pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;
11 |
• provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and/or directors of the Company; and
• provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.
We will be required to include a report of management on the effectiveness of our internal control over financial reporting in certain of our periodic filings. We expect to incur additional expenses and diversion of management’s time as a result of performing the system and process evaluation, testing and remediation required in order to comply with the management certification requirements.
We do not have a sufficient number of employees to segregate responsibilities and may be unable to afford increasing our staff or engaging outside consultants or professionals to overcome our lack of employees. During the course of our testing, we may identify other deficiencies that we may not be able to timely remediate. Moreover, effective internal controls, particularly those related to revenue recognition, are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could drop significantly.
The Jumpstart Our Business Startups Act of 2012 (the “Jobs Act”) has reduced the information that the Company will be is required to disclose.
Under the Jobs Act, the information that the Company will be required to disclose following effectiveness of this registration statement has been reduced in a number of ways.
As a company that had gross revenues of less than $1 billion during the Company’s last fiscal year, the Company is an “ emerging growth company ,” as defined in the Jobs Act (an “ EGC ”). The Company will retain that status until the earliest of (a) the last day of the fiscal year which the Company has total annual gross revenues of $1,000,000,000 (as indexed for inflation in the manner set forth in the Jobs Act) or more; (b) the last day of the fiscal year of following the fifth anniversary of the date of the first sale of the common stock pursuant to an effective registration statement under the Securities Act of 1933 (the “ Securities Act ”); (c) the date on which the Company has, during the previous three year period, issued more than $1,000,000,000 in non-convertible debt; or (d) the date on which the Company is deemed to be a “ large accelerated filer ,” as defined in Rule 12b-2 under the Exchange Act or any successor thereto. As an EGC, the Company is relieved from the following:
• The Company is excluded from Section 404(b) of Sarbanes-Oxley Act (“ Sarbanes-Oxley ”), which otherwise would have required the Company’s auditors to attest to and report on the Company’s internal control over financial reporting. The JOBS Act also amended Section 103(a)(3) of Sarbanes-Oxley to provide that (i) any new rules that may be adopted by the PCAOB requiring mandatory audit firm rotation or changes to the auditor’s report to include auditor discussion and analysis (each of which is currently under consideration by the PCAOB) shall not apply to an audit of an EGC; and (ii) any other future rules adopted by the PCAOB will not apply to the Company’s audits unless the SEC determines otherwise.
• The Jobs Act amended Section 7(a) of the Securities Act to provide that the Company need not present more than two years of audited financial statements in an initial public offering registration statement and in any other registration statement, need not present selected financial data pursuant to Item 301 of Regulation S-K for any period prior to the earliest audited period presented in connection with such initial public offering. In addition, the Company is not required to comply with any new or revised financial accounting standard until such date as a private company (i.e., a company that is not an “ issuer ” as defined by Section 2(a) of Sarbanes-Oxley) is required to comply with such new or revised accounting standard. Corresponding changes have been made to the Exchange Act, which relates to periodic reporting requirements, which would be applicable if the Company were required to comply with them.
• As long as the Company is an EGC, the Company may comply with Item 402 of Regulation S-K, which requires extensive quantitative and qualitative disclosure regarding executive compensation, by disclosing the more limited information required of a “smaller reporting company.”
12 |
• In the event that the Company registers the common stock under the Exchange Act as it intends to do, the Jobs Act will also exempt the Company from the following additional compensation-related disclosure provisions that were imposed on U.S. public companies pursuant to the Dodd-Frank Act: (i) the advisory vote on executive compensation required by Section 14A(a) of the Exchange Act; (ii) the requirements of Section 14A(b) of the Exchange Act relating to shareholder advisory votes on “ golden parachute ” compensation; (iii) the requirements of Section 14(i) of the Exchange Act as to disclosure relating to the relationship between executive compensation and our financial performance; and (iv) the requirement of Section 953(b)(1)of the Dodd-Frank Act, which requires disclosure as to the relationship between the compensation of the Company’s chief executive officer and median employee pay.
In addition to the foregoing, Section 107 of the Jobs Act provides that an EGC can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. An emerging growth company can therefore delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. However, we are choosing to “opt out” of such extended transition period, and as a result, we will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for companies that are not EGCs. Section 107 of the Jobs Act provides that our decision to “opt out” of the extended transition period for complying with new or revised accounting standards is irrevocable.
Risk Factors Related to our Common Stock
We cannot guarantee the continued existence of an active established public trading market for our common stock.
Our common stock currently is listed for trading on the OTCQX tier of the over-the-counter market operated by OTC Markets Group, Inc. Trading in stock quoted on the OTCQX is often thin and characterized by wide fluctuations in trading prices, due to many factors that may have little to do with our operations or business prospects. This volatility could depress the market price of our common stock for reasons unrelated to operating performance. Accordingly, OTCQX may provide less liquidity for holders of our common stock than a national securities exchange such as the Nasdaq Stock Market. Although we intend to list our common stock for trading on the Nasdaq Stock Market concurrent with or as soon as practicable after the effectiveness of this registration statement, there is no assurance that we can successfully do so or that in any event, we can maintain an active established trading market for our common stock.
Market prices for our common stock may also be influenced by a number of other factors, including:
• | the issuance of new equity securities pursuant to a public or private offering; |
• | changes in interest rates; |
• | competitive developments, including announcements by competitors of new products or services or significant contracts, acquisitions, strategic partnerships, joint ventures or capital commitments; |
• | variations in quarterly operating results; |
• | change in financial estimates by securities analysts; |
• | the depth and liquidity of the market for our common stock; |
• | investor perceptions of Celsius and the functional beverage industry generally; and |
• | general economic and other national conditions. |
Our common stock is currently deemed to be a “penny stock” and is restricted by the SEC’s penny stock regulations and FINRA’s sales practice requirements, which may limit a shareholder’s ability to buy and sell our common stock .
Our common stock is currently classified as a “ penny stock .” The SEC has adopted Rule 15g-9 which generally defines “ penny stock ” to be any equity security that has a market price (as defined) less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. Our common stock is covered by the penny stock rules, which impose additional sales practice requirements on broker-dealers who sell to persons other than established customers and “ accredited investors .” The term “ accredited investor ” refers generally to institutions with assets in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the SEC which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the stock that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe that the penny stock rules discourage investor interest in, and limit the marketability of, our common stock.
13 |
In addition to the “ penny stock ” rules promulgated by the SEC, the Financial Industry Regulatory Authority (“ FINRA ”) has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, the FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. FINRA’s requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock.
The market for penny stocks has experienced numerous frauds and abuses that could adversely impact investors in our common stock.
Company management believes that the market for penny stocks has suffered from patterns of fraud and abuse. Such patterns include:
• | control of the market for the security by one or a few broker-dealers that are often related to a promoter or issuer; |
• | manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases; |
• | “boiler room” practices involving high pressure sales tactics and unrealistic price projections by sales persons; |
• | excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and |
• | wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the inevitable collapse of those prices with consequent investor losses. |
Our board of directors has the authority, without shareholder approval, to issue preferred stock with terms that may not be beneficial to common shareholders and with the ability to affect adversely shareholder voting power and perpetuate their control over us.
Our Articles of Incorporation allows us to issue shares of preferred stock without any vote or further action by our shareholders. Our board of directors has the authority to fix and determine the relative rights and preferences of preferred stock. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders the preferred right to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, prior to the redemption of our common stock.
The ability of our principal shareholders to control our business may limit or eliminate minority shareholders’ ability to influence corporate affairs.
Our principal shareholders own common stock and/or preferred stock which holds a majority of the voting power of our issued and outstanding capital. Accordingly, they will be able to effectively control the election of directors, as well as all other matters requiring shareholder approval. The interests of our principal shareholders may differ from the interests of other shareholders with respect to the issuance of shares, business transactions with or sales to other companies, selection of other directors and other business decisions. The minority shareholders have no way of overriding decisions made by our principal shareholders. This level of control may also have an adverse impact on the market value of our shares because our principal shareholders may institute or undertake transactions, policies or programs that result in losses, may not take any steps to increase our visibility in the financial community and / or may sell sufficient numbers of shares to significantly decrease our price per share.
14 |
We do not expect to pay cash dividends in the foreseeable future .
We have never paid cash dividends on our common stock. We do not expect to pay cash dividends on our common stock at any time in the foreseeable future. The future payment of dividends directly depends upon our future earnings, capital requirements, financial requirements and other factors that our board of directors will consider. Since we do not anticipate paying cash dividends on our common stock, return on your investment, if any, will depend solely on an increase, if any, in the market value of our common stock.
The “market overhang” from our outstanding options, warrants and convertible securities could adversely impact the market price of our common stock .
We have 53,201,132 shares of common stock issuable upon exercise of outstanding options and warrants and conversion of outstanding convertible securities. Such “ market overhang ” could adversely impact the market price of our common stock as a result of the dilution which would result if such securities were exercised for or converted into shares of common stock.
Item 2. | Financial Information |
Management's Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion in conjunction with the audited financial statements and the corresponding notes, the unaudited financial statements and the corresponding notes included elsewhere in this information statement. This Item 2 contains forward-looking statements. The matters discussed in these forward-looking statements are subject to risk, uncertainties, and other factors that could cause actual results to differ materially from those made, projected or implied in the forward-looking statements. Please refer to " Item 1A. Risk Factors " for a discussion of the uncertainties, risks and assumptions associated with these statements.
Results of Operations
Six months ended June 30, 2016 compared to six months ended June 30, 2015
Revenue
For the six months ended June 30, 2016, revenue was approximately $9.85 million, an increase of $545,000 or 6% from $9.30 million for same period in the prior year. The revenue increase of 6% was attributable in large part to 71% growth in domestic revenues associated from blended growth rates of 90% in retail accounts arising mainly from expansion of convenience store distribution initiatives, 33% in health and fitness accounts and 44% growth in internet retailer accounts from the same period in 2015. The increase in revenue from the 2015 period to the 2016 period was primarily attributable to an increase in sales volume, as opposed to increases in product pricing. This growth was offset by a 40% decrease in international revenue from our Swedish distribution partner, who was adversely affected by a rebalancing of inventory during the first quarter of 2016 resulting from a determination to reduce the number of weeks on hand of such inventory.
The following table sets forth the amount of revenues by category and changes therein for the six months ended June 30. 2016 and 2015:
Six months ended June 30, | ||||||||||||
Revenue Source | 2016 | 2015 | Change | |||||||||
Total Revenue | $ | 9,850,397 | $ | 9,304,910 | 6 | % | ||||||
International Revenue | $ | 3,242,052 | $ | 5,446,856 | -40 | % | ||||||
Domestic Revenue | $ | 6,608,345 | $ | 3,858,054 | 71 | % | ||||||
Retail accounts | $ | 4,753,812 | $ | 2,506,720 | 90 | % | ||||||
Health & Fitness accounts | $ | 1,037,117 | $ | 782,145 | 33 | % | ||||||
Internet Retailer accounts | $ | 817,416 | $ | 569,189 | 44 | % |
Gross profit
For the six months ended June 30, 2016, gross profit increased by approximately $417,000 or 10.8% to $4.28 million from $3.87 million for the same period in 2015. Gross profit margins improved 1.9% to 43.5% for the six months ended June 30, 2016 from the same period in 2015 for comparable reasons. The increases in gross profit and the improvement in gross profit margins from the 2015 to the 2016 periods are primarily attributable to the increases in revenue and reductions in the cost of raw materials.
Sales and marketing expenses
Sales and marketing expenses for the six months ended June 30, 2016 were approximately $4.97 million, an increase of $2.93 million or 143% from $2.04 million in the same period in 2015. The increase is due primarily to increases in investments in marketing programs of $1.84 million and increases in human resource investments of $1.09 million.
General and administrative expenses
General and administrative expenses for the six months ended June 30, 2016 were approximately $1.86 million, a decrease of $36,000, or 2%, from $1.89 million for the six months ended June 30, 2015. The decrease was primarily due to savings in option expense of $547,000 and depreciation and amortization of $11,000, offset by increases in professional fees of $265,000, increases in travel of $96,000, investments in human resources of $76,000, office related costs of $60,000 and research and development costs of $21,000.
Other expense
Total other expense decreased to approximately $114,000 for six months ended June 30, 2016 from $207,000 for the same period in 2015, as a result of $93,000 in savings in interest expense.
Net Loss
We incurred a net loss of $2.8 million during six months ended June 30, 2016, as compared to a net loss of $381,877 during the six months ended June 30, 2015.
15 |
Year ended December 31, 2015 compared to year ended December 31, 2014
Revenue
For the year ended December 31, 2015, revenue was approximately $17.2 million, an increase of $2.6 million or 18% from $14.6 million in revenue for year ending December 31, 2014. The revenue growth of 18% from 2014 to the 2015 was mainly associated with blended growth rates of 13% growth in international revenue growth and 22% growth in domestic sales. The domestic sales growth of 22% was mainly associated from blended growth rates of 18% in retail accounts, 21% in health and fitness accounts and 46% in Internet retailer accounts from 2014. The increase in revenue from 2014 to 2015 was primarily attributable to an increase in sales volume, as opposed to increases in product pricing.
The following table sets forth the amount of revenues by category and changes therein for the six months ended June 30. 2016 and 2015:
Year Ending December 31, | ||||||||||||
Revenue Source | 2015 | 2014 | Change | |||||||||
Total Revenue | $ | 17,217,944 | $ | 14,610,090 | 18 | % | ||||||
International Revenue | $ | 8,442,971 | $ | 7,439,129 | 13 | % | ||||||
Domestic Revenue | $ | 8,774,973 | $ | 7,170,961 | 22 | % | ||||||
Retail accounts | $ | 5,879,104 | $ | 4,970,602 | 18 | % | ||||||
Health & Fitness accounts | $ | 1,550,821 | $ | 1,277,673 | 21 | % | ||||||
Internet Retailer accounts | $ | 1,345,048 | $ | 922,686 | 46 | % |
Gross profit
For the year ended December 31, 2015, gross profit increased by approximately $1.44 million or 25.8% to $7.04 million compared to $5.60 million for 2014. Gross profit margins improved 2.6% to 40.9% in the fiscal year ended December 31, 2015 from 2014. The increases in gross profit and the improvement in gross profit margins from 2014 to 2015 are primarily attributable to the increases in revenue and a reduction in the cost of raw materials.
Sales and marketing expenses
Sales and marketing expenses for the year ended December 31, 2015 were approximately $5.70 million, an increase of $880,000, or 18.2% from $4.82 million in 2014. The increase is due primarily to increases in investments in marketing programs of $596,000, increases in human resource investments of $239,000 and increases in warehousing costs totaling $44,000.
General and administrative expenses
General and administrative expenses for the year ended December 31, 2015 were approximately $3.17 million, an increase of $860,000, or 37.3%, from $2.31 million for the year ended December 31, 2014. The increase was primarily due to increases in stock based compensation of $582,000, professional fees of $129,000, research and development costs of $46,000, office related costs of $47,000, commercial insurance of $19,000, investor relations of $17,000, human resources of $13,000, and other general administration expenses of $12,000, offset by savings in depreciation and amortization of $4,000.
Other expense
Total other expense decreased to approximately $322,000 for year ended December 31, 2015 from $497,000 for the same period in 2014, as a result of $175,000 in savings in interest expense.
16 |
Net Loss
As a result of the all above, for the year ended December 31, 2015, Celsius had a net loss of $2,149,804, and after giving effect to preferred stock dividends of $420,493, a net loss of $2,570,297 or $0.07 per share based on a weighted average of 33,175,826 shares outstanding. In comparison, for the year ended December 31, 2014 we had a net loss of $2,027,136, and after giving effect to preferred stock dividends of $133,836, a net loss of $2,160,972 or $0.10 per share based on a weighted average of 20,392,594 shares outstanding.
Liquidity and Capital Resources
As of June 30, 2016, we had cash of approximately $7.3 million and working capital of $11.4 million. Cash used in operations during the six months ended June 30, 2016 totaled $2.8 million, reflecting capital investments in sales and marketing programs and human resources initiatives.
In addition to cash flow from operations, our primary sources of working capital have been private placements of our securities and our credit facility with CD Financial, LLC (“ CD Financial ”), an affiliate of Carl DeSantis, a principal shareholder of the Company.
As more fully described in “ Item 10. Recent Sales of Unregistered Securities ,” in April 2015, the Company issued a total of 12,921,348 shares of common stock at $0.89 per share to an investor group in a private transaction for gross proceeds of $11.5 million.
We originally entered into a loan and security agreement with CD Financial in July 2010, which provided us with a line of credit to fund operations. As amended in connection with the April 2015 private investment and related transactions described in “ Item 10. Recent Sales of Unregistered Securities ,” the loan and security agreement provides Celsius with a revolving line of credit pursuant to which Celsius can borrow up to an aggregate maximum of $4.5 million from time to time until maturity in January 2020. The credit facility requires quarterly cash payments of interest only at the rate of five percent (5%) per annum until maturity and is secured by a pledge of substantially all the Company’s assets. As of June 30, 2016, the principal amount outstanding under the credit facility with CD Financial was $4.5 million.
Our current operating plan for next twelve (12) months plans on a sufficient financial condition and we do not contemplate obtaining additional financing. However, if our sales volumes do not meet our projections, expenses exceed our expectations, or our plans change, we may be unable to generate enough cash flow from operations to cover our working capital requirements. In such case, we may be required to adjust our business plan, by reducing marketing and other expenses or seek additional financing. There can be no assurance that such financing, if required, will be available on commercially reasonable terms if at all.
Off Balance Sheet Arrangements
As of June 30, 2016 and December 31, 2015, we had no off-balance sheet arrangements.
Item 3. | Properties |
At present, we do not own any real property. We currently lease our principal executive offices located at 2424 N Federal Highway, Boca Raton, Florida 33431. Our premises are leased for a monthly cost of $$6,408. The current lease expires on October 2020. The Company has no warehouses or other facilities as we store our product at third party contract warehouse facilities.
17 |
Item 4. | Security Ownership of Certain Beneficial Owners and Management |
The following table sets forth, as of the date of this registration statement, the beneficial ownership of our common stock by each executive officer and director, by each person known by us to beneficially own 5% or more of our common stock and by executive officers and directors as a group. The address of the each of the executive officers and directors set forth in the table is c/o the Company, 2424 North Federal Highway, Suite 208, Boca Raton, Florida 33431.
Number of | ||||||||
Names and addresses of | Shares | |||||||
beneficial owners | of common stock (1) | Percentage of class (%) | ||||||
Gerry David | 716,667 | (2) | 1.9 | |||||
John Fieldly | 370,833 | (2) | 1.0 | |||||
Nicholas Castaldo | 161,111 | (2) | * | |||||
Hal Kravitz | 0 | 0 | ||||||
Kevin Harrington | 161,111 | (2) | * | |||||
Christopher Lai | 0 | 0 | ||||||
Tim Leissner | 3,539,826 | 9.2 | ||||||
Thomas E. Lynch | 163,111 | (2) | * | |||||
William H. Milmoe | 19,842,434 | (3) | 51.7 | |||||
all officers and directors as a group (nine (9) persons) | 24,955,093 | (4) | 65.0 | |||||
Other 5% or greater shareholders: | ||||||||
Carl De Santis | 19,678,823 | (5) | 51.3 | |||||
3161 Jasmine Drive Delray Beach, Florida 33483 |
||||||||
Li Ka Shing | 6,910,113 | (6) | 18.0 | |||||
7/F Cheung Kong Center 2 Queen’s Road Central Hong Kong |
||||||||
Solina Chau Hoi Shuen | 4,842,697 | (7) | 12.5 | |||||
House 4 2 Island Road, Hong Kong. |
* Less than 1%
The persons named above have full voting and investment power with respect to the shares indicated. Under the rules of the SEC, a person (or group of persons) is deemed to be a “ beneficial owner ” of a security if he or she, directly or indirectly, has or shares the power to vote or to direct the voting of such security, or the power to dispose of or to direct the disposition of such security. Accordingly, more than one person may be deemed to be a beneficial owner of the same security.
(1) Includes shares of our common stock that are issuable upon exercise of stock options or conversion of preferred stock as of the date of this registration statement or within sixty (60) days thereafter.
(2) Represents shares of common stock issuable upon the exercise of stock options.
(3) Represents (a) 500 shares of common stock held of record by Mr. Milmoe; (b) 163,111 shares of common stock issuable upon exercise of stock options; (c) 8,554,289 shares of common stock held of record by CDS Ventures, LLC (“ CDS Ventures ”); (d) 4,576,923 shares of common stock issuable upon conversion of Preferred C Shares held of record by CDS Ventures; (e)1,896,448 shares of common stock held of record by CD Financial, LLC (“ CD Financial ”); and (f) 4,651,163 shares of common stock issuable upon conversion of Preferred D Shares held of record by CD Financial. Mr. Milmoe and Carl DeSantis share voting power with respect to shares of common stock beneficially owned by CDS Ventures and CD Financial. Mr. Milmoe does not have dispositive power with respect to such shares.
18 |
(4) Includes (a) the shares of common stock issuable upon the exercise of stock options held and the conversion of preferred stock beneficially owned by Mr. Milmoe as set forth in footnote (3) above; and (b) 1,735,944 shares of common stock issuable upon the exercise of stock options held by the Company’s other officers and directors.
(5) Represents (a) 8,554,289 shares of common stock held of record by CDS Ventures; (b) 4,576,923 shares of common stock issuable upon conversion of Preferred C Shares held of record by CDS Ventures; (c) 1,896,448 shares of common stock held of record by CD Financial; and (d) 4,651,163 shares of common stock issuable upon conversion of Preferred D Shares held of record by CD Financial. Voting power of shares of common stock beneficially owned by CDS Ventures and CD Financial is shared by Mr. DeSantis and William H. Milmoe. Mr. De Santis has sole dispositive power with respect to such shares
(6) Represents shares of common stock held of record by Charmnew Limited, over which shares Mr. Li has voting and dispositive power.
(7) Represents shares of common stock held of record by Grieg International Limited and Oscar Time Limited, over which shares Ms. Chau has voting and dispositive power
Item 5. | Directors and Executive Officers |
The following sets forth the name of each of our officers and, directors and control persons and their positions with Celsius. The address for each of such individuals is c/o Celsius, 2424 N Federal Highway, Boca Raton, Florida 33431.
Name | Age | Position with the Company | ||
Gerry David | 64 | Chief Executive Officer | ||
John Fieldly | 36 | Chief Financial Officer | ||
Nicholas Castaldo | 65 | Director | ||
Hal Kravitz | 59 | Director | ||
Kevin Harrington | 60 | Director | ||
Chris Lai | 29 | Director | ||
Tim Leissner | 47 | Director | ||
Thomas E. Lynch | 69 | Director | ||
William H. Milmoe | 68 | Director |
Gerry David joined Celsius in October 2011 as its Chief Executive Officer and has served in that position since that time. Prior to joining the Company, Mr. David served as Executive Vice President of Oragenics, Inc., a publicly held pharmaceutical development company based in Tampa, Florida, from September 2008 until October 2011.
John Fieldly joined Celsius in January 2012 as its Chief Financial Officer and has served in that position since that time. Mr. Fieldly joined the Company from Oragenics, Inc., where he served as corporate controller from April 2010 until January 2012.
Nicholas Castaldo became a director of Celsius in March 2013. Since September 2004 he has served as Senior Vice President and Chief Marketing Officer of Anthony’s Coal Fired Pizza, Inc., a Florida based chain of casual dining restaurants.
19 |
Hal Kravitz became a director of Celsius in April 2016. Since November 2014, Mr. Kravitz has served as Chief Executive Officer of AQUAhydrate, Inc., a company engaged in the manufacture, distribution and marketing of bottled water. He also served as a consultant to AQUAhydrate from August to November 2014 and in 2013, Mr. Kravitz helped form InterContinental Beverage Capital, a New York-based merchant bank focused on investments in the beverage industry. For over thirty (30) years prior thereto, Mr. Kravitz served as an executive officer and in other management positions in various units of the Coca-Cola system
Kevin Harrington joined Celsius’ board of directors in March 2013. He has almost forty (40) years experience in product introduction and direct marketing, being one of the first to market products through infomercials. Since 2005, he has been Chief Executive Officer of Harrington Business Development, Inc., a privately-held consulting firm. A serial entrepreneur, Mr. Harrington appeared as one of the original panelists on the ABC television program, “ Shark Tank .” He currently also serves as Chairman of the Board of As Seen On TV, Inc., a public company which focuses on marketing products through infomercials and other direct marketing.
Chris Lai joined our board of directors in April 2015. Since September 2012, he has served as a Project Manager for Horizon Ventures, Limited (“ Horizon Ventures ”), a Hong Kong based private investment fund. From April 2011 to September 2012, Mr. Lai was an analyst with Mooreland Partners, LLC, another private investment concern. Mr. Lai serves on the Board as one of two designees of an investor group led by Horizon Ventures (the “ Investors ”), pursuant to an Investors’ Rights Agreement entered into in April 2015 (the “ Investors’ Rights Agreement ”) by among the Company, the Investors, CD Financial and CDS Ventures, both of which are affiliates of Carl De Santis, one of our principal shareholders. The terms of April 2015 investment by the Investors and related transactions with CD Financial and CDS Ventures, as well as the terms of the Investors’ Rights Agreement and other related agreements entered into in connection with those transactions are more fully set forth in Item 10 of this registration statement.
Tim Leissner joined Celsius’ board of directors in April 2016 as the second designee of the Investors pursuant to the Investors’ Rights agreement. From December 2002 to February 2016, Mr. Leissner was a partner at Goldman Sachs, Inc. Since that time, he has been acting a private investor and business consultant. Mr. Leissner serves as a member of the board of directors of All Def Digital, Inc. (“ All Def Digital ”).
Thomas E. Lynch became a director of the Company in November, 2009. For over forty (40) years, Mr. Lynch has served as President of the Plastridge Agency, Inc., a five-office insurance agency based in Delray Beach, Florida, which traces its origins to 1919. He also serves as a director of First United Bancorp, Inc.
William H. Milmoe has served as a director of Celsius since August. 2008. Since June 2000, Mr. Milmoe has served as President of CDS International Holdings, Inc., a privately-held holding company based in Boca Raton, Florida, which oversees the business investments and holdings of Carl De Santis, one of our principal shareholders.
Terms of Directors and Executive Officers
Our directors are appointed for a one-year term to hold office until the next annual meeting of our shareholders and until their successors are appointed and qualified, or until their removal, resignation, or death. Pursuant to the Investors’ Rights Agreement, the number of directors is set at seven (7) and the Investors have the right to appoint two (2) designees to the board of directors. Officers of the Company serve at the pleasure of the board of directors.
Family Relationships
There are no familial relationships among our officers and directors.
Board Committees and Independence
Our board of directors has established three standing committees, an audit committee, a compensation committee and a nominating and corporate governance committee. The audit committee currently consists of Messrs. Lynch, Kravitz and Milmoe, the compensation committee currently consists of Messrs. Lai, Castaldo and Harrington and the nominating and corporate governance committee currently consists of Messrs. Milmoe, Leissner and Lai. Our board of directors has determined that each of our directors is “ independent ” within the meaning of the applicable rules and regulations of the SEC and the listing standards of the Nasdaq Stock Market.
20 |
In addition, we believe each of Messrs. Lynch, Kravitz, and Milmoe qualifies an “ audit committee financial expert ” as the term is defined by the applicable rules and regulations of the SEC and the Nasdaq Stock Market listing standards, based on their respective business professional experience in the financial and accounting fields. At the time of the listing of our common stock on the Nasdaq Stock Market, we will be required to certify to the Nasdaq Stock Market, that our audit committee has, and will continue to have, at least one member who has past employment experience in finance or accounting, requisite professional certification in accounting, or other comparable experience or background that results in the individual’s financial sophistication.
Audit Committee
The audit committee assists our board of directors in its oversight of the company’s accounting and financial reporting processes and the audits of the company’s financial statements, including (i) the quality and integrity of the company’s financial statements, (ii) the company’s compliance with legal and regulatory requirements, (iii) the independent auditors’ qualifications and independence and (iv) the performance of our company’s internal audit functions and independent auditors, as well as other matters which may come before it as directed by the board of directors. Further, the audit committee, to the extent it deems necessary or appropriate, among its several other responsibilities, shall:
` | • | be responsible for the appointment, compensation, retention, termination and oversight of the work of any independent auditor engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for our company; |
• | discuss the annual audited financial statements and the quarterly unaudited financial statements with management and the independent auditor prior to their filing with the Securities and Exchange Commission in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q; |
• | review with the company’s financial management on a period basis (a) issues regarding accounting principles and financial statement presentations, including any significant changes in our company’s selection or application of accounting principles, and (b) the effect of any regulatory and accounting initiatives, as well as off-balance sheet structures, on the financial statements of our company; |
• | monitor our Company’s policies for compliance with federal, state, local and foreign laws and regulations and our company’s policies on corporate conduct; |
• | maintain open, continuing and direct communication between the board of directors, the audit committee and our independent auditors; and |
• | monitor our compliance with legal and regulatory requirements and shall have the authority to initiate any special investigations of conflicts of interest, and compliance with federal, state and local laws and regulations, including the Foreign Corrupt Practices Act, as may be warranted. |
Mr. Lynch is the chairman of our audit committee.
Compensation Committee
The compensation committee aids our board of directors in meeting its responsibilities relating to the compensation of our company’s executive officers and to administer all incentive compensation plans and equity-based plans of the company, including the plans under which company securities may be acquired by directors, executive officers, employees and consultants. Further, the compensation committee, to the extent it deems necessary or appropriate, among its several other responsibilities, shall:
• | review periodically our company’s philosophy regarding executive compensation to (i) ensure the attraction and retention of corporate officers; (ii) ensure the motivation of corporate officers to achieve our company’s business objectives, and (iii) align the interests of key management with the long-term interests of our company’s shareholders; |
21 |
• | review and approve corporate goals and objectives relating to Chief Executive Officer compensation and other executive officers of Celsius; |
• | make recommendations to the board of directors regarding compensation for non-employee directors, and review periodically non-employee director compensation in relation to other comparable companies and in light of such factors as the compensation committee may deem appropriate; and |
• | review periodically reports from management regarding funding our company’s pension, retirement, long-term disability and other management welfare and benefit plans. |
Mr. Lai is the chairman of our compensation committee.
Nominating and Corporate Governance Committee
The nominating and corporate governance committee recommends to the board of directors individuals qualified to serve as directors and on committees of the board of directors to advise the board of directors with respect to the board of directors composition, procedures and committees to develop and recommend to the board of directors a set of corporate governance principles applicable to the Company; and to oversee the evaluation of the board of directors and Celsius’ management.
Further, the nominating and corporate governance committee, to the extent it deems necessary or appropriate, among its several other responsibilities shall:
• | recommend to the board of directors and for approval by a majority of independent directors for election by shareholders or appointment by the board of directors as the case may be, pursuant to our bylaws and consistent with the board of director’s evidence for selecting new directors; |
• | review the suitability for continued service as a director of each member of the board of directors when his or her term expires or when he or she has a significant change in status; |
• | review annually the composition of the board of directors and to review periodically the size of the board of directors; |
• | make recommendations on the frequency and structure of board of directors meetings or any other aspect of procedures of the board of directors; |
• | make recommendations regarding the chairmanship and composition of standing committees and monitor their functions; |
• | review annually committee assignments and chairmanships; |
• | recommend the establishment of special committees as may be necessary or desirable from time to time; and |
• | develop and review periodically corporate governance procedures and consider any other corporate governance issue. |
Messrs. Milmoe and Leissner are the co-chairman of our nominating and corporate governance committee.
Code of Ethics
We have adopted a code of ethics that applies to all of our executive officers, directors and employees. The code of ethics codifies the business and ethical principles that govern all aspects of our business. This document will be made available in print, free of charge, to any shareholder requesting a copy in writing from our Secretary at our executive offices in Boca Raton, Florida. A copy of our code of ethics is available on our website at www.celsius.com .
22 |
Board of Directors Role in Risk Oversight
Members of the board of directors have periodic meetings with management and the Company’s independent auditors to perform risk oversight with respect to the Company’s internal control processes. The Company believes that the board’s role in risk oversight does not materially affect the leadership structure of the Company .
Item 6. | Executive Compensation |
Summary Compensation Table
The following table sets forth certain information concerning the compensation paid to our Chief Executive Officer, and Chief Financial Officer, who are our two executive officers, during the years ended December 31, 2015 and 2014.
Stock | ||||||||||||||||||||||||
Name and Principal Position | Year | Salary ($) | Bonus ($) | Awards (#) | Other ($) | Total ($) | ||||||||||||||||||
Gerry David, CEO | 2015 | 230,850 | 45,825 | 90,000 | (1) | 10,200 | (2) | 286,875 | ||||||||||||||||
2014 | 225,000 | 56,025 | 100,000 | (1) | 20,400 | (2) | 301,425 | |||||||||||||||||
John Fieldly, CFO | 2015 | 169,290 | 31,230 | 90,000 | (1) | 3,150 | (2) | 203,670 | ||||||||||||||||
2014 | 165,000 | 36,630 | 100,000 | (1) | 10,800 | (2) | 212,430 |
(1) Represents stock options granted under our 2006 Stock Incentive Plan to purchase 90,000 shares of common stock at an exercise price of $1.05 per share and stock options granted to purchase 100,000 shares of common stock at an exercise price of $0.34 per share. The options vest in three annual installments commencing one year from the date of grant, subject to continued employment and expire ten (10) years from the date of grant.
(2) Represents housing allowances.
In addition, Messrs. David and Fieldly are entitled to participate in benefit plans maintained for employees of the Company generally.
Employment Agreements
Effective January 1, 2016, we entered into one-year employment agreements with each of Gerry David and John Fieldly, our Chief Executive Officer and Chief Financial Officer, respectively. The employment agreements provide for base annual salaries of $237,780 and $174,370 for Messrs. David and Fieldly, respectively, eligibility for performance-based incentive bonuses, pursuant to such criteria as may be established by our compensation committee, the grant of options to each executive officer to purchase 100,000 shares of our common stock and certain automobile and housing allowances. The employment agreements also provide for (a)severance payments equal to (i) two months salary in the event of termination upon death of the executive officer; and (ii) six months’ salary and continued benefits for such period in the event of termination other than for “ cause ” (as defined therein); and (b) a “ golden parachute ” payment in an amount equal to twice the executive officer’s then base salary in the event of termination without “ cause ” following a “ change in control ” (as defined therein). The employment agreements contain customary confidentiality and non-competition provisions.
23 |
Compensation of Directors Table
The following table summarizes all compensation paid to our directors for the fiscal year ended December 31, 2015.
Fees | ||||||||||||||||||||||||||||
Earned | Non-Qualified | |||||||||||||||||||||||||||
or | Non-Equity | Deferred | All | |||||||||||||||||||||||||
Paid in | Stock | Option | Plan | Compensation | Other | |||||||||||||||||||||||
Cash | Awards | Awards | Compensation | Earnings | Compensation | Total | ||||||||||||||||||||||
Name | ($) | ($) | (#) (1) | ($) | ($) | ($) | ($) | |||||||||||||||||||||
Nicholas Castaldo | 12,000 | — | 40,000 | — | — | — | 12,000 | |||||||||||||||||||||
Kathleen M. Dwyer (2) | 12,000 | — | 40,000 | — | — | — | 12,000 | |||||||||||||||||||||
Kevin Harrington | 12,000 | — | 40,000 | — | — | — | 12,000 | |||||||||||||||||||||
Thomas E. Lynch | 12,000 | — | 40,000 | — | — | — | 12,000 | |||||||||||||||||||||
William H. Milmoe | 12,000 | — | 40,000 | — | — | — | 12,000 | |||||||||||||||||||||
Timothy Leissner | 9,000 | — | — | — | — | — | 9,000 | |||||||||||||||||||||
Chris Lai | — | — | — | — | — | — | — |
(1) | Represents options to purchase 40,000 shares of common stock at an exercise price of $1.05 per share granted under the 2006 Plan. |
(2) | Ms. Dwyer did not stand for reelection at the expiration of her term in April 2016. |
Narrative Disclosure to the Director Compensation Table
Our non-employee directors will be compensated with options to purchase common stock or awards of common stock as determined by the Compensation Committee. Non-employee directors are also reimbursed for out-of-pocket costs incurred in connection with attending meetings.
Outstanding Equity Awards at Fiscal Year-End
The following table sets forth information with respect to stock awards and grants of options to purchase our common stock outstanding to the named executive officers at December 31, 2015.
Number of securities
underlying unexercised |
Number of securities underlying | Weighted average | ||||||||||||||||
Options (#) (1) | unexercised unearned options | option exercise price | Option expiration | |||||||||||||||
Name | Exercisable | Unexercisable | (#) (1) | ($) (1) | date | |||||||||||||
Gerry David CEO | 716,667 | 73,333 | 73,333 | $ | 0.35 | 2021-2025 | ||||||||||||
John Fieldly CFO | 370,833 | 69,167 | 69,167 | $ | 0.44 | 2022-2025 |
(1) | Represents grants under our Amended 2006 Stock Incentive Plan. |
24 |
Amended 2006 Incentive Stock Plan
In January 2007, we adopted our 2006 Incentive Stock Plan, which was amended in July 2009 (as amended, the “ 2006 Plan ”). The 2006 Plan provided for equity incentives to be granted to our employees, officers or directors or to key advisers or consultants. Equity incentives may be in the form of stock options with an exercise price not less than the fair market value of the underlying shares as determined pursuant to the 2006 Plan, stock appreciation rights, restricted stock awards, stock bonus awards, other stock-based awards, or any combination of the foregoing. The 2006 Plan is administered by the compensation committee of the board of directors. Options to purchase 4,634,166 shares of common stock are outstanding under the 2006 Plan as of the date of this registration statement and awards covering up to an additional 321,275 shares may be granted under the 2006 Plan prior to its expiration in January 2017.
2015 Incentive Stock Plan
Our 2015 Incentive Stock Plan (the “ 2015 Plan ”), adopted in April 2015, provides for equity incentives to be granted to our employees, executive officers or directors or to key advisers or consultants. Equity incentives may be in the form of stock options with an exercise price not less than the fair market value of the underlying shares as determined pursuant to the 2015 Plan, restricted stock awards, other stock based awards, or any combination of the foregoing. The 2015 Plan is administered by the compensation committee of the board of directors. 5,000,000 shares of our common stock are reserved for issuance pursuant to the exercise of awards under the 2015 Plan. The number of shares so reserved automatically adjusts upward on January 1 of each year, so that the number of shares covered by the 2015 Plan is equal to 15% of our issued and outstanding common stock. Stock options to purchase an aggregate of 908,500 shares of our common stock are outstanding under the 2015 Plan as of the date of this registration statement.
Compensation Committee Interlocks and Insider Participation
None.
Item 7. | Certain Relationships and Related Transactions, and Director Independence |
Lease of Executive Offices
The Company’s executive offices located at 2424 N Federal Highway, Boca Raton, Florida 33431 are leased from a company affiliated with CD Financial. The lease expires in October 2020 and provides for monthly rent of $6,408. We believe that the monthly rent is commensurate with other properties available in the market.
Marketing and Advisory Services Agreement with All Def Digital
In April 2015, the Company entered into a strategic marketing and advisory services agreement (the “ Advisory Services Agreement ”) with All Def Digital. Tim Leissner, a director of the Company is also a director of All Def Digital. The Company has paid All Def Digital $152,437 and $237,959 for services rendered pursuant to the Advisory Services Agreement during the six months ended June 30, 2016 and the year ended December 31, 2015, respectively.
April 2015 Transactions with CD Financial, CDS Ventures and other Related Persons
See “ Item 10. Recent Sales of Unregistered Securities ” with respect to the April 2015 investment by the Investors and related transactions with CD Financial and CDS Ventures.
The following sets forth the name and approximate dollar value of the investment made by each related person in connection with the April 2015 common stock purchase transactions more fully described in Item 10 :
Name | Investment Amount | |
Li Ka Shing | $6,150,000 (invested through Charmnew Limited) | |
Solina Chau Hoi Shuen | $4,310,000 (invested through Grieg International Limited and Oscar Time Limited) | |
Tim Leissner | $3,150,000 (invested through Nu Horizons Investment Group, LLC) |
Investors’ Rights Agreement
At closing of the April 2015 investment and related transactions described in “ Item 10. Recent Sales of Unregistered Securities ,” Celsius, the Investors, CDS Ventures and CD Financial entered into the Investors’ Rights Agreement, pursuant to which, among matters, our board of directors was expanded to seven (7), two of whom shall be designated by the Investors, the shareholder parties were accorded certain registration rights for their respective shares of our common stock or underlying shares of common stock, as the case may be, under the Securities Act and the shareholder parties were granted certain participation rights as to future offerings of securities by Celsius.
Pursuant to the Investor’s Rights Agreement the following matters require investor director approval: (i) liquidation, dissolution or winding-up of the business and affairs of the Company or effecting any change of control; (ii) amending the Articles of Incorporation or Bylaws of the Company in a manner that adversely affects Investor rights; (iii) purchasing or redeeming, or paying or declaring any dividend or making any distribution on, certain shares of capital stock of the Company; (iv) authorization or issuance of any debt security creating indebtedness that would exceed $1,000,000; (v) changing the authorized number of members of the board of directors; (vi) entering into or materially amending certain distribution or other commercialization agreements for the Company’s products; (vii) making any loan or advance to, or owning any stock or other securities of, any subsidiary or other entity unless it is wholly owned by the Company; (viii) making any loan or advance to any person, except advances in the ordinary course of business or under the terms of an employee stock or option plan approved by the board of directors; (ix) guarantee, directly or indirectly, any indebtedness except for indebtedness of the Company or any subsidiary; (x) certain transactions with any director, officer, or employee of the Company or their associates; (xi) hiring, terminating, or certain changes to the compensation of the executive officers; (xii) materially changing the principal business of the Company; (xiii) the sale, assignment, license, pledge, or encumbering of material technology or intellectual property, other than licenses granted in the ordinary course of business; and (xiv) entering into any corporate strategic relationship involving money or assets greater than $1,000,000.
In addition to CDS Ventures and CD Financial, the following related persons are party to the Investors’ Rights Agreement: (i) Charmnew Limited (an affiliate of Li Ka Shing); (ii) Grieg International Limited (an affiliate of Solina Chau Hoi Shuen); and (iii) Nu Horizons Investment Group, LLC (an affiliate of Tim Leissner).
Loan and Security Agreement with CD Financial
We originally entered into a loan and security agreement with CD Financial in July 2010, which provided us with a line of credit to fund operations. The original line of credit was up to $3,000,000 and it was subsequently increased to $9,800,000. The loan and security agreement was then amended in connection with the April 2015 investment and related transactions described in “ Item 10. Recent Sales of Unregistered Securities .”
Pursuant to the amendment, contemporaneously with the closing of the April 2015 investment transactions, the Company repaid $300,000 to CD Financial and converted $4,000,000 of the outstanding principal balance of the line of credit into shares of Series D Convertible Preferred Stock. As amended, the loan and security agreement now provides Celsius with a revolving line of credit pursuant to which Celsius can borrow up to an aggregate maximum of $4.5 million from time to time until maturity in January 2020. The credit facility requires quarterly cash payments of interest only at the rate of five percent (5%) of the outstanding balance per annum until maturity and is secured by a pledge of substantially all the Company’s assets. As of June 30, 2016, the principal amount outstanding under the credit facility with CD Financial was $4.5 million. Cash interest payments to CD Financial pursuant to the credit facility were $113,750 and $220,042 during the six months ended June 30, 2016 and the year ended December 31, 2016, respectively. Cash interest payments to CD Financial pursuant to the credit facility were $257,851 and $403,888 during the years ended December 31, 2013 and December 31, 2014, respectively.
Approval of Related Party Transactions
All related party transactions are subject to the review, approval or ratification of our board of directors or an appropriate committee thereof.
Item 8. | Legal Proceedings |
From time to time, we may become party to litigation or other legal proceedings that we consider to be a part of the ordinary course of our business. We are not currently involved in any legal proceedings that could reasonably be expected to have a material adverse effect on our business, prospects, financial condition or results of operations. We may become involved in material legal proceedings in the future.
25 |
Item 9. | Market Price of and Dividends on the Registrant’s Common Equity and Related Stockholder Matters |
Since January 11, 2016, our common stock has been on the OTCQX tier of the over-the-counter market maintained by OTC Markets Group, Inc., under the trading ticker “CELH.” Prior thereto, our common stock was quoted on the OTCPink tier of the over-the counter market maintained by OTC Markets Group, Inc. The trading price of our common stock has been volatile at times. Further, the stock market has from time to time experienced extreme volatility that has often been unrelated to the operating performance of particular companies. These kinds of broad market fluctuations may adversely affect the market price of our common stock. For additional information, see “ Item 1A. Risk Factors ” above.
The following table sets forth the quarterly high and low sale prices of our common stock for the two most recent fiscal years, as reported on the OTC Markets Group, Inc. quotation system:
High Sale | Low Sale | |||||||
Fiscal Quarters | Price | Price | ||||||
2016 | ||||||||
Second Quarter 2016 | $ | 2.54 | $ | 2.13 | ||||
First Quarter 2016 | $ | 2.40 | $ | 1.56 | ||||
2015 | ||||||||
Fourth Quarter 2015 | $ | 2.48 | $ | 1.49 | ||||
Third Quarter 2015 | $ | 2.83 | $ | 1.71 | ||||
Second Quarter 2015 | $ | 3.55 | $ | 1.25 | ||||
First Quarter 2015 | $ | 1.25 | $ | 0.44 | ||||
2014 | ||||||||
Fourth Quarter 2014 | $ | 0.61 | $ | 0.35 | ||||
Third Quarter 2014 | $ | 0.77 | $ | 0.44 | ||||
Second Quarter 2014 | $ | 0.94 | $ | 0.51 | ||||
First Quarter 2014 | $ | 1.20 | $ | 0.33 |
Holders
As of August 22, 2016, there were 52 holders of record of our common stock and in excess of 5,000 beneficial owners of our common stock.
Dividends
We have never declared or paid cash dividends on our common stock. We anticipate that in the future we will retain any earnings for operation of our business. Accordingly, we do not anticipate declaring or paying any cash dividends in the foreseeable future.
Options, Warrants and Convertible Securities
As of the date of this report, there were:
· 4,412,775 shares of our common stock reserved for issuance upon exercise of outstanding options granted under the 2006 Plan and the 2015 Plan; and
26 |
· 9,228,086 shares of our common stock reserved for issuance upon conversion of our outstanding convertible preferred stock.
Securities Authorized for Issuance under Equity Compensation Plans
Plan category |
Number of securities to
be issued upon exercise of outstanding options, warrants and rights |
Weighted-average
exercise price of outstanding options, warrants and rights |
Number of securities
remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
||||||
Equity compensation plans approved by security holders | 5,542,666 shares | (1) | $ | 1.00 | 4,412,775 shares | (1) | |||
Equity Compensation plans not approved by security holders | 0 shares | n/a | 0 shares | ||||||
Total | 5,542,666 shares | (1) | None issued | 4,412,775 shares | (1) |
(1) | Represents shares of common stock reserved for issuance under the 2005 Plan and the 2015 Plan. |
Item 10. | Recent Sales of Unregistered Securities |
April 2015 Transactions:
· | On April 20, 2015, the Company entered into a common stock purchase agreement (the “ 2015 Purchase Agreement ”) with the Investors, pursuant to which the Company sold 12,921,348 shares of its common stock on a private placement basis (the “ Private Placement Shares ”) to the Investors for an aggregate consideration of $11,388,159, net of expenses. Certain of the Investors contemporaneously acquired an additional 5,000,000 shares of our common stock (the “ Conversion Shares ”) by purchasing an outstanding $1.5 million convertible note held by CDS Ventures (the “ CDS Note ”) and immediately converting the CDS Note into the Conversion Shares. In connection with the issuance of the Private Placement Shares and the Conversion Shares, Celsius relied upon the exemptions from registration afforded by Sections 4(a)(2) and 3(a)(9) of the Securities Act, respectively. The Private Placement Shares and the Conversion Shares are “ restricted securities ” of the Company. The certificates evidencing the Private Placement Shares and the Conversion Shares bear a legend (a) stating that the shares have not been registered under the Securities Act and applicable state securities laws; and (b) setting forth and referring to the restrictions on transferability and sale of the shares under the Securities Act and applicable state securities laws. |
· | We currently have shares of Series C Preferred Stock (the “ Preferred C Shares ”) and shares of Series D Preferred Stock (the “ Preferred D Shares ”) outstanding. On April 16, 2015, contemporaneously with the transactions with the Investors, the Company entered into an amendment to its existing loan and security agreement (the “ Amendment ”) with CD Financial. Pursuant to the Amendment, the outstanding principal amount of the line of credit with CD Financial was reduced by $4.0 million, which amount was converted into 4,000 Preferred D Shares. Contemporaneously with the issuance of the Preferred D Shares, $180,000 of accrued but unpaid dividends on outstanding Preferred C Shares was paid through the issuance of an additional 180 Preferred C Shares (the “ Additional Preferred C Shares ”). In connection with the issuance of the Preferred D Shares and the Additional Preferred C Shares, Celsius relied upon the exemption from afforded by Section 4(a)(2) of the Securities Act. The Preferred D Shares and the Additional Preferred C Shares issued by Celsius are “ restricted securities ” of the Company. The certificates evidencing the Preferred D Shares and the Additional Preferred C Shares issued by Celsius bear a legend (i) stating that the shares have not been registered under the Securities Act and applicable state securities laws, and (ii) setting forth and referring to the restrictions on transferability and sale of the shares under the Securities Act and applicable state securities laws. |
27 |
· | At closing of the April 20, 2015 transactions, Celsius, the Investors, CDS Ventures and CD Financial into the Investors’ Rights Agreement, pursuant to which, among matters, our board of directors was expanded to seven (7), two of whom shall be designated by the Investors, the shareholder parties were accorded certain registration rights for their respective shares of our common stock or underlying shares of common stock, as the case may be, under the Securities Act and the shareholder parties were granted certain participation rights as to future offerings of securities by Celsius. In order to effect the transactions, Celsius’ Amended and Restated Articles of Incorporation were amended as authorized by our board of directors, which amendment increased required), to increase the number of authorized shares of the which amendment increased the number of authorized shares of common stock from 50,000,000 to 75,000,000, increased the number of authorized Preferred C Shares from 2,200 to 3,000 and designated the newly created Preferred D Shares. |
Other Issuances of Common Stock
During 2014, the Company issued a total of 280,000 “ restricted ” shares of its common stock as compensation pursuant to celebrity endorsement agreements at an aggregate fair value of $216,100, 250,000 shares were issued at $0.79 per share on March 11, 2014 and 30,000 shares were issued at $0.62 per share on August 13, 2014 with each per share valuation representing the closing stock price on the day of issuance.
On April 12, 2016, the Company issued a total 250,000 “ restricted ” shares of its common stock as compensation pursuant to celebrity endorsement agreements at a fair value of $560,000, or $2.24 per share representing, the closing stock price on that date.
Item 11. | Description of Registrant’s Securities to be Registered |
Capital Stock
Our authorized capital stock consists of 75,000,000 shares of common stock, par value $0.001 per share and 2,500,000 shares of preferred stock, par value $0.001 per share. Our shares of common stock are the securities covered by this registration statement.
Common Stock
As of the date of this report, we have 38,666,451 shares of our common stock issued and outstanding. All shares of our common stock that are presently issued and outstanding are fully paid and non-assessable. Holders of our common stock are entitled to one vote for each share on all matters submitted to a shareholder vote. Holders of common stock do not have cumulative voting rights. Therefore, holders of a majority of the shares of common stock, voting together with holders of our Preferred C Shares and Preferred D Shares as a single class, can elect all of the directors. Holders of our capital stock representing a majority of the voting power of our capital stock entitled to vote, represented in person or by proxy, are necessary to constitute a quorum at any meeting of our shareholders. A vote by the holders of a majority of our outstanding capital stock entitled to vote is required to effectuate certain fundamental corporate changes such as liquidation, merger or an amendment to our Articles of Incorporation.
Holders of common stock are entitled to share in all dividends that our board of directors, in its discretion, declares from legally available funds, subject to preferences granted to shares of preferred stock. In the event of liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock, including shares of preferred stock. Holders of our common stock have no pre-emptive rights, no conversion rights and there are no redemption provisions applicable to our common stock.
28 |
Preferred Stock
General
Our board of directors has the authority, without further action by the shareholders, to issue such shares of preferred stock in one or more series and to fix the rights, preferences and the number of shares constituting any series or the designation of such series. While our Articles and bylaws do not contain any provisions that may delay, defer or prevent a change in control, the issuance of preferred stock may have the effect of delaying or preventing a change in control or make removal of our management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of the common stock and may adversely affect the voting and other rights of the holders of common stock. We currently have 3,000 shares of preferred stock designated as Preferred C Shares designated, of which 2,380 Preferred C Shares are issued and outstanding and 4,000 shares of preferred stock designated as Preferred D Shares, all of which are issued and outstanding.
Preferred C Shares
The Preferred C Shares are convertible into our common stock at the option of the holder thereof at a conversion price of $0.52 per share at any time until December 31, 2018, at which time they will automatically convert into shares of our common stock determined by dividing the liquidation preference of $1,000 per Preferred C Share by the conversion price then in effect. The conversion price is subject to adjustment in the event of stock dividends, stock splits and similar events. The Preferred C Shares accrue cumulative annual dividends at the rate of 6% per annum, payable by the issuance of additional Preferred C Shares. The holder of Preferred C Shares votes on an “as converted” basis, together with holders of common stock as a single class on all matters presented to shareholders for a vote, except as required by law.
Preferred D Shares
The Preferred D Shares are convertible into our common stock at the option of the holder thereof at a conversion price of $0.86 per share until the earlier of the January 2, 2020 due date of our line of credit with CD Financial or such earlier date as the line of credit is satisfied (the “ Mandatory Redemption Date ”). The conversion price is subject to adjustment in the event of stock dividends, stock splits and similar events. The Preferred D Shares accrue cumulative annual cash dividends at the rate of 5% per annum, payable quarterly in cash and have a liquidation preference of $1,000 per share. On the Mandatory Redemption Date, the Preferred D Shares automatically convert into shares of our common stock in a number determined by dividing the $1,000 per Preferred D Share liquidation preference plus any accrued but unpaid dividends, by the conversion price then in effect. The Preferred D Shares may also be redeemed by us at any time on or after December 31, 2016, at a redemption price equal to 104% of the liquidation preference. The holder of the Preferred D Shares votes on an “as converted” basis, together with holders of common stock as a single class on all matters presented to shareholders for a vote, except as required by law.
Item 12. | Indemnification of Directors and Officers |
Pursuant to our Articles of Incorporation and Bylaws, we may indemnify an officer or director who is made a party to any proceeding, including a lawsuit, because of his or her position, if he or she acted in good faith and in a manner he or she reasonably believed to be in our best interest. In certain cases, we may advance expenses incurred in defending any such proceeding. To the extent that the officer or director is successful on the merits in any such proceeding as to which such person is to be indemnified, we must indemnify him or her against all expenses incurred, including attorney's fees. With respect to a derivative action, indemnity may be made only for expenses actually and reasonably incurred in defending the proceeding, and if the officer or director is judged liable, only by a court order. The indemnification is intended to be to the fullest extent permitted by the laws of the State of Nevada.
29 |
Item 13. | Financial Statements and Supplementary Data |
The financial statements and supplementary data listed in “ Item 15 Financials Statements and Exhibits ” are included with this registration statement.
Item 14. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure |
None.
Item 15. | Financial Statements and Exhibits |
(a) | Financial Statements |
The following consolidated financial statements of the Company are included herewith:
(b)
Exhibit No. | Description | |
3.1 | Articles of Incorporation, as amended* | |
3.2 | Bylaws, as amended* | |
10.1 | Loan and Security Agreement with CD Financial, LLC, as amended* | |
10.2 | Investors’ Rights Agreement dated April 20, 2015* | |
10.3 | Amended 2006 Stock Incentive Plan* + | |
10.4 | 2015 Stock Incentive Plan* + | |
10.5 | Code of Ethics* | |
10.6 | Audit Committee Charter* | |
10.7 | Compensation Committee Charter* | |
10.8 | Nominating and Corporate Governance Committee Charter* | |
10.9 | Employment Agreement with Gerry David* + | |
10.10 | Employment Agreement with John Fieldly* + | |
10.11 | Common Stock Purchase Agreement dated April 20, 2015** | |
10.12 | Distribution Agreement with People’s Choice AB** | |
21.1 | Subsidiaries of Registrant* | |
23.1 | Consent of Independent Registered Public Accounting Firm** |
*Previously filed.
+ Management compensation plan or arrangement.
**Filed herewith.
30 |
SIGNATURES
Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: September 19, 2016 | CELSIUS HOLDINGS,, INC. | |
By: | /s/ Gerry David | |
Gerry David, Chief Executive Officer | ||
By: | /s/ John Fieldly | |
John Fieldly, Chief Financial Officer |
31 |
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
F- 1 |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Stockholders and Board of Directors
Celsius Holdings, Inc. and Subsidiaries
We have audited the accompanying consolidated balance sheets of Celsius Holdings, Inc. and Subsidiaries as of December 31, 2015 and 2014 and the related consolidated statements of operations, changes in stockholders’ equity (deficit), and cash flows for each of the two years ended in the period December 31, 2015. These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly we express no such opinion. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the consolidated financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall consolidated financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of Celsius Holdings, Inc. and Subsidiaries as of December 31, 2015 and 2014 and the results of their operations and their cash flows for each of the two years in the period ended December 31, 2015, in conformity with accounting principles generally accepted in the United States of America.
/s/ D’Arelli Pruzansky, P.A. | |
Certified Public Accountants |
Coconut Creek, Florida
March 24, 2016
F- 2 |
Celsius Holdings, Inc. and Subsidiaries
Consolidated Balance Sheets
December 31,
2015 |
December 31,
2014 |
|||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash | $ | 10,128,320 | $ | 349,072 | ||||
Accounts receivable, net | 2,127,060 | 2,612,191 | ||||||
Inventories, net | 2,322,904 | 1,686,935 | ||||||
Prepaid expenses and other current assets | 666,267 | 259,056 | ||||||
Total current assets | 15,244,551 | 4,907,254 | ||||||
Property and equipment, net | 21,319 | 43,950 | ||||||
Total Assets | $ | 15,265,870 | $ | 4,951,204 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
Current liabilities: | ||||||||
Accounts payable and accrued expenses | $ | 1,805,931 | $ | 828,049 | ||||
Accrued preferred dividend | 190,847 | 180,403 | ||||||
Deferred revenue and other current liabilities | 25,057 | 356,602 | ||||||
Total current liabilities | 2,021,835 | 1,365,054 | ||||||
Long-term liabilities: | ||||||||
Convertible note payable - related party | - | 1,500,000 | ||||||
Line of credit note payable-related party | 4,500,000 | 9,250,000 | ||||||
Total Liabilities | 6,521,835 | 12,115,054 | ||||||
Stockholders’ Equity (Deficit): | ||||||||
Preferred Stock, $0.001 par value; 2,500,000 shares authorized, 6,380 and 2,200 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively | 6 | 2 | ||||||
Common stock, $0.001 par value; 75,000,000 shares authorized, 38,380,380 and 20,459,032 shares issued and outstanding at December 31, 2015 and December 31, 2014, respectively | 38,380 | 20,459 | ||||||
Additional paid-in capital | 58,626,212 | 40,165,955 | ||||||
Accumulated deficit | (49,920,563 | ) | (47,350,266 | ) | ||||
Total Stockholders’ Equity (Deficit) | 8,744,035 | (7,163,850 | ) | |||||
Total Liabilities and Stockholders’ Equity (Deficit) | $ | 15,265,870 | $ | 4,951,204 |
The accompanying notes are an integral part of these consolidated financial statements
F- 3 |
Celsius Holdings, Inc. and Subsidiaries
Consolidated Statements of Operations
For the year | ||||||||
ended December 31, | ||||||||
2015 | 2014 | |||||||
Revenue | $ | 17,217,944 | $ | 14,610,090 | ||||
Cost of revenue | 10,177,986 | 9,011,923 | ||||||
Gross profit | 7,039,958 | 5,598,167 | ||||||
Selling and marketing expenses | 5,701,845 | 4,823,014 | ||||||
General and administrative expenses | 3,165,573 | 2,305,086 | ||||||
Total operating expense | 8,867,418 | 7,128,100 | ||||||
Loss from operations | (1,827,460 | ) | (1,529,933 | ) | ||||
Other Income (Expense): | ||||||||
Interest expense | (322,344 | ) | (497,203 | ) | ||||
Total Other Income (Expense) | (322,344 | ) | (497,203 | ) | ||||
Net Loss | (2,149,804 | ) | (2,027,136 | ) | ||||
Preferred stock dividend - beneficial conversion feature | (139,535 | ) | ||||||
Preferred stock dividend - other | (280,958 | ) | (133,836 | ) | ||||
Net Loss available to common stockholders | $ | (2,570,297 | ) | $ | (2,160,972 | ) | ||
Weighted average shares outstanding | 33,175,826 | 20,392,594 | ||||||
Loss per share, basic and diluted | $ | (0.07 | ) | $ | (0.10 | ) |
The accompanying notes are an integral part of these consolidated financial statements
F- 4 |
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
For the Years Ended December 31, 2015 and 2014
Additional | ||||||||||||||||||||||||||||
Preferred Stock | Common Stock | Paid-In | Accumulated | |||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Capital | Deficit | Total | ||||||||||||||||||||||
Balance at December 31, 2013 | 2,200 | $ | 2 | 20,179,032 | $ | 20,179 | $ | 39,263,208 | (45,189,294 | ) | $ | (5,905,905 | ) | |||||||||||||||
Issuance of common stock in exchange of service | 280,000 | 280 | 215,820 | 216,100 | ||||||||||||||||||||||||
Stock option expense | 686,927 | 686,927 | ||||||||||||||||||||||||||
Preferred stock dividend | (133,836 | ) | (133,836 | ) | ||||||||||||||||||||||||
Net loss | (2,027,136 | ) | (2,027,136 | ) | ||||||||||||||||||||||||
Balance at December 31, 2014 | 2,200 | 2 | 20,459,032 | 20,459 | 40,165,955 | (47,350,266 | ) | (7,163,850 | ) | |||||||||||||||||||
Issuance of preferred stock in exchange of note | 4,000 | 4 | 3,999,996 | 4,000,000 | ||||||||||||||||||||||||
Issuance of preferred stock in exchange of accrued dividend | 180 | 0.18 | 180,000 | 180,000 | ||||||||||||||||||||||||
Issuance of common stock upon conversion of convertible note | 5,000,000 | 5,000 | 1,495,000 | 1,500,000 | ||||||||||||||||||||||||
Issuance of common stock pursuant to private placement | 12,921,348 | 12,921 | 11,375,238 | 11,388,159 | ||||||||||||||||||||||||
Stock option expense | 1,270,488 | 1,270,488 | ||||||||||||||||||||||||||
Preferred stock dividend - beneficial conversion feature | 139,535 | (139,535 | ) | - | ||||||||||||||||||||||||
Preferred stock dividend - other | (280,958 | ) | (280,958 | ) | ||||||||||||||||||||||||
Net loss | (2,149,804 | ) | (2,149,804 | ) | ||||||||||||||||||||||||
Balance at December 31, 2015 | 6,380 | $ | 6 | 38,380,380 | $ | 38,380 | $ | 58,626,212 | (49,920,563 | ) | $ | 8,744,035 |
The accompanying notes are an integral part of these consolidated financial statements
F- 5 |
Celsius Holdings, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
For the year ended | ||||||||
December 31,
2015 |
December 31,
2014 |
|||||||
Cash flows from operating activities: | ||||||||
Net Loss | $ | (2,149,804 | ) | $ | (2,027,136 | ) | ||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 33,043 | 37,256 | ||||||
Stock-based compensation expense | 1,270,488 | 903,027 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | 485,131 | (1,120,641 | ) | |||||
Inventory | (635,969 | ) | (865,664 | ) | ||||
Prepaid expenses and other current assets | (313,942 | ) | 258,338 | |||||
Accounts payable and accrued expenses | 1,168,400 | 121,828 | ||||||
Accrued preferred dividends | (280,958 | ) | (133,836 | ) | ||||
Deposits/deferred revenue and other current liabilities | (331,544 | ) | (92,389 | ) | ||||
Net cash used in operating activities | (755,155 | ) | (2,919,217 | ) | ||||
Cash flows from investing activities: | ||||||||
Purchase of property and equipment | (10,412 | ) | (12,493 | ) | ||||
Net cash (used in) investing activities | (10,412 | ) | (12,493 | ) | ||||
Cash flows from financing activities: | ||||||||
Borrowing under revolving note payable, related-party | 450,000 | 3,150,000 | ||||||
Repayment on short term notes payable, related-party | (1,200,000 | ) | - | |||||
Net proceeds from sale of common stock | 11,388,084 | - | ||||||
Payments on short term notes payable | (93,269 | ) | (91,124 | ) | ||||
Net cash provided by financing activities | 10,544,815 | 3,058,876 | ||||||
Net increase in cash and cash equivalents | 9,779,248 | 127,166 | ||||||
Cash and cash equivalents at beginning of the year | 349,072 | 221,906 | ||||||
Cash and cash equivalents at end of the year | $ | 10,128,320 | $ | 349,072 | ||||
Supplemental disclosures: | ||||||||
Cash paid during period for: | ||||||||
Interest | $ | 401,808 | $ | 460,589 | ||||
Taxes | $ | - | $ | - | ||||
Non-cash investing and financing activities: | ||||||||
Borrowing under short term notes payable for prepaid expense | $ | 93,269 | $ | 91,124 | ||||
Accrued preferred dividends | $ | 280,958 | $ | 133,836 | ||||
Preferred stock issued in exchange for cancellation of revolving note payable - related party | $ | 4,000,000 | $ | - | ||||
Conversion of convertible note to common shares - related party | $ | 1,500,000 | $ | - | ||||
Conversion of accrued preferred dividend into preferred shares - related party | $ | 180,000 | $ | - |
The accompanying notes are an integral part of these consolidated financial statements
F- 6 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
1. | ORGANIZATION AND DESCRIPTION OF BUSINESS |
Business —Celsius Holdings, Inc. (the “Company” or “Celsius Holdings”) was incorporated under the laws of the State of Nevada on April 26, 2005. On January 24, 2007, the Company entered into a merger agreement and plan of reorganization with Elite FX, Inc., a Florida corporation. Under the terms of the Merger Agreement, Elite FX, Inc. was merged into the Company’s subsidiary, Celsius, Inc. and became a wholly-owned subsidiary of the Company on January 26, 2007. In addition, on March 28, 2007 the Company established Celsius Netshipments, Inc. a Florida corporation as a wholly-owned subsidiary of the Company.
Since the merger, the Company is engaged in the development, marketing, sale and distribution of “functional” calorie-burning fitness beverages under the Celsius® brand name.
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).
Consolidation Policy — The accompanying consolidated financial statements include the accounts of Celsius Holdings, Inc. and its subsidiaries. All material inter-company balances and transactions have been eliminated in consolidation.
Significant Estimates — The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. Significant estimates include the allowance for doubtful accounts, reserves for inventory obsolescence, the useful lives and values of property, fixtures and equipment, valuation of stock based compensation, and deferred tax asset valuation allowance.
Segment Reporting — Although the Company has a number of operating divisions, separate segment data has not been presented, as they meet the criteria for aggregation as permitted by ASC Topic 280, Segment Reporting, (formerly Statement of Financial Accounting Standards (SFAS) No. 131, Disclosed About Segments of an Enterprise and Related Information.)
Our chief operating decision-maker is considered to be our Chief Executive Officer (CEO). The CEO reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The financial information reviewed by the CEO is identical to the information presented in the accompanying consolidated statement of operations. Therefore, the Company has determined that it operates in a single operating segment. For the years ended December 31, 2015 and 2014 all material assets and revenues of the Company were in the United States except as disclosed in Note 2.
Concentrations of Risk — Substantially all of the Company’s revenue derives from the sale of Celsius ® beverages.
The Company uses single supplier relationships for its raw materials purchases and filling capacity, which potentially subjects the Company to a concentration of business risk. If these suppliers had operational problems or ceased making product available to the Company, operations could be adversely affected.
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company places its cash and cash equivalents with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation limit. At December 31, 2015 the Company had approximately $10.0 million in excess of the Federal Deposit Insurance Corporation limit.
F- 7 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
At December 31, 2015 and 2014, the Company had the following 10 percent or greater concentrations of revenue with its customers:
2015 | 2014 | |||||||
A* | 48.3 | % | 49.8 | % | ||||
B | 9.1 | % | 10.0 | % | ||||
All other | 42.6 | % | 40.2 | % | ||||
Total | 100.0 | % | 100.0 | % |
At December 31, 2015 and 2014, the Company had the following 10 percent or greater concentrations of accounts receivable with its customers:
2015 | 2014 | |||||||
A* | 50.0 | % | 68.0 | % | ||||
B | 11.8 | % | 8.5 | % | ||||
All other | 38.2 | % | 23.5 | % | ||||
Total | 100.0 | % | 100.0 | % |
*Revenues and receivables from customer A are derived from a distributor located in Sweden.
Cash Equivalents — The Company considers all highly liquid instruments with maturities of three months or less when purchased to be cash equivalents. At December 31, 2015 and December 31, 2014, the Company did not have any investments with maturities of three months or less.
Accounts Receivable — Accounts receivable are reported at net realizable value. The Company establishes an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written-off when it is determined that the amounts are uncollectible. At December 31, 2015 and December 31, 2014, there was an allowance for doubtful accounts of $3,500 and $3,500, respectively.
F- 8 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
Inventories — Inventories include only the purchase cost and are stated at the lower of cost or market. Cost is determined using the FIFO method. Inventories consist of raw materials and finished products. The Company reserved against inventory during the period in which such materials and products are no longer usable or marketable. In 2015 and 2014, the Company recorded a reserve of $329,075 and $30,059, respectively. The changes in reserve are included in cost of revenue. Free Samples are recorded as cost of sales.
Property and Equipment — Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful life of the asset generally ranging from three to seven years.
Impairment of Long-Lived Assets — In accordance with ASC Topic 360, “Property, Plant, and Equipment” the Company reviews the carrying value of intangibles and other long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair value.
Revenue Recognition — Revenue is derived from the sale of beverages. Revenue is recognized when persuasive evidence of an agreement exists, the products are delivered, sales price is fixed or determinable, and collectability is reasonably assured. Any discounts, slotting fees, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue.
Deferred Revenue — From time to time the Company requires prepayments for deposits in advance of delivery of products and/or production runs. Such amounts are initially recorded as deferred revenue. The Company recognizes such revenue as it is earned in accordance with revenue recognition policies.
Advertising Costs — Advertising costs are expensed as incurred. The Company uses mainly radio, local sampling events, sponsorships, endorsements, and digital advertising. The Company incurred advertising expense of approximately $3.2 million and $2.2 million, during year ending December 31, 2015 and 2014, respectively.
Research and Development — Research and development costs are charged to operations as incurred and consist primarily of consulting fees, raw material usage and test productions of beverages. The Company incurred expenses of $71,166 and $25,510 during year ending December 31, 2015 and 2014, respectively.
Fair Value of Financial Instruments — The carrying value of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and notes payable approximates fair value due to their relative short-term maturity and market interest rates.
F- 9 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
Fair Value Measurements - ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:
Level 1: | Observable inputs such as quoted market prices in active markets for identical assets or liabilities. |
Level 2: | Observable market-based inputs or unobservable inputs that are corroborated by market data. |
Level 3: | Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. |
The Company did not have any assets or liabilities measured at fair value at December 31, 2015 and December 31, 2014.
Income Taxes — The Company accounts for income taxes pursuant to the provisions of ASC 740-10, “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized. The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.
F- 10 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
Income Taxes (continued) — Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.
The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open.
The Company files its tax returns on a fiscal year September 30 th tax year. The Company’s tax returns for tax years ended September 30, 2015 (although not yet filed), 2014, 2013, and 2012 remain subject to potential examination by the taxing authorities.
Earnings per Share — Basic earnings per share are calculated by dividing net income (loss) available to stockholders by the weighted-average number of common shares outstanding during each period. Diluted earnings per share are computed using the weighted average number of common and dilutive common share equivalents outstanding during the period. Dilutive common share equivalents consist of shares issuable upon conversion of convertible debt, exercise of stock options and warrants (calculated using the reverse treasury stock method). As of December 31, 2015 there were options outstanding to purchase 4.6 million shares, which exercise price averaged $0.80, Series C Preferred Stock warrants outstanding to convert to 4.6 million common shares at $0.52 price per share and Series D Preferred Stock warrants outstanding to convert to 4.7 million common shares at $0.86 price per share. There were no other dilutive common shares equivalents, including convertible notes and warrants, as no common share equivalents had an exercise price below the ending closing price of the year. The effects of dilutive instruments have not been presented as the effects would be anti-dilutive.
F- 11 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
Share-Based Payments —Effective January 1, 2006, the Company has fully adopted the provisions of ASC Topic 718 “Compensation — Stock Compensation” and related interpretations. As such, compensation cost is measured on the date of grant at the fair value of the share-based payments. Such compensation amounts, if any, are amortized over the respective vesting periods of the grants. On April 30, 2015, the Company adopted the 2015 Stock Incentive Plan, This plan is intended to provide incentives which will attract and retain highly competent persons at all levels as employees of the Company, as well as independent contractors providing consulting or advisory services to the Company, by providing them opportunities to acquire the Company's common stock or to receive monetary payments based on the value of such shares pursuant to Awards issued. The 2015 Plan permits the grant of options and shares for up to 5,000,000 shares. In addition, there is a provision for an annual increase of 15% to the shares included under the plan, with the shares to be added on the first day of each calendar year, beginning on January 1, 2016.
Shipping and Handling Costs — Shipping and handling costs for freight expense on goods shipped are included in cost of sales. Freight expense on goods shipped for year ended December 31, 2015 and 2014 was $1,161,088 and 1,007,054, respectively.
Recent Accounting Pronouncements
The Company adopts all applicable, new accounting pronouncements as of the specified effective dates.
In September 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2015-16, Simplifying the Accounting for Measurement-Period Adjustments (“ASU 2015-16”). ASU 2015-16 simplifies the accounting for adjustments made to provisional amounts recognized in a business combination by requiring the acquirer to (i) recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined, (ii) record, in the same period, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date, and (iii) present separately or disclose the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years, and interim periods within, beginning after December 15, 2015. Early adoption is permitted. The Company is evaluating the impact of the adoption of ASU 2015-16 on January 1, 2016 to its consolidated financial position or results of operations.
In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). ASU 2015-03 simplifies the presentation of debt issuance costs and requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability (consistent with debt discounts).
F- 12 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
Recent Accounting Pronouncements (continued)
In August 2015, the FASB issued ASU No. 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting) (“ASU 2015-15”). ASU 2015-15 allows debt issuance costs related to line-of-credit agreements to be presented in the balance sheet as an asset. ASU 2015-03 and ASU 2015-15 are effective for fiscal years, and interim periods within, beginning after December 15, 2015. Early adoption is permitted. The Company plans to early adopt ASU 2015-03 and ASU 2015-15 as of December 31, 2015; the adoption is not expected to have a material impact on its consolidated financial position or results of operations.
All new accounting pronouncements issued but not yet effective are not expected to have a material impact on our results of operations, cash flows or financial position.
Liquidity — These financial statements have been prepared assuming the Company will be able to continue as a going concern. At December 31, 2015, the Company had an accumulated deficit of $49,920,563 which includes a net loss available to common stockholders of $2,570,297 for year ended December 31, 2015. While these factors alone may raise doubt as to the Company’s ability to continue as a going concern, the Company’s sale of common stock to an investor group on April 20, 2015 for a total of $11.5 million is deemed sufficient to alleviate substantial doubt regarding the Company’s ability to continue as a going concern.
3. | INVENTORIES |
Inventories consist of the following at:
December 31, | December 31, | |||||||
2015 | 2014 | |||||||
Finished goods | $ | 2,309,288 | $ | 1,570,201 | ||||
Raw Materials | 342,691 | 146,793 | ||||||
Less: Inventory Reserve | (329,075 | ) | (30,059 | ) | ||||
Inventories, net | $ | 2,322,904 | $ | 1,686,935 |
F- 13 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
4. | PREPAID EXPENSES AND OTHER CURRENT ASSETS |
Prepaid expenses and other current assets total $666,267 and $259,056, at December 31, 2015 and December 31, 2014, respectively, and consist mainly of prepaid consulting agreement with D3M Licensing Group, advertising, prepaid insurance, prepaid slotting fees, deposits on purchases, and customer deposits.
5. | PROPERTY AND EQUIPMENT |
Property and equipment consist of the following at:
December 31, | December 31, | |||||||
2015 | 2014 | |||||||
Furniture and equipment | $ | 264,495 | $ | 254,083 | ||||
Less: accumulated depreciation | (243,176 | ) | (210,133 | ) | ||||
Total | $ | 21,319 | $ | 43,950 |
Depreciation expense amounted to $33,043 and $37,256 during year ended December 31, 2015 and 2014, respectively
6. | ACCOUNTS PAYABLE AND ACCRUED EXPENSES |
Accounts payable and accrued expenses consist of the following at:
December 31, | December 31, | |||||||
2015 | 2014 | |||||||
Accounts payable | $ | 1,207,353 | $ | 360,062 | ||||
Accrued expenses | 598,578 | 467,987 | ||||||
Total | $ | 1,805,931 | $ | 828,049 |
F- 14 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
7. | DEFERRED REVENUE AND OTHER CURRENT LIABILITIES |
Deferred revenue and other current liabilities consist of the following at:
December 31, | December 31, | |||||||
2015 | 2014 | |||||||
Customer deposits | $ | 13,063 | $ | 351,716 | ||||
State bottle bill liability | 11,994 | 4,886 | ||||||
Total | $ | 25,057 | $ | 356,602 |
8. | LINE OF CREDIT NOTE PAYABLE - RELATED PARTIES |
Line of credit note payable - related parties consists of the following as of:
December 31, | December 31, | |||||||
2015 | 2014 | |||||||
Note Payable – line of credit | ||||||||
In July 2010, the Company entered into a line of credit note payable with a related party which carries interest of five percent per annum. The Company can borrow up to $4,500,000. The Company has pledged all of its assets as security for the line of credit. The notes mature in January 2020, at which time the principal amount is due. During April 2015, the Company issued $4,000,000 of convertible series D preferred series in exchange for cancellation of $4,000,000 of this line. | ||||||||
Long-term portion | $ | 4,500,000 | $ | 9,250,000 |
9. | CONVERTIBLE NOTE PAYABLE - RELATED PARTIES |
Convertible note payable | December 31, | December 31, | ||||||
2015 | 2014 | |||||||
Convertible note payable, related party | $ | 0 | $ | 1,500,000 |
In September 2009, the Company entered into a convertible note payable with a related party, a majority shareholder which carries interest at six percent per annum. The outstanding balance is convertible into the Company’s common stock at a conversion price of $0.30 per share. The Company is obligated to file a registration statement upon written notice from the creditor and such registration statement must be effective within 180 days of the date of notice. If after the 180 days the Company has not complied with the agreement it shall pay $65,000 per month in penalty, until the registration statement is effective.
F- 15 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
9. | CONVERTIBLE NOTE PAYABLE - RELATED PARTIES (CONTINUED) |
The note matures in December 2016, at which time the principal amount is due. In April 2015, the note holder converted the outstanding portion of $1,500,000, into shares of common stock in accordance with the conversion terms of the agreement. The creditor also terminated all registration rights and waived any penalties that might have been incurred in connection therewith. The outstanding balance on the loan as of December 31, 2015 and December 31, 2014 was $0 and $1,500,000, respectively.
10. | PREFERRED STOCK – RELATED PARTY |
On August 26, 2013, the Company entered into a securities purchase agreement (the “2013 Purchase Agreement”) with CDS Ventures of South Florida, LLC (“CDS”) and CD Financial, LLC (“CD”). CDS and CD are limited liability companies which are affiliates of Carl DeSantis, the Company’s principal shareholder. The Company issued 2,200 shares of its Series C Preferred Stock (the “Preferred C Shares”) in exchange for the conversion of a $550,000 short term loan from CDS and the conversion of $1,650,000 in indebtedness under the Company’s line of credit with CD (the “CD Line of Credit”). The Preferred C Shares are convertible into our common stock at the option of the holder thereof at a conversion price of $0.52 per share at any time until December 31, 2018, at which time they will automatically convert into shares of our common stock determined by dividing the liquidation preference of $1,000 per Preferred C Share by the conversion price then in effect. The conversion price is subject to adjustment in the event of stock dividends, stock splits and similar events. The Preferred C Shares accrue cumulative annual dividends at the rate of 6% per annum, payable by the issuance of additional Preferred C Shares. The holder of Preferred C Shares votes on an “as converted” basis, together with holders of common stock as a single class on all matters presented to shareholders for a vote, except as required by law. In April 2015, the Company issued 180 Preferred C Shares valued at $180,000 in settlement of $180,000 in accrued preferred C dividends. As of December 31, 2015, $139,736 of dividends has been accrued. The Preferred C Shares mature on December 31, 2018 and are redeemable only in exchange for shares of Company common stock.
On April 16, 2015, the Company entered into an amendment to its existing Loan and Security Agreement (the “Amendment”) with CD an affiliate of CDS Ventures and Mr. DeSantis. Pursuant to the Amendment, the outstanding principal amount of the CD Line of Credit was reduced by $4.0 million, which amount was converted into 4,000 shares of a newly-designated Series D Preferred Stock (the “Preferred D Shares”). This related party was given a conversion price of $0.86 per common share, whereas other investors purchased common shares at $0.89 in the private placement, as discussed in note 12. The difference of $0.03 per share, which resulted in $139,535, was recorded as a dividend in accordance with ASC 470-20-35, subsequent measurement for debt with conversion and other options. The Preferred D Shares are convertible into our common stock at the option of the holder thereof at a conversion price of $0.86 per share until the earlier of the January 2, 2020 due date of our line of credit with CD Financial or such earlier date as the line of credit is satisfied (the “ Mandatory Redemption Date ”). The conversion price is subject to adjustment in the event of stock dividends, stock splits and similar events. The Preferred D Shares accrue cumulative annual cash dividends at the rate of 5% per annum, payable quarterly in cash and have a liquidation preference of $1,000 per share. On the Mandatory Redemption Date, the Preferred D Shares automatically convert into shares of our common stock in a number determined by dividing the $1,000 per Preferred D Share liquidation preference plus any accrued but unpaid dividends, by the conversion price then in effect. The Preferred D Shares may also be redeemed by us at any time on or after December 31, 2016, at a redemption price equal to 104% of the liquidation preference. The holder of the Preferred D Shares votes on an “as converted” basis, together with holders of common stock as a single class on all matters presented to shareholders for a vote, except as required by law. As of December 31, 2015, $51,111 of dividends has been accrued regarding these shares.
F- 16 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
11. | RELATED PARTY TRANSACTIONS |
The Company’s office is rented from a company affiliated with CD which is controlled by our majority shareholder Carl DeSantis. Currently, the lease expires on October 2020 with monthly rent of $6,408. The rental fee is commensurate with other properties available in the market.
In April 2015, the Company entered into a strategic marketing and advisory services agreement with All Def Digital. Tim Leissner, a director and shareholder of the Company is also a director and shareholder in All Def Digital. As of December 31, 2015, the Company has paid All Def Digital $237,959, for services relating to the strategic marketing and advisory services agreement.
Other related party transactions are discussed in notes 8, 9, and 10,
12. | STOCKHOLDERS’ EQUITY (DEFICIT) |
Issuance of common stock pursuant to services performed
During 2014, the Company issued a total of 280,000 unregistered shares as compensation in connection with celebrity endorsement agreements at an aggregate fair value of $216,100, 250,000 shares were issued at $0.79 per share on March 11 th , 2014 and 30,000 shares were issued at $0.62 per share on August 13 th , 2014, with each per share valuation representing the closing stock price on the day of issuance.
Issuance of common stock pursuant to conversion of note
In April 2015, the Company issued 5,000,000 unregistered common shares upon conversion of $1,500,000 of convertible notes, at contractual terms.
Issuance of common stock pursuant to private placement
In April 2015, the Company issued a total of 12,921,348 shares of common stock at $0.89 per share for gross proceeds of $11.5 million (see note 10). Expenses incurred of $111,841 were charged to additional paid in capital and the Company received net proceeds of $11,388,159.
Issuance of preferred stock pursuant to private placement
Refer to note 10 for discussion on preferred stock issuances.
13. | INCOME TAXES |
Due to recurring losses for book and tax purposes, for the years ended December 31, 2015 and 2014, the Company’s net tax provision was zero.
F- 17 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
13. | INCOME TAXES (CONTINUED) |
The difference between the effective income tax rate and the applicable statutory federal income tax rate is summarized as follows:
2015 | 2014 | |||||||
Statutory federal rate | (35.0 | )% | (35.0 | )% | ||||
State income tax rate, net of federal benefit | (3.5 | )% | (3.5 | )% | ||||
Permanent differences, including stock based compensation | 25.3 | % | 18.5 | % | ||||
Change in valuation allowance | 13.5 | % | 20.0 | % | ||||
Effective tax rate | 0.0 | % | 0.0 | % |
At December 31, 2015 and 2014, the Company’s deferred tax assets were as follows:
Deferred Tax Assets | 2015 | 2014 | ||||||
Net operating loss carry forwards | 16,029,000 | 16,303,000 | ||||||
Less: Valuation allowance net deferred tax assets | (16,029,000 | ) | (16,303,000 | ) | ||||
Net deferred tax assets | 0.0 | 0.0 |
Due to taxable income before net operating loss carryforwards during tax year ending in 2015, the valuation allowance decreased by approximately $274,000 in 2015. Total net operating loss carry forwards at December 31, 2015 were approximately $41.6 million. The losses, if unused, expire through 2035.The Company’s net operating loss carry forwards may be limited due to ownership changes pursuant to Internal Revenue Code section 382.
14. | STOCK-BASED COMPENSATION |
The Company adopted an Incentive Stock Plan on January 18, 2007. This plan is intended to provide incentives which will attract and retain highly competent persons at all levels as employees of the Company, as well as independent contractors providing consulting or advisory services to the Company, by providing them opportunities to acquire the Company's common stock or to receive monetary payments based on the value of such shares pursuant to Awards issued. While the plan terminates 10 years after the adoption date, issued options have their own schedule of termination. During 2013 the majority of the shareholders approved to increase the total available shares in the plan from 2.5 million to 3.5 million shares of common stock. During May 2014, the majority of the shareholders approved to increase the total available shares in the plan from 3.5 million to 4.25 million shares of common stock, during February 2015, the majority of the shareholders approved to increase the total available shares in the plan from 4.25 million to 4.6 million shares of common stock and during April 2015, the majority of the shareholders approved to increase the total available shares in the plan from 4.6 million to 5.1 million shares of common stock. Until 2017, options to acquire shares of common stock may be granted at no less than fair market value on the date of grant. Upon exercise, shares of new common stock are issued by the Company.
F- 18 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
14. | STOCK-BASED COMPENSATION (CONTINUED) |
The Company adopted the 2015 Stock Incentive Plan on April 30, 2015. This plan is intended to provide incentives which will attract and retain highly competent persons at all levels as employees of the Company, as well as independent contractors providing consulting or advisory services to the Company, by providing them opportunities to acquire the Company's common stock or to receive monetary payments based on the value of such shares pursuant to Awards issued. The 2015 Plan permits the grant of options and shares for up to 5,000,000 shares. In addition, there is a provision for an annual increase of 15% to the shares included under the plan, with the shares to be added on the first day of each calendar year, beginning on January 1, 2016.
Cumulatively since inception, the Company has issued options to purchase approximately 4.6 million shares at an average price of $0.81 with a fair value of $5.3 million. For the year 2015 and 2014, the Company issued options to purchase 1.3 million and 1.4 million shares. For the year ended December 31, 2015 and 2014, the Company recognized an expense of $1,270,488 and $686,927, respectively, of non-cash compensation expense (included in General and Administrative expense in the accompanying Consolidated Statement of Operations) determined by application of a Black Scholes option pricing model with the following inputs: exercise price, dividend yields, risk-free interest rate, and expected annual volatility. As of December 31, 2015, the Company had approximately $742,000 of unrecognized pre-tax non-cash compensation expense, which the Company expects to recognize, based on a weighted-average period of 0.5 years. The Company used straight-line amortization of compensation expense over the two to three year requisite service or vesting period of the grant. There are options to purchase approximately 4.3 million shares that have vested, of which 267,000 shares were exercised as of December 31, 2015.
The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards and warrant issuances. The calculation of the fair value of the awards using the Black - Scholes option-pricing model is affected by the Company’s stock price on the date of grant as well as assumptions regarding the following:
Year ended December 31, | |||||
2015 | 2014 | ||||
Expected volatility | 306 | % | 172% - 328% | ||
Expected term | 4 Years | 3 - 5 Years | |||
Risk-free interest rate | 0.89 | % | 0.91% - 1.69% | ||
Forfeiture Rate | 0.00 | % | 0.00% | ||
Expected dividend yield | 0.00 | % | 0.00% |
F- 19 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
14. | STOCK-BASED COMPENSATION (CONTINUED) |
The expected volatility was determined with reference to the historical volatility of the Company’s stock. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury rate in effect at the time of grant.
A summary of the status of the Company’s outstanding stock options as of December 31, 2015 and changes during the period ending on that date is as follows:
Weighted | ||||||||||||||||||||
Weighted Average | Aggregate | Average | ||||||||||||||||||
Exercise | Fair | Intrinsic | Remaining | |||||||||||||||||
Shares | Price | Value | Value | Term (Yrs) | ||||||||||||||||
Options | ||||||||||||||||||||
At December 31, 2013 | 2,374 | $ | 0.44 | $ | 0.33 | $ | 366 | 8.5 | ||||||||||||
Granted | 1,417 | 0.78 | 0.56 | |||||||||||||||||
Exercised | ||||||||||||||||||||
Forfeiture and cancelled | (295 | ) | 0.42 | 0.38 | ||||||||||||||||
At December 31, 2014 | 3,496 | $ | 0.49 | $ | 0.41 | $ | 588 | 6.5 | ||||||||||||
Granted | 1,306 | 1.61 | 0.33 | |||||||||||||||||
Exercised | ||||||||||||||||||||
Forfeiture and cancelled | (168 | ) | 0.52 | 0.38 | ||||||||||||||||
At December 31, 2015 | 4,634 | $ | 0.81 | $ | 0.41 | $ | 5,300 | 5.49 | ||||||||||||
Exercisable at December 31, 2015 | 4,056 | $ | 0.73 | $ | 1.21 | $ | 477 | 6.1 |
The following table summarizes information about employee stock options outstanding at December 31, 2015:
Outstanding Options | Vested Options | |||||||||||||||||||||||
Number | Number | |||||||||||||||||||||||
Outstanding | Weighted | Weighted | Exercisable | Weighted | Weighted | |||||||||||||||||||
Range of | at | Averaged | Averaged | at | Averaged | Averaged | ||||||||||||||||||
Exercise | December 31, | Remaining | Exercise | December 31, | Exercise | Remaining | ||||||||||||||||||
Price | 2015 (000's) | Life | Price | 2015 (000's) | Price | Life | ||||||||||||||||||
$0.20 - $0.42 | 2,522 | 5.90 | $ | 0.26 | 2,495 | $ | 0.26 | 5.96 | ||||||||||||||||
$0.53 - $1.42 | 1,431 | 5.37 | $ | 0.87 | 1,009 | $ | 0.80 | 7.61 | ||||||||||||||||
$1.80 - $3.80 | 637 | 4.30 | $ | 2.29 | 509 | $ | 2.26 | 5.39 | ||||||||||||||||
$4.25 - $9.40 | 30 | 3.89 | $ | 5.57 | 30 | 5.57 | 3.89 | |||||||||||||||||
$10.80 - $22.00 | 14 | 2.78 | $ | 14.87 | 14 | $ | 14.87 | 2.78 | ||||||||||||||||
Outstanding options | 4,634 | 5.49 | $ | 0.81 | 2,707 | $ | 0.55 | 6.28 |
F- 20 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements
December 31, 2015
15. | COMMITMENTS AND CONTINGENCIES |
The Company has entered into distribution agreements with liquidated damages in case the Company cancels the distribution agreements without cause. Cause has been defined in various ways. It is management’s belief that no such agreement has created any liability as of December 31, 2015.
The Company entered into an office lease with a related party (see note 11) effective October 2015. The monthly rent amounts to $6,408 per month and the lease terminates in October 2020. Future annual minimum payments required under operating lease obligations at December 31, 2015 are as follows:
Future Minimum Lease Payments
2016 | $ | 77,803 | ||
2017 | $ | 82,792 | ||
2018 | $ | 85,276 | ||
2019 | $ | 87,834 | ||
2020 | $ | 75,016 | ||
Total | $ | 408,721 |
16. | SUBSEQUENT EVENTS |
We have evaluated events and transactions that occurred subsequent to December 31, 2015 through March 24, 2016, the date these financial statements were issued, for potential recognition or disclosure in the accompanying financial statements. We did not identify any events or transactions that should be recognized or disclosed in the accompanying financial statements.
F- 21 |
Celsius Holdings, Inc. and Subsidiaries
Consolidated Balance Sheets
June 30,
2016 (Unaudited) |
December 31,
2015 (1) |
|||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash | $ | 7,347,403 | $ | 10,128,320 | ||||
Accounts receivable, net | 3,059,167 | 2,127,060 | ||||||
Inventories, net | 2,573,768 | 2,322,904 | ||||||
Prepaid expenses and other current assets | 1,103,418 | 666,267 | ||||||
Total current assets | 14,083,756 | 15,244,551 | ||||||
Property and equipment, net | 26,281 | 21,319 | ||||||
Total Assets | $ | 14,110,037 | $ | 15,265,870 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable and accrued expenses | $ | 1,574,408 | $ | 1,805,931 | ||||
Accrued preferred dividend | 262,486 | 190,847 | ||||||
Deferred revenue and other current liabilities | 800,029 | 25,057 | ||||||
Total current liabilities | 2,636,923 | 2,021,835 | ||||||
Long-term liabilities: | ||||||||
Line of credit note payable-related party | 4,500,000 | 4,500,000 | ||||||
Total Liabilities | 7,136,923 | 6,521,835 | ||||||
Stockholders’ Equity: | ||||||||
Preferred Stock, $0.001 par value; 2,500,000 shares authorized, 6,380 and 6,380 shares issued and outstanding at June 30, 2016 and December 31, 2015 | 6 | 6 | ||||||
Common stock, $0.001 par value; 75,000,000 shares authorized, 38,666,451 and 38,380,380 shares issued and outstanding at June 30, 2016 and December 31, 2015, respectively | 38,666 | 38,380 | ||||||
Additional paid-in capital | 59,686,334 | 58,626,212 | ||||||
Accumulated deficit | (52,751,892 | ) | (49,920,563 | ) | ||||
Total Stockholders’ Equity | 6,973,114 | 8,744,035 | ||||||
Total Liabilities and Stockholders’ Equity | $ | 14,110,037 | $ | 15,265,870 |
(1) | Derived from Audited Financial Statements |
The accompanying notes are an integral part of these consolidated financial statements
F- 22 |
Celsius Holdings, Inc. and Subsidiaries
Consolidated Statements of Operations
(Unaudited)
For the six months | ||||||||
ended June 30, | ||||||||
2016 | 2015 | |||||||
Revenue | $ | 9,850,397 | $ | 9,304,910 | ||||
Cost of revenue | 5,566,354 | 5,438,221 | ||||||
Gross profit | 4,284,043 | 3,866,689 | ||||||
Selling and marketing expenses | 4,973,316 | 2,042,506 | ||||||
General and administrative expenses | 1,855,000 | 1,891,385 | ||||||
Total operating expense | 6,828,316 | 3,933,891 | ||||||
Income (Loss) from operations | (2,544,273 | ) | (67,202 | ) | ||||
Other Income (Expense): | ||||||||
Interest expense | (113,750 | ) | (206,733 | ) | ||||
Total Other Income (Expense) | (113,750 | ) | (206,733 | ) | ||||
Net Income (Loss) | $ | (2,658,023 | ) | $ | (273,935 | ) | ||
Preferred stock dividend | (173,306 | ) | (107,942 | ) | ||||
Net Income (Loss) available to common stockholders | $ | (2,831,329 | ) | $ | (381,877 | ) | ||
Income (Loss) per share: | ||||||||
Basic | $ | (0.07 | ) | $ | (0.01 | ) | ||
Diluted | $ | (0.07 | ) | $ | (0.01 | ) | ||
Weighted average shares outstanding: | ||||||||
Basic | 38,461,318 | 27,885,006 | ||||||
Diluted | 38,461,318 | 27,885,006 |
The accompanying notes are an integral part of these consolidated financial statements
F- 23 |
Celsius Holdings, Inc. and Subsidiaries
Consolidated Statements of Cash Flows
(Unaudited)
For the six months
ended |
||||||||
June 30,
2016 |
June 30,
2015 |
|||||||
Cash flows from operating activities: | ||||||||
Net Loss | $ | (2,658,023 | ) | $ | (273,935 | ) | ||
Adjustments to reconcile net income (loss) to net cash used in operating activities: | ||||||||
Depreciation and amortization | 7,368 | 17,851 | ||||||
Stock-based compensation expense | 1,055,108 | 1,042,103 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable, net | (932,107 | ) | 537,451 | |||||
Inventories net | (250,864 | ) | 241,765 | |||||
Prepaid expenses and other current assets | (437,151 | ) | (837,824 | ) | ||||
Accounts payable and accrued expenses | (159,884 | ) | 434,219 | |||||
Accrued preferred dividends | (173,306 | ) | (107,942 | ) | ||||
Deferred revenue and other current liabilities | 774,972 | (352,967 | ) | |||||
Net cash provided by (used in) in operating activities | (2,773,887 | ) | 700,721 | |||||
Cash flows from investing activities: | ||||||||
Purchase of property and equipment | (12,330 | ) | - | |||||
Net cash (used in) investing activities | (12,330 | ) | - | |||||
Cash flows from financing activities: | ||||||||
Borrowing under revolving note payable, related-party | - | 450,000 | ||||||
Repayment on short term notes payable, related-party | - | (1,200,000 | ) | |||||
Net proceeds from issuance of common stock | - | 11,388,084 | ||||||
Proceeds from exercise of stock options | 5,300 | - | ||||||
Payments on short term notes payable | - | (44,684 | ) | |||||
Net cash (used in) financing activities | 5,300 | 10,593,400 | ||||||
Net (decrease) increase in cash | (2,780,917 | ) | 11,294,121 | |||||
Cash at beginning of the period | 10,128,320 | 349,072 | ||||||
Cash at end of the period | $ | 7,347,403 | $ | 11,643,193 | ||||
Supplemental disclosures: | ||||||||
Cash paid during period for: | ||||||||
Interest | $ | 113,750 | $ | 206,733 | ||||
Income Taxes | $ | - | $ | - | ||||
Non-cash investing and financing activities: | ||||||||
Borrowing under short term notes payable for prepaid expense | $ | - | $ | 91,099 | ||||
Accrued preferred dividends | $ | 86,652 | $ | 107,942 | ||||
Preferred stock issuance in exchange for cancellation of revolving note payable, related-party | - | 4,000,000 | ||||||
Conversion of convertible note to common shares, related-party | - | 1,500,000 | ||||||
Conversion of accrued preferred dividend into preferred shares, related-party | - | 180,000 |
The accompanying notes are an integral part of these consolidated financial statements
F- 24 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
1. | ORGANIZATION AND DESCRIPTION OF BUSINESS |
Business —Celsius Holdings, Inc. (the “Company” or “Celsius Holdings”) was incorporated under the laws of the State of Nevada on April 26, 2005. On January 24, 2007, the Company entered into a merger agreement and plan of reorganization with Elite FX, Inc., a Florida corporation. Under the terms of the Merger Agreement, Elite FX, Inc. was merged into the Company’s subsidiary, Celsius, Inc. and became a wholly-owned subsidiary of the Company on January 26, 2007. In addition, on March 28, 2007 the Company established Celsius Netshipments, Inc. a Florida corporation as a wholly-owned subsidiary of the Company.
Since the merger, the Company is engaged in the development, marketing, sale and distribution of “functional” calorie-burning fitness beverages under the Celsius® brand name.
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES |
The consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”).
Consolidation Policy — The accompanying consolidated financial statements include the accounts of Celsius Holdings, Inc. and its subsidiaries. All material inter-company balances and transactions have been eliminated in consolidation.
Significant Estimates — The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses and disclosure of contingent assets and liabilities at the date of the financial statements. Actual results could differ from those estimates. Significant estimates include the allowance for doubtful accounts, reserves for inventory obsolescence, the useful lives and values of property and equipment, valuation of stock based compensation, and deferred tax asset valuation allowance.
Segment Reporting —Although the Company has a number of operating divisions, separate segment data has not been presented, as they meet the criteria for aggregation as permitted by ASC Topic 280, Segment Reporting, (formerly Statement of Financial Accounting Standards (SFAS) No. 131, Disclosed About Segments of an Enterprise and Related Information.) Our chief operating decision-maker is considered to be our Chief Executive Officer (CEO). The CEO reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The financial information reviewed by the CEO is identical to the information presented in the accompanying consolidated statement of operations. Therefore, the Company has determined that it operates in a single operating segment. For the six months ended June 30, 2016 and 2015 all material assets and revenues of the Company were in the United States except as disclosed in Note 2.
Concentrations of Risk — Substantially all of the Company’s revenue derives from the sale of Celsius ® beverages.
The Company uses single supplier relationships for its raw materials purchases and filling capacity, which potentially subjects the Company to a concentration of business risk. If these suppliers had operational problems or ceased making product available to the Company, operations could be adversely affected.
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and accounts receivable. The Company places its cash with high-quality financial institutions. At times, balances in the Company’s cash accounts may exceed the Federal Deposit Insurance Corporation limit. At June 30, 2016 the Company had approximately $7.0 million in excess of the Federal Deposit Insurance Corporation limit but has incurred no losses with respect to these accounts.
F- 25 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
At June 30, 2016 and 2015, the Company had the following 10 percent or greater concentrations of revenue with its customers:
2016 | 2015 | |||||||
A* | 31.4 | % | 58.3 | % | ||||
B | 12.3 | % | 1.0 | % | ||||
All other | 56.3 | % | 40.7 | % | ||||
Total | 100.0 | % | 100.0 | % |
At June 30, 2016 and December 31, 2015, the Company had the following 10 percent or greater concentrations of accounts receivable with its customers:
2016 | 2015 | |||||||
A* | 54.3 | % | 50.0 | % | ||||
B | 7.4 | % | 11.8 | % | ||||
All other | 38.3 | % | 38.2 | % | ||||
Total | 100.0 | % | 100.0 | % |
*Revenues and receivables from customer A are derived from a distributor located in Sweden.
Cash Equivalents — The Company considers all highly liquid instruments with maturities of three months or less when purchased to be cash equivalents. At June 30, 2016 and December 31, 2015, the Company did not have any investments with maturities of three months or less.
Accounts Receivable — Accounts receivable are reported at net realizable value. The Company establishes an allowance for doubtful accounts based upon factors pertaining to the credit risk of specific customers, historical trends, and other information. Delinquent accounts are written-off when it is determined that the amounts are uncollectible. At June 30, 2016 and December 31, 2015, there was an allowance for doubtful accounts of $79,332 and $3,500.
F- 26 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
Inventories — Inventories include only the purchase cost and are stated at the lower of cost or market. Cost is determined using the FIFO method. Inventories consist of raw materials and finished products. The Company reserves against inventory during the period in which such materials and products are no longer usable or marketable. At June 30, 2016 and December 31, 2015, the Company recorded a reserve of $112,807 and $329,075, respectively. The changes in reserve are included in cost of revenue. Free Samples are also recorded as cost of revenue.
Property and Equipment — Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful life of the asset generally ranging from three to seven years.
Impairment of Long-Lived Assets — In accordance with ASC Topic 360, “Property, Plant, and Equipment” the Company reviews the carrying value of long-lived assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of long-lived assets is measured by comparison of its carrying amount to the undiscounted cash flows that the asset or asset group is expected to generate. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the property, if any, exceeds its fair value.
Revenue Recognition — Revenue is derived from the sale of beverages. Revenue is recognized when persuasive evidence of an agreement exists, the products are delivered, sales price is fixed or determinable, and collectability is reasonably assured. Any discounts, slotting fees, sales incentives or similar arrangements with the customer are estimated at time of sale and deducted from revenue.
Deferred Revenue — From time to time the Company requires prepayments for deposits in advance of delivery of products and/or production runs. Such amounts are initially recorded as deferred revenue. The Company recognizes such revenue as it is earned in accordance with revenue recognition policies.
Advertising Costs — Advertising costs are expensed as incurred. The Company uses mainly radio, local sampling events, sponsorships, endorsements, and digital advertising. The Company incurred advertising expense of approximately $2.8 million and $0.9 million during the six months ending June 30, 2016 and 2015, respectively.
Research and Development — Research and development costs are charged to operations as incurred and consist primarily of consulting fees, raw material usage and test productions of beverages. The Company incurred there expenses of $45,800 and $24,900 during the six months ending June 30, 2016 and 2015, respectively.
Fair Value of Financial Instruments — The carrying value of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses, and notes payable approximates fair value due to their relative short-term maturity and market interest rates.
F- 27 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
Fair Value Measurements - ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Additionally, ASC 820 requires the use of valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. These inputs are prioritized below:
Level 1: | Observable inputs such as quoted market prices in active markets for identical assets or liabilities. |
Level 2: | Observable market-based inputs or unobservable inputs that are corroborated by market data. |
Level 3: |
Unobservable inputs for which there is little or no market data, which require the use of the reporting entity’s own assumptions. |
The Company did not have any assets or liabilities measured at fair value at June 30, 2016 and December 31, 2015.
Income Taxes — The Company accounts for income taxes pursuant to the provisions of ASC 740-10, “Accounting for Income Taxes,” which requires, among other things, an asset and liability approach to calculating deferred income taxes. The asset and liability approach requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. A valuation allowance is provided to offset any net deferred tax assets for which management believes it is more likely than not that the net deferred asset will not be realized. The Company follows the provisions of the ASC 740 -10 related to, Accounting for Uncertain Income Tax Positions. When tax returns are filed, it is highly certain that some positions taken would be sustained upon examination by the taxing authorities, while others are subject to uncertainty about the merits of the position taken or the amount of the position that would be ultimately sustained. In accordance with the guidance of ASC 740-10, the benefit of a tax position is recognized in the financial statements in the period during which, based on all available evidence, management believes it is more likely than not that the position will be sustained upon examination, including the resolution of appeals or litigation processes, if any.
F- 28 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
3. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
Income Taxes (continued) — Tax positions taken are not offset or aggregated with other positions. Tax positions that meet the more-likely-than-not recognition threshold are measured as the largest amount of tax benefit that is more than 50 percent likely of being realized upon settlement with the applicable taxing authority. The portion of the benefits associated with tax positions taken that exceeds the amount measured as described above should be reflected as a liability for uncertain tax benefits in the accompanying balance sheet along with any associated interest and penalties that would be payable to the taxing authorities upon examination. The Company believes its tax positions are all highly certain of being upheld upon examination. As such, the Company has not recorded a liability for uncertain tax benefits.
The Company has adopted ASC 740-10-25 Definition of Settlement, which provides guidance on how an entity should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits and provides that a tax position can be effectively settled upon the completion of an examination by a taxing authority without being legally extinguished. For tax positions considered effectively settled, an entity would recognize the full amount of tax benefit, even if the tax position is not considered more likely than not to be sustained based solely on the basis of its technical merits and the statute of limitations remains open.
The Company files its tax returns on a fiscal year September 30 th tax year. The Company’s tax returns for tax years ended September 30, 2015, 2014, and 2013 remain subject to potential examination by the taxing authorities.
Earnings per Share — Basic earnings per share are calculated by dividing net income (loss) available to common stockholders by the weighted-average number of common shares outstanding during each period. Diluted earnings per share are computed using the weighted average number of common and dilutive common share equivalents outstanding during the period. Dilutive common share equivalents consist of shares issuable upon conversion of convertible debt, exercise of stock options and warrants (calculated using the reverse treasury stock method). As of June 30, 2016 there were options outstanding to purchase 5.6 million shares, which exercise price averaged $1.00, Series C Preferred Stock warrants outstanding to convert to 4.6 million common shares at $0.52 price per share and Series D Preferred Stock warrants outstanding to convert to 4.7 million common shares at $0.86 price per share. There were no other dilutive common shares equivalents, including convertible notes and warrants, as no common share equivalents had an exercise price below the ending closing price of the year. The effects of dilutive instruments have not been presented for the three and six months ended June 30, 2016, as the effects would be anti-dilutive.
F- 29 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
Share-Based Payments —Effective January 1, 2006, the Company has fully adopted the provisions of ASC Topic 718 “Compensation — Stock Compensation” and related interpretations. As such, compensation cost is measured on the date of grant at the fair value of the share-based payments. Such compensation amounts, if any, are amortized over the respective vesting periods of the grants. On April 30, 2015, the Company adopted the 2015 Stock Incentive Plan, This plan is intended to provide incentives which will attract and retain highly competent persons at all levels as employees of the Company, as well as independent contractors providing consulting or advisory services to the Company, by providing them opportunities to acquire the Company's common stock or to receive monetary payments based on the value of such shares pursuant to Awards issued. The 2015 Plan permits the grant of options and shares for up to 5,147,000 shares. In addition, there is a provision for an annual increase of 15% of the issued shares under the plan to the shares included under the plan, with the shares to be added on the first day of each calendar year, beginning on January 1, 2016. On January 1 st , 2016, the permitted number of available option grants increased 147,000 (see also note 12).
Shipping and Handling Costs — Shipping and handling costs for freight expense on goods shipped are included in cost of sales. Freight expense on goods shipped for six months ended June 30, 2016 and 2015 was $958,000 and $539,000, respectively.
Recent Accounting Pronouncements
The Company adopts all applicable, new accounting pronouncements as of the specified effective dates.
In September 2015, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) No. 2015-16, Simplifying the Accounting for Measurement-Period Adjustments (“ASU 2015-16”). ASU 2015-16 simplifies the accounting for adjustments made to provisional amounts recognized in a business combination by requiring the acquirer to (i) recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amount is determined, (ii) record, in the same period, the effect on earnings of changes in depreciation, amortization, or other income effects, if any, as a result of the change to the provisional amounts, calculated as if the accounting had been completed at the acquisition date, and (iii) present separately or disclose the portion of the amount recorded in current-period earnings by line item that would have been recorded in previous reporting periods if the adjustment to the provisional amounts had been recognized as of the acquisition date. ASU 2015-16 is effective for fiscal years, and interim periods within, beginning after December 15, 2015. Early adoption is permitted. The Company is evaluating the impact of the adoption of ASU 2015-16 on January 1, 2016 to its consolidated financial position or results of operations.
F- 30 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
2. | BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) |
Recent Accounting Pronouncements (continued)
In April 2015, the FASB issued ASU No. 2015-03, Simplifying the Presentation of Debt Issuance Costs (“ASU 2015-03”). ASU 2015-03 simplifies the presentation of debt issuance costs and requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability (consistent with debt discounts).
In August 2015, the FASB issued ASU No. 2015-15, Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line-of-Credit Arrangements (Amendments to SEC Paragraphs Pursuant to Staff Announcement at June 18, 2015 EITF Meeting) (“ASU 2015-15”). ASU 2015-15 allows debt issuance costs related to line-of-credit agreements to be presented in the balance sheet as an asset. ASU 2015-03 and ASU 2015-15 are effective for fiscal years, and interim periods within, beginning after December 15, 2015. Early adoption is permitted. The Company has adopted ASU 2015-03 and ASU 2015-15 as of December 31, 2015; the adoption is not expected to have a material impact on its consolidated financial position or results of operations.
All new accounting pronouncements issued but not yet effective are not expected to have a material impact on our results of operations, cash flows or financial position.
Liquidity — These financial statements have been prepared assuming the Company will be able to continue as a going concern. At June 30, 2016, the Company had an accumulated deficit of $52,751,892 which includes a net loss available to common stockholders of $2,831,329 for the six months ended June 30, 2016. While these factors alone may raise doubt as to the Company’s ability to continue as a going concern, the proceeds remaining from the Company’s sale of common stock to an investor group on April 20, 2015 for a total of $11.5 million (see note 11) is deemed sufficient to alleviate substantial doubt regarding the Company’s ability to continue as a going concern.
3. | INVENTORIES |
Inventories consist of the following at:
June 30, | December 31, | |||||||
2016 | 2015 | |||||||
Finished goods | $ | 2,459,786 | $ | 2,309,288 | ||||
Raw Materials | 226,789 | 342,691 | ||||||
Less: Inventory Reserve | (112,807 | ) | (329,075 | ) | ||||
Inventories, net | $ | 2,573,768 | $ | 2,322,904 |
F- 31 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
4. | PREPAID EXPENSES AND OTHER CURRENT ASSETS |
Prepaid expenses and other current assets total $1,103,418 and $666,267, at June 30, 2016 and December 31, 2015, respectively, and consist mainly of prepaid consulting agreement with D3M Licensing Group, advertising, prepaid insurance, prepaid slotting fees, deposits on purchases, and customer deposits.
5. | PROPERTY AND EQUIPMENT |
Property and equipment consist of the following at:
June 30, | December 31, | |||||||
2016 | 2015 | |||||||
Furniture and equipment | $ | 276,825 | $ | 264,495 | ||||
Less: accumulated depreciation | (250,544 | ) | (243,176 | ) | ||||
Total | $ | 26,281 | $ | 21,319 |
Depreciation expense amounted to $7,368 and $17,851 during the six months ended June 30, 2016 and 2015, respectively
6. | ACCOUNTS PAYABLE AND ACCRUED EXPENSES |
Accounts payable and accrued expenses consist of the following at:
June 30, | December 31, | |||||||
2016 | 2015 | |||||||
Accounts payable | $ | 875,847 | $ | 1,207,353 | ||||
Accrued expenses | 698,561 | 598,578 | ||||||
Total | $ | 1,574,408 | $ | 1,805,931 |
F- 32 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
7. | DEFERRED REVENUE AND OTHER CURRENT LIABILITIES |
Deferred revenue and other current liabilities consist of the following at:
June 30, | December 31, | |||||||
2016 | 2015 | |||||||
Customer deposits | $ | 793,380 | $ | 13,063 | ||||
State bottle bill liability | 6,649 | 11,994 | ||||||
Total | $ | 800,029 | $ | 25,057 |
LINE OF CREDIT NOTE PAYABLE - RELATED PARTIES
Line of credit note payable - related parties consists of the following as of:
June 30, | December 31, | |||||||
2016 | 2015 | |||||||
Note Payable – line of credit | ||||||||
In July 2010, the Company entered into a line of credit note payable with a related party which carries interest of five percent per annum. The Company can borrow up to $4,500,000. The Company has pledged all of its assets as security for the line of credit. The notes mature in January 2020, at which time the principal amount is due. During April 2015, the Company issued $4,000,000 of convertible series D preferred series in exchange for cancellation of $4,000,000 of this line. | ||||||||
Long-term portion | $ | 4,500,000 | $ | 4,500,000 |
F- 33 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
9. | PREFERRED STOCK – RELATED PARTY |
On August 26, 2013, the Company entered into a securities purchase agreement (the “2013 Purchase Agreement”) with CDS Ventures of South Florida, LLC (“CDS”) and CD Financial, LLC (“CD”). CDS and CD are limited liability companies which are affiliates of Carl DeSantis, the Company’s principal shareholder. The Company issued 2,200 shares of its Series C Preferred Stock (the “Preferred C Shares”) in exchange for the conversion of a $550,000 short term loan from CDS and the conversion of $1,650,000 in indebtedness under the Company’s line of credit with CD (the “CD Line of Credit”). The Preferred C Shares can be converted into Company common stock at any time until December 31, 2018 at a conversion price of $0.52 per share. The conversion price per share is based on the weighted average of the ten daily VWAPs for the 10 trading days immediately preceding the closing date of August 26, 2013. The Preferred C Shares accrue a 6% annual cumulative dividend, payable in additional Preferred C Shares. The Preferred C Shares are mandatorily redeemable on December 31, 2018 and are redeemable only in shares of the Company’s common stock. In April 2015, the Company issued 180 Preferred C Shares valued at $180,000 in settlement of $180,000 in accrued preferred C dividends. As of June 30, 2016, $211,930 of dividends has been accrued. The Preferred C Shares mature on December 31, 2018 and are redeemable only in exchange for shares of Company common stock.
On April 16, 2015, the Company entered into an amendment to its existing Loan and Security Agreement (the “Amendment”) with CD an affiliate of CDS Ventures and Mr. DeSantis. Pursuant to the Amendment, the outstanding principal amount of the CD Line of Credit was reduced by $4.0 million, which amount was converted into 4,000 shares of a newly-designated Series D Preferred Stock (the “Preferred D Shares”). This related party was given a conversion price of $0.86 per common share, whereas other investors purchased common shares at $0.89 in the private placement, as discussed in note 12. The difference of $0.03 per share, which resulted in $139,535, was recorded as a dividend in accordance with ASC 470-20-35, subsequent measurement for debt with conversion and other options. The Preferred D Shares can be converted into Company common stock at any time until the expiration date of the line of credit in 2020 or its earlier satisfaction in full, at a conversion price of $0.86 per share. The Preferred D Shares accrue a 5% annual cumulative cash dividend, payable quarterly and accords the holders thereof voting rights on an “as converted” basis. As of June 30, 2016, $50,556 of dividends has been accrued regarding these shares.
F- 34 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
10. | RELATED PARTY TRANSACTIONS |
The Company’s office is rented from a company affiliated with CD which is controlled by our majority shareholder Carl DeSantis (see note 13). Currently, the lease expires on October 2020 with monthly rent of $6,408. The rental fee is commensurate with other properties available in the market.
In April 2015, the Company entered into a strategic marketing and advisory services agreement with All Def Digital. Tim Leissner, a director and shareholder of the Company is also a director and shareholder in All Def Digital. For the six months ending as of June 30, 2016, the Company has paid All Def Digital $152,438, for services relating to the strategic marketing and advisory services agreement.
Other related party transactions are discussed in notes 8 and 9.
11. | STOCKHOLDERS’ EQUITY (DEFICIT) |
Issuance of common stock pursuant to services performed
In April 2016, the Company issued a total 250,000 “restricted” shares of its common stock as compensation pursuant to celebrity endorsement agreements at a fair value of $560,000, or $2.24 per share representing the closing stock price on that date.
Issuance of common stock pursuant to conversion of note
In April 2015, the Company issued 5,000,000 unregistered common shares upon conversion of $1,500,000 of convertible notes, at contractual terms.
Issuance of common stock pursuant to private placement
In April 2015, the Company issued a total of 12,921,348 shares of common stock at $0.89 per share for gross proceeds of $11.5 million (see note 2). Expenses incurred of $111,841 were charged to additional paid in capital and the Company received net proceeds of $11,388,159.
Issuance of preferred stock pursuant to private placement
Refer to note 9 for discussion on preferred stock issuances.
Issuance of common stock pursuant to exercise of stock options
During the six months ended June 30, 2016, the Company issued an aggregate of 36,071 shares of its common stock pursuant to the exercise of stock options granted under the Company’s 2006 Stock Incentive Plan. The Company received aggregate proceeds of $5,300 for options exercised for cash, with the balance of the options having been exercised on a “cashless” basis.
F- 35 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
12. | STOCK-BASED COMPENSATION |
The Company adopted an Incentive Stock Plan on January 18, 2007. This plan is intended to provide incentives which will attract and retain highly competent persons at all levels as employees of the Company, as well as independent contractors providing consulting or advisory services to the Company, by providing them opportunities to acquire the Company's common stock or to receive monetary payments based on the value of such shares pursuant to Awards issued. While the plan terminates 10 years after the adoption date, issued options have their own schedule of termination. During 2013 the majority of the shareholders approved to increase the total available shares in the plan from 2.5 million to 3.5 million shares of common stock. During May 2014, the majority of the shareholders approved to increase the total available shares in the plan from 3.5 million to 4.25 million shares of common stock, during February 2015, the majority of the shareholders approved to increase the total available shares in the plan from 4.25 million to 4.6 million shares of common stock and during April 2015, the majority of the shareholders approved to increase the total available shares in the plan from 4.6 million to 5.1 million shares of common stock. Until 2017, options to acquire shares of common stock may be granted at no less than fair market value on the date of grant. Upon exercise, shares of new common stock are issued by the Company.
The Company adopted the 2015 Stock Incentive Plan on April 30, 2015. This plan is intended to provide incentives which will attract and retain highly competent persons at all levels as employees of the Company, as well as independent contractors providing consulting or advisory services to the Company, by providing them opportunities to acquire the Company's common stock or to receive monetary payments based on the value of such shares pursuant to Awards issued. The 2015 Plan permits the grant of options and shares for up to 5,147,000 shares. In addition, there is a provision for an annual increase of 15% of the issued shares under the plan to the shares included under the plan, with the shares to be added on the first day of each calendar year, beginning on January 1, 2016. On January 1 st , 2016, the permitted number of available option grants increased 147,000 (see also note 2).
Cumulatively since inception, the Company has issued options to purchase approximately 5.6 million shares at an average price of $1.00 with a fair value of $1.1 million. For the six months ended June 30, 2016 and 2015, the Company recognized an expense of $495,108 and $1,042,103, respectively, of non-cash compensation expense (included in General and Administrative expense in the accompanying Consolidated Statement of Operations) determined by application of a Black Scholes option pricing model with the following inputs: exercise price, dividend yields, risk-free interest rate, and expected annual volatility. As of June 30, 2016, the Company had approximately $2,361,716 of unrecognized pre-tax non-cash compensation expense, which the Company expects to recognize, based on a weighted-average period of 3 years. The Company used straight-line amortization of compensation expense over the two to three year requisite service or vesting period of the grant. There are options to purchase approximately 4.3 million shares that have vested, of which 307,000 shares were exercised as of June 30, 2016.
F- 36 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
12. | STOCK-BASED COMPENSATION (CONTINUED) |
The Company uses the Black-Scholes option-pricing model to estimate the fair value of its stock option awards and warrant issuances. The calculation of the fair value of the awards using the Black - Scholes option-pricing model is affected by the Company’s stock price on the date of grant as well as assumptions regarding the following:
Six months ended June 30, | ||||
2016 | 2015 | |||
Expected volatility | 381% - 390% | 306% | ||
Expected term | 4 Years | 4 Years | ||
Risk-free interest rate | 1.23% - 1.36% | 0.91% - 1.69% | ||
Forfeiture Rate | 0.00% | 0.00% | ||
Expected dividend yield | 0.00% | 0.00% |
The expected volatility was determined with reference to the historical volatility of the Company’s stock. The Company uses historical data to estimate option exercise and employee termination within the valuation model. The expected term of options granted represents the period of time that options granted are expected to be outstanding. The risk-free interest rate for periods within the contractual life of the option is based on the U.S. Treasury rate in effect at the time of grant.
A summary of the status of the Company’s outstanding stock options as of June 30, 2016 and changes during the period ending on that date is as follows:
Weighted
Average |
Aggregate | Average | ||||||||||||||
Exercise | Intrinsic | Remaining | ||||||||||||||
Shares | Price | Value | Term (Yrs) | |||||||||||||
Options | ||||||||||||||||
Balance at December 31, 2015 | 4,634,166 | $ | 0.81 | $ | 5,346,349 | 5.49 | ||||||||||
Granted | 1,008,500 | $ | 1.98 | |||||||||||||
Exercised | (40,000 | ) | $ | 0.42 | ||||||||||||
Forfeiture and cancelled | (89,301 | ) | $ | 2.07 | ||||||||||||
At June 30, 2016 | 5,513,365 | $ | 1.02 | $ | 1,154,756 | 5.50 | ||||||||||
Exercisable at June 30, 2016 | 4,280,115 | $ | 0.78 |
F- 37 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
13. | COMMITMENTS AND CONTINGENCIES |
The Company has entered into distribution agreements with liquidated damages in case the Company cancels the distribution agreements without cause. Cause has been defined in various ways. It is management’s belief that no such agreement has created any liability as of June 30, 2016.
The Company entered into an office lease with a related party (see note 10) effective October 2015. The monthly rent amounts to $6,408 per month and the lease terminates in October 2020. Future annual minimum payments required under operating lease obligations at June 30, 2016 are as follows:
Future Minimum Lease Payments
Year ending December 31, | ||||
2016 | $ | 38,448 | ||
2017 | $ | 82,792 | ||
2018 | $ | 85,276 | ||
2019 | $ | 87,834 | ||
2020 | $ | 75,016 | ||
Total | $ | 369,366 |
14. | SUBSEQUENT EVENTS |
We have evaluated events and transactions that occurred subsequent to June 30, 2016 through August 11, 2016, the date these financial statements were issued, for potential recognition or disclosure in the accompanying financial statements. Other than the disclosures shown and presented below, we did not identify any events or transactions that should be recognized or disclosed in the accompanying financial statements.
Lease Agreement – On July 25 th , 2016 we amended our existing lease for 2424 North Federal Hwy. Suite 208, Boca Raton, FL 33431. This amended lease is effective on September 1, 2016, the term of the lease shall be extended for a period of fifty months so that the termination date shall be October 31, 2020.
F- 38 |
Celsius Holdings, Inc. and Subsidiaries
Notes to Consolidated Financial Statements (unaudited)
June 30, 2016
14. | SUBSEQUENT EVENTS (CONTINUED) |
Future Minimum Lease Payments
Year ending December 31, | ||||
2016 | $ | 50,052 | ||
2017 | $ | 113,460 | ||
2018 | $ | 116,718 | ||
2019 | $ | 120,080 | ||
2020 | $ | 103,250 | ||
Total | $ | 503,560 |
F- 39 |
Exhibit 10.11
COMMON STOCK PURCHASE AGREEMENT
This COMMON STOCK PURCHASE AGREEMENT (this “Agreement” ), dated as of April 20, 2015, is made by and among CELSIUS HOLDINGS, INC., a Nevada corporation (the “Company” ) and the parties named on Schedule 1.2 hereto (each, a “Purchaser” and collectively, the “Purchasers” ).
RECITALS
WHEREAS, the Company wishes to sell to the Purchasers, and the Purchasers wish to purchase from the Company an aggregate of up to 12,921,348 newly issued shares (the “Shares” ) of the Company’s Common Stock, par value $0,001 per share (the “Common Stock” ), having the rights, powers, restrictions and limitations set forth in the Company’s Articles of Incorporation, as amended, and as provided by the Nevada Corporations Code (Title 7, Chapter 78 of the Nevada Revised Statutes), all on the terms and conditions set forth herein.
AGREEMENT
NOW, THEREFORE, in consideration of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy are hereby acknowledged, the Company and the Purchasers agree as follows:
ARTICLE I
CONSIDERATION
1.1 Sale of Shares . Subject to the terms and conditions set forth in this Agreement, at Closing (as hereinafter defined), the Company shall sell the Shares to the Purchasers and the Purchasers shall, severally and not jointly, purchase and acquire the Shares from the Company, for an aggregate purchase price of Eleven Million Five Hundred Thousand Dollars ($11,500,000.00), or $0.89 per Share (the “Purchase Price” ).
1.2 Payment of the Purchase Price . The Purchase Price shall be payable in full at Closing by wire transfer in immediately available funds to such bank account as may be designated by the Company. Contemporaneously with the Purchasers’ payment of the aggregate Purchase Price, the Company will issue certificates to the Purchasers evidencing the Shares registered in the Purchasers’ names and in the amounts set forth on Schedule 1.2 hereto.
1.3 Closing . The closing of the sale and purchase of the Shares contemplated by this Agreement (the “Closing” ) shall take place contemporaneously with the execution of this Agreement. The date and time of the Closing shall be referred herein as the “Closing Date.” In the event that any of the shares of Common Stock authorized for sale hereunder are not sold on the Closing Date because the signature pages or funds from any of the proposed Purchasers are not received by the Company by the Closing Date, the Company may sell such remaining shares of Common Stock to such proposed purchasers at an additional closing (“Additional Closing” ) within fifteen (15) days after the Closing (or within such longer period as may be approved by the Company). At any such Additional Closing, the Purchaser participating in such Additional Closing shall deliver a counterpart signature page hereto and to the Investors’ Rights Agreement, and shall wire the funds for the payment of the shares of Common Stock being purchased by such Purchaser at the Additional Closing, and the Company shall promptly deliver a share certificate for such shares of Common Stock. Any such Purchaser at an Additional Closing shall be deemed a Purchaser for all purposes hereunder.
1.4 Closing Deliveries by the Company . The obligations of each Purchaser to purchase Shares at the Closing are subject to the fulfillment, on or before the Closing, of each of the following conditions unless otherwise waived:
(a) The representations and warranties of the Company contained in Section 2.1 shall be true and correct in all respects as of the Closing.
(b) The Company shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Company on or before the Closing.
(c) The President of the Company shall deliver to the Purchasers at the Closing a certificate certifying that the conditions specified in Subsections 1.4(a) and 1.4(b) have been fulfilled.
(d) As of the Closing, the authorized size of the Board of Directors shall be seven (7), and the Board of Directors shall be comprised of the five (5) current directors and two (2) designees of the Purchasers (the “Purchaser Designees” ), who shall initially be Tim Leissner and one designee of Horizons (as defined in the Investors’ Rights Agreement), and shall be subject to further modification in accordance with the Investors’ Rights Agreement. The Company shall have executed and delivered an Indemnification Agreement in the form attached hereto as Exhibit A to each Purchaser Designee.
(e) The Company shall deliver certificates evidencing the Shares purchased by each Purchaser, registered in their respective names.
(f) The Company, each other Purchaser and the other shareholders of the Company named as parties thereto shall have executed the Investors’ Rights Agreement in the form of Exhibit B hereto (the “Investors’ Rights Agreement” ).
(g) The Company shall deliver copies of all material consents, authorizations, filings, licenses, approvals, and notice required or otherwise reasonably requested by the Purchasers in connection with the execution, delivery and performance by the Company, or the validity and enforceability of, this Agreement and all the Other Agreements (as hereinafter defined) to which each Purchaser is a party.
(h) The secretary of the Company shall deliver to each Purchaser a certificate certifying the Articles of Incorporation and bylaws of the Company, the resolutions adopted by the directors and shareholders of the Company in connection with this Agreement and the transactions contemplated hereby, and the incumbency of certain officers of the Company in the form of Exhibit C hereto.
2
(i) The Company shall deliver to each Purchaser copies of certificates issued by the appropriate governmental authorities evidencing the good standing of the Company as of a date not more than three (3) days prior to the Closing Date as a corporation organized under the laws of the State of Nevada.
(j) The Company shall deliver to each Purchaser copies of certificates issued by the appropriate governmental authorities evidencing the good standing of each Subsidiary (as hereinafter defined) as of a date not more than three (3) days prior to the Closing Date as a corporation organized under the laws of their respective jurisdictions of incorporation.
(k) The Company shall have filed a Certificate of Designation with respect to the shares of Preferred Stock being issued upon conversion of the LOC Note (as defined below) as contemplated by Section 1.4(q)(i) with the Secretary of State of the State of Nevada and shall be in full force and effect..
(1) The Purchasers shall have received from Gutierrez Bergman Boulris PLLC, counsel for the Company, an opinion, dated as of the Closing, in substantially the form of Exhibit D attached to this Agreement.
(m) The Company shall deliver to each Purchaser such other documents as may be necessary to effect the consummation of the transactions contemplated by this Agreement.
(n) The Purchasers shall have completed their legal, financial, management, technical, intellectual properties, business operation, permits and regulatory compliance and business due diligence investigation of the Company to their satisfaction.
(o) The Company shall have entered into a summary of terms outlining the material terms of a proposed joint venture in a form acceptable to the Purchasers (the “JV” ).
(p) Any existing registration rights, other than registration rights in favor of CD Financial, LLC ( “CD Financial” ) or its Affiliates pursuant to the Investors’ Rights Agreement, shall have been terminated.
(q) The consummation of the following contemporaneous financial transactions:
(i) Contemporaneously with and/or prior to Closing, the principal balance of the Company’s current line of credit note (“LOC Note” ) as of April 16, 2015 in the amount of $8,800,000, payable to CD Financial, LLC (“CD Financial” ), will be reduced by $4,000,000. In addition, at Closing, the maturity date of the LOC Note shall be extended to January 2, 2020 and the borrowing cap thereunder shall be reduced to $4,500,000. All other terms of the LOC Note will remain unchanged. The $4,000,000 principal reduction will be converted at Closing by CD Financial into a new series of preferred stock of the Company, designated as Series D Preferred Stock with terms comparable to the other outstanding series of preferred stock held by CD Financial and reasonably satisfactory the Purchasers. The Series D Preferred Stock will bear a cash dividend of 5% per annum, payable quarterly, and will be convertible, at the holder’s option, into shares of Common Stock at a conversion rate of $0.86 per share (subject to customary anti-dilution adjustments), through January 2, 2020 or through such earlier date as the LOC Note is repaid in full, if CD Financial elects not to exercise its conversion rights thereunder.
3
(ii) The current $1.5 million convertible note (the “CDS Note” ) payable by the Company to CDS Ventures of South Florida, LLC (“CDS Ventures”), will be purchased at Closing by certain of the Purchasers from CDS Ventures for $4,450,000 and thereupon, converted in full into shares of Common Stock of the Company in accordance with its terms.
1.5 Closing Deliveries by the Purchasers . The obligations of the Company to sell the Shares and consummate the transactions contemplated hereby at the Closing are subject to the fulfillment, on or before the Closing, of each of the following conditions unless otherwise waived by the Company (and by CD Financial and CDS Ventures in the case of Section 1.5(g) ):
(a) The representations and warranties of the Purchasers contained in Section 2.2 shall be true and correct in all respects as of the Closing.
(b) Each Purchaser shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by such Purchaser Company on or before the Closing.
(c) the Purchasers shall deliver or cause to be delivered to the Company the aggregate Purchase Price, as provided in Section 1.2;
(d) the Purchasers shall deliver or cause to be delivered to the Company the Investors’ Rights Agreement, duly executed by the Purchasers;
(e) the Purchasers shall deliver or cause to be delivered to the Company copies of all consents, authorizations, filings, licenses, approvals, and further assurances, if any, required or otherwise reasonably requested by the Company in connection with the execution, delivery and performance by the Purchasers or the validity and enforceability of, this Agreement and all Other Agreements to which the Purchasers are parties;
(f) the transactions contemplated by Section 1.4(q) shall be consummated concurrently with the Closing; and
(g) the Purchasers shall deliver or cause to be delivered to the Company such other documents as may be necessary to effect the consummation of the transactions contemplated by this Agreement.
4
ARTICLE II
REPRESENTATIONS AND WARRANTIES OF THE PARTIES
2.1 Representations and Warranties of the Company . The Company hereby makes the following representations and warranties to the Purchasers:
(a) Organization, Good Standing and Qualification .
(i) The Company is a corporation, duly incorporated, validly existing and in good standing under the laws of the State of Nevada, with the requisite corporate power and authority to own and use its properties and assets and to carry on its business as currently conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify could be reasonably expected to result in a material adverse effect on the business, assets (including intangible assets), liabilities, financial condition, property, prospects or results of operations of the Company and the Subsidiaries (as hereinafter defined), taken as a whole (a “Material Adverse Effect” ).
(ii) The subsidiaries of the Company and their respective jurisdictions of incorporation are set forth on Schedule 2.1(c) attached hereto (collectively, the “Subsidiaries” and individually, a “Subsidiary”). Each Subsidiary is duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation, with the requisite corporate power and authority to own and use its properties and assets and to carry on its business as currently conducted. Each Subsidiary is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify could be reasonably expected to result in a Material Adverse Effect.
(b) Authorization; Enforcement . The Company has the requisite corporate power and authority to enter into and to consummate the transactions contemplated by this Agreement, and otherwise to carry out its obligations hereunder. The execution and delivery of this Agreement by the Company, the other agreements contemplated hereby (the “Other Agreements” ) and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company. This Agreement and each of the Other Agreements has been duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligations of the Company enforceable against the Company in accordance with their respective terms. The Company is not in violation of any of the provisions of its Articles of Incorporation or bylaws.
5
(c) Capitalization; Subsidiaries .
(i) As of the date of this Agreement, the authorized capital stock of the Company consists of (i) 75,000,000 shares of Common Stock and (ii) 2,500,000 shares of preferred stock, par value $0,001 per share (the “Preferred Stock” ). The issued and outstanding capital stock of the Company as of the date hereof is set forth on Schedule 2.1(c)(i) hereto. Except as set forth on Schedule 2.1(c)(i) , no shares of capital stock of the Company are entitled to preemptive or similar rights, nor is any holder of capital stock of the Company entitled to statutory preemptive or similar rights arising out of any agreement or understanding with the Company. Except for (A) the securities described on Schedule 2.1 (c)(i) ; (B) the rights provided for in the Investors’ Rights Agreement; and (C) the securities and rights, privileges and preferences of the Company’s Preferred Stock stated in the Company’s Articles of Incorporation and as provided by the Nevada Corporations Code, there are no outstanding options, warrants, rights (including conversion and rights of first refusal and similar rights) to subscribe to, calls, or commitments of any character whatsoever relating to securities, rights or obligations convertible into or exchangeable for, or giving any individual, corporation, partnership, trust, limited liability company, association or other entity (any of the foregoing, a “Person” ) any right to subscribe for or acquire any shares of capital stock of the Company, or contracts, commitments, understandings, or arrangements by which the Company is or may become bound to issue additional shares of capital stock of the Company, or securities or rights convertible or exchangeable into shares of capital stock of the Company.
(ii) All issued and outstanding shares of the Company’s Common Stock and Preferred Stock (i) have been duly authorized and validly issued and are fully paid and nonassessable, and (ii) were issued in compliance with all applicable state and federal laws concerning the issuance of securities.
(iii) The Company is the sole shareholder of each Subsidiary. There are no outstanding options, warrants, rights (including conversion and rights of first refusal and similar rights) to subscribe to, calls, or commitments of any character whatsoever relating to securities, rights or obligations convertible into or exchangeable for, or giving any Person any right to subscribe for or acquire any shares of capital stock of each Subsidiary, or contracts, commitments, understandings, or arrangements by which each Subsidiary is or may become bound to issue additional shares of capital stock of each Subsidiary, or securities or rights convertible or exchangeable into shares of capital stock of each Subsidiary.
(iv) No shares of Series A Preferred Stock or Series B Preferred Stock are outstanding and there are no special rights, preferences or privileges attached to any of the shares of common stock issued upon conversion of such Series A Preferred Stock and Series B Preferred Stock, including without limitation any contractual rights, registration rights, affirmative or negative covenants or protective provisions, except as listed on Schedule 2.1(c)(iv) .
(v) All agreements related to the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock and any convertible securities, including convertible notes (other than options granted pursuant to their standard form option agreement) are listed on Schedule 2.1(c) (v) of the Disclosure Schedule.
6
(d) Issuance of the Securities . The Shares are duly authorized, and when issued and paid for in accordance with the terms hereof, shall be duly and validly issued, fully paid and nonassessable, and free and clear of all liens, encumbrances and rights of first refusal of any kind (collectively, “Liens” ). Based in part upon the representations of the Purchasers set forth in Section 2.2(b) of this Agreement, the Shares will be issued in compliance with all applicable federal and state securities laws.
(e) No Conflicts . The execution, delivery and performance of this Agreement and the Other Agreements by the Company and the consummation by the Company of the transactions contemplated hereby and thereby do not and will not (i) conflict with or violate any provision of the Company’s Articles of Incorporation or bylaws (each as amended through the date hereof); (ii) conflict with, or constitute a default (or an event which with notice or lapse of time, or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time, or both) of, any agreement, credit facility, indenture or instrument (evidencing an the Company debt or otherwise) to which the Company or any Subsidiary is a party or by which any property or asset of the Company or any Subsidiary is bound or affected; or (iii) result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or any Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the Company or any Subsidiary is bound or affected, except in the case of each of clauses (ii) and (iii), as could not, individually or in the aggregate, reasonably be expected to result in a Material Adverse Effect. The business of the Company and the Subsidiaries is conducted in compliance in all material respects with all laws, ordinances or regulations of any governmental authority.
(f) Filings. Consents and Approvals . The Company is not required to obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other U.S. or foreign federal, state, local or other governmental authority or other person in connection with the execution, delivery and performance by the Company of this Agreement and the Other Agreements, other than filings which may be required under federal and state securities laws.
(g) Litigation; Proceedings . There is no action, suit, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company or any of its properties (including for these purposes the Subsidiaries) before or by any court, governmental or administrative agency, or regulatory authority (U.S. federal, state, county, local or foreign), nor is the Company aware of any reasonable basis therefore. Neither the Company nor, to the Company’s knowledge, any of its officers, directors or any of its employees is a party or is named as subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the case of officers, directors or employees, such as would affect the Company). There is no action, suit, proceeding or investigation by the Company or any Subsidiary pending or which the Company or any Subsidiary intends to initiate. The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or threatened in writing (or any basis therefor known to the Company) involving the prior employment of any of the Company’s employees, their services provided in connection with the Company’s business, any information or techniques allegedly proprietary to any of their former employers or their obligations under any agreements with prior employers.
7
(h) No Default or Violation . Neither the Company nor any Subsidiary (i) is in material default under or in violation of (and no event has occurred that has not been waived that, with notice or lapse of time or both, would result in a material default), nor has the Company or any Subsidiary received written notice of a claim that it is in material default under or is in material violation of any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound, (ii) is not in violation in any material respect of any order of any court, arbitrator or governmental body, or (iii) is not in violation in any material respect of any statute, rule or regulation of any governmental authority.
(f) Brokers Fees . No fees or commissions will be payable by the Company to any broker, financial advisor or consultant, finder, placement agent, investment banker, or bank with respect to the transactions contemplated by this Agreement.
(j) Intellectual Property .
(i) Each of the Company and the Subsidiaries owns or possesses sufficient legal rights to its respective Intellectual Property (as defined below) necessary for its business as now conducted and as presently proposed to be conducted. To the Company’s knowledge, no product or service marketed or sold (or proposed to be marketed or sold) by the Company or the Subsidiaries violates or will violate any license or infringes or will infringe any intellectual property rights of any other party. Other than with respect to commercially available software products under standard end-user object code license agreements, there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating to the Intellectual Property, nor is the Company or the Subsidiaries bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, proprietary rights and processes of any other Person. Neither the Company nor any Subsidiary has received any communications alleging that the Company or any Subsidiary, as the case may be, has violated, or by conducting its business, would violate any of the patents, trademarks, service marks, trade names, copyrights, trade secrets, mask works or other proprietary rights or processes of any other Person. Each of the Company and the Subsidiaries has obtained and possesses valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices that it owns or leases or that it has otherwise provided to its employees for their use in connection with its business. To the Company’s knowledge, it will not be necessary to use any inventions of any of its employees or consultants (or Persons it currently intends to hire) made prior to their employment by the Company or the Subsidiaries. Each employee and consultant has assigned to the Company or the Subsidiaries, as the case may be, all intellectual property rights he or she owns that are related to the Company’s or each Subsidiary’s business as now conducted and as presently proposed to be conducted. Neither the Company nor any Subsidiary has embedded any open source, copyleft or community source code in any of its products generally available or in development. For purposes of this Agreement, “Intellectual Property” means all patents, patent applications, trademarks, trademark applications, service marks, service mark applications, trade names, copyrights, trade secrets, domain names, mask works, information and proprietary rights and processes, similar or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing, and any and all such cases that are owned or used by the Company or the Subsidiary in the conduct of its respective businesses as now conducted and as presently proposed to be conducted.
8
(ii) All material licenses or other agreements under which the Company or any Subsidiary is granted Intellectual Property (excluding licenses to use software utilized in the Company’s or such Subsidiary’s internal operations and which is generally commercially available) are in full force and effect and, to the Company’s knowledge, there is no material default by any party thereto. The Company has no reason to believe that the licensors under such licenses and other agreements do not have and did not have all requisite power and authority to grant the rights to the Intellectual Property purported to be granted thereby.
(iii) All licenses or other agreements under which the Company or any Subsidiary has granted rights to Intellectual Property to others (including all end-user agreements) are in full force and effect, there has been no material default by the Company or any Subsidiary thereunder and, to the Company’s knowledge, there is no material default of any provision thereof relating to Intellectual Property by any other party thereto.
(iv) Each of the Company and the Subsidiaries has taken all steps required in accordance with commercially reasonable business practice to establish and preserve their ownership in their owned Intellectual Property and to keep confidential all material technical information developed by or belonging to the Company or such Company which has not been patented or copyrighted.
(k) Regulatory Permits . Each of the Company and the Subsidiaries possesses all certificates, authorizations and permits issued by the appropriate U.S. federal, state or foreign regulatory authorities materially necessary to conduct its business (“Permits” ), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Permit.
(l) Title . Neither the Company nor any Subsidiary owns any real property. Each of the Company and the Subsidiaries has good and marketable title to all personal property owned by each of them that is material to its respective business, in each case free and clear of all Liens, except for Liens that do not materially affect the value of such property and do not interfere with the use made and proposed to be made of such property by the Company or the Subsidiaries. Any real property and facilities held under lease by the Company and the Subsidiaries is held under valid, subsisting and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made of such property and buildings by the Company or the Subsidiaries, as the case may be.
9
(m) Agreement Actions .
(i) Except for the Other Agreements and the employment agreements set forth on Schedule 2.1(m)(i) (the “Employment Agreements” ), there are no agreements, understandings, instruments, contracts or proposed transactions to which the Company or any Subsidiary is a party or by which any of them is bound that involve (i) obligations (contingent or otherwise) of, or payments to, the Company in excess of $50,000; (ii) the license of any patent, copyright, trademark, trade secret or other proprietary right to or from the Company or any Subsidiary; (iii) the grant of rights to manufacture, produce, license, market, or sell its products to any other Person that limit the Company’s or any Subsidiary’s exclusive right to develop, manufacture, distribute, market or sell its products; or (iv) indemnification by the Company or any Subsidiary with respect to infringements of proprietary rights.
(ii) Except as set forth on Schedule 2.1(m)(ii) , the Company has not (i) declared or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or incurred any other liabilities individually in excess of $20,000 or in excess of $50,000 in the aggregate, (iii) made any loans or advances to any Person, other than ordinary advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory in the ordinary course of business. Neither the Company nor any Subsidiary is a guarantor or indemnitor of any indebtedness of any other Person.
(iii) A true, complete and accurate list of all agreements or other arrangements with sales representatives, distributors, or other third parties selling the Company’s products, including the territories covered by such arrangements is attached as Schedule 2.1(m)(iii) to the Disclosure Schedule, and such Schedule 2.1(m)(iii) includes any exclusive rights granted to any party.
(n) Certain Transactions .
(i) Other than (i) standard employee benefits generally made available to all employees, (ii) standard director and officer indemnification agreements approved by the Board of Directors, (iii) this Agreement and the Other Agreements, (iv) the Employment Agreements and (v) as described in the notes to the Financial Statements (as hereinafter defined) or as set forth on Schedule 2.1(n)(i) , there are no agreements, understandings or between Company and any of its officers, directors, any members of their immediate families, or any Affiliate of the foregoing. For purposed of this Agreement “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person.
10
(ii) Except as set forth on Schedule 2.1(n)(i), the Company is not indebted, directly or indirectly, to any of its directors, officers or employees or any members of their immediate families, or any Affiliate of the foregoing, other than in connection with expenses or advances of expenses incurred in the ordinary course of business or employee relocation expenses and for other customary employee benefits made generally available to all employees. None of the Company’s directors, officers or employees, or any members of their immediate families, or any Affiliate of the foregoing are, directly or indirectly, indebted to the Company or have any (i) material commercial, industrial, banking, consulting, legal, accounting, charitable or familial relationship with any of the Company’s customers, suppliers, service providers, joint venture partners, licensees and competitors, (ii) direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a business relationship, or any firm or corporation which competes with the Company except that directors, officers, employees or shareholders of the Company may own stock in (but not exceeding two percent (2%) of the outstanding capital stock of) publicly traded companies that may compete with the Company; or (iii) financial interest in any contract with the Company.
(o) Rights of Registration, Voting Rights and Other Special Rights . Except as provided in the Investors’ Rights Agreement or as set forth on Schedule 2.1(o), the Company is not under any obligation to register under the Securities Act of 1933, as amended (the “Securities Act’ ) any of its currently outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities. Except as provided in the Investors’ Rights Agreement or as set forth on Schedule 2.1(o), no shareholder of the Company has entered into any agreements with respect to the voting of capital shares of the Company or any other agreement that provides such shareholder protective provisions, special approval rights, negative covenants over the operations of the Company or that otherwise places restrictions on the Company’s business.
(p) Financial Statements . The Company has delivered to the Purchasers its unaudited consolidated financial statements (consisting of consolidated unaudited balance sheets, consolidated unaudited statements of operations and consolidated unaudited statements of changes in stockholders’ deficit as of and for the years ended December 31, 2013 and 2014 (collectively, the “Financial Statements” ). For purposes hereof, December 31, 2014 shall be referred to as of the “Financial Statement Date”. The Financial Statements fairly present in all material respects the consolidated financial condition and consolidated operating results of the Company and Subsidiaries as of the dates, and for the periods, indicated therein. Except as set forth in the Financial Statements, neither the Company nor the Subsidiaries has any material liabilities or obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary course of business subsequent to the Financial Statement Date; (ii) obligations under contracts and commitments incurred in the ordinary course of business.
11
(q) Changes . Except as contemplated hereby, since the Financial Statement Date there has not been:
(i) any material change in the assets, liabilities, financial condition or operating results of the Company (on a consolidated basis) from that reflected in the Financial Statements, except changes in the ordinary course of business;
(ii) any damage, destruction or loss, whether or not covered by insurance, that would have a Material Adverse Effect;
(iii) any waiver or compromise by the Company or any Subsidiary of a valuable right or of a material debt owed to it;
(iv) any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Company or any Subsidiary, except in the ordinary course of business and the satisfaction or discharge of which would not have a Material Adverse Effect;
(v) any material change to a material contract or agreement by which the Company or any of its assets is bound or subject;
(vi) any material change in any compensation arrangement or agreement with any employee, officer, director or shareholder;
(vii) any mortgage, pledge, transfer of a security interest in, or lien, created by the Company or any Subsidiary, with respect to any of their respective material properties or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially impair the Company’s or Subsidiary’s ownership or use of such property or assets;
(viii) any loans or guarantees made by the Company or any Subsidiary to or for the benefit of its employees, officers or directors, or any members of their immediate families, other than travel advances and other advances made in the ordinary course of its business;
(ix) any declaration, setting aside or payment or other distribution in respect of any of the Company’s capital stock, or any direct or indirect redemption, purchase, or other acquisition of any of such stock by the Company;
(x) any sale, assignment or transfer of any material Intellectual Property;
(xi) any receipt of notice from any supplier, distributor or customer of the Company that the Company is in breach of any agreement or that such supplier, distributor or customer of the company is canceling, materially reducing or otherwise terminating its business with the Company or that it intends to cancel, reduce or otherwise terminate its relationship with the Company;
12
(xii) any receipt of notice that there has been a loss of, or material order cancellation by, any major customer of the Company;
(xiii) to the Company’s knowledge, any other event or condition of any character, other than events affecting the economy or the Company’s or any Subsidiary’s industry generally, that could reasonably be expected to result in a Material Adverse Effect; or
(xiv) any arrangement or commitment by the Company or any Subsidiary to do any of the things described in this Section 2.1(q).
(r) Employee Agreements . Each current and former employee of the Company listed on Schedule 2.1(r), consultant and officer of the Company has executed an agreement with the Company regarding confidentiality and proprietary information substantially in the form or forms delivered to the counsel for the Purchaser (the “Confidential Information Agreements” ). No current or former employee has excluded works or inventions from his or her assignment of inventions pursuant to such employee’s Confidential Information Agreement.
(s) Foreign Corrupt Practices . Neither the Company nor any Subsidiary nor any of the Company’s directors, officers, employees or agents have, directly or indirectly, made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any “foreign official” (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA” )), foreign political party or official thereof or candidate for foreign political office for the purpose of (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority, or (iii) securing any improper advantage, in the case of (i), (ii) and (iii) above in order to assist the Company or any of its affiliates in obtaining or retaining business for or with, or directing business to, any person. Neither the Company nor any of its directors, officers, employees or agents have made or authorized any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any funds in violation of any law, rule or regulation. The Company further represents that it has maintained, and has caused each of its Subsidiaries and affiliates to maintain, systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA or any other applicable anti-bribery or anti-corruption law. Neither the Company, or, to the Company’s knowledge, any of its officers, directors or employees are the subject of any allegation, voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other anti-corruption law.
(t) Key Employees . The Company has no knowledge of any fact or circumstance (including, without limitation, (i) the terms of any agreement to which such person is a party or any litigation in which such person is or may become involved and (ii) any illness or medical condition that could reasonably be expected to result in the disability or incapacity of such person) that would limit or prevent any “executive officers” (as defined in Rule 501(f) of the Securities Act) of the Company (each, a “Key Employee” ) from serving in such capacity on a full-time basis in the reasonably foreseeable future, or of any intention on the part of any such person to limit or terminate his or her employment with the Company or any Subsidiary. No Key Employee has borrowed money pursuant to a currently outstanding loan that is secured by Common Stock or any right or option to receive Common Stock.
13
(u) Environment . Neither the Company nor any Subsidiary has any liabilities under any Environmental Law, nor, to the Company’s knowledge, do any factors exist that are reasonably likely to give rise to any such liability, materially affecting any of the properties owned or leased by the Company or any Subsidiary. Neither the Company nor any Subsidiary has violated in any material respect any Environmental Law applicable to it now or previously in effect. For purposes of this Agreement, “Environmental Law” means any federal, state, provincial, local or foreign law, statute, code or ordinance, principle of common law, rule or regulation, as well as any permit, order, decree, judgment or injunction issued, promulgated, approved or entered thereunder, relating to pollution or the protection, cleanup or restoration of the environment or natural resources, or to the public health or safety, or otherwise governing the generation, use, handling, collection, treatment, storage, transportation, recovery, recycling, discharge or disposal of hazardous materials.
(v) Taxes . Each of the Company and Subsidiaries has prepared in good faith and duly and timely filed all tax returns required to be filed by it and such returns are complete and accurate in all material respects, except for tax returns that would not reasonably be expected to have a Material Adverse Effect; and each of the Company and Subsidiaries has paid all taxes required to have been paid by it, except for taxes which it reasonably disputes in good faith or the failure of which to pay has not had or would not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any Subsidiary has any liability with respect to taxes that accrued on or before the date of the most recent balance sheet of the Company in excess of the amounts accrued with respect thereto that are reflected on such balance sheet
(w) Corporate Documents. The Articles of Incorporation and bylaws of the Company and each Subsidiary are in the forms provided to the Purchaser. The copy of the minute books of the Company and each Subsidiary provided to the Purchaser contains minutes of all meetings of directors and shareholders and all actions by written consent without a meeting by the directors and shareholders since the date of incorporation and accurately reflects in all material respects all actions by the directors (and any committee of directors) and shareholders with respect to all transactions referred to in such minutes.
(x) Data Privacy . In connection with its collection, storage, transfer (including, without limitation, any transfer across national borders) and/or use of any personally identifiable information from any individuals, including, without limitation, any customers, prospective customers, employees and/or other third parties (collectively “Personal Information”), the Company is and has been, to the Company’s knowledge, in compliance with all applicable laws in all relevant jurisdictions, the Company’s privacy policies and the requirements of any contract or codes of conduct to which the Company is a party. The Company has commercially reasonable physical, technical, organizational and administrative security measures and policies in place to protect all Personal Information collected by it or on its behalf from and against unauthorized access, use and/or disclosure. The Company is and has been in compliance in all material respects with all laws relating to data loss, theft and breach of security notification obligations.
14
(y) No “Bad Actor” Disqualification . The Company has exercised reasonable care to determine whether any Company Covered Person (as defined below) is subject to any of the “bad actor” disqualifications described in Rule 506(d)(l)(i) through (viii), as modified by Rules 506(d)(2) and (d)(3), under the Securities Act (such disqualifications, the “Disqualification Events” ). To the Company’s knowledge, no Company Covered Person is subject to a Disqualification Event. The Company has complied, to the extent required, with any disclosure obligations under Rule 506(e) under the Securities Act. For purposes of this Agreement, “Company Covered Persons” are those persons specified in Rule 506(d)(1) under the Securities Act; provided, however, that Company Covered Persons do not include (a) any Purchaser, (b) any person or entity that is deemed to be an affiliated issuer of the Company solely as a result of the relationship between the Company and any Purchaser (c) any director of the Company that has been designated by any Purchaser.
(z) Disclosure . No representation or warranty of the Company contained in this Agreement, as qualified by the Disclosure Schedule, and no certificate furnished or to be furnished to Purchasers at the Closing contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in light of the circumstances under which they were made.
2.2 Representations and Warranties of the Purchasers . Each Purchaser, for himself, herself or itself and not for any other Purchaser, hereby represents and warrants to the Company as follows:
(a) Authorization; Enforcement . The Purchaser has all necessary power and authority (corporate or otherwise) to execute and deliver this Agreement and to carry out its provisions. All action on the Purchaser’s part required for the lawful execution and delivery of this Agreement has been taken. Upon its execution and delivery, this Agreement will be a valid and binding obligation of the Purchaser, enforceable in accordance with its terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium or other laws of general application affecting enforcement of creditors’ rights; and (b) as limited by general principles of equity that restrict the availability of equitable remedies.
(b) Investment Representations and Covenants of the Purchasers . Each Purchaser, for himself, herself or itself and not for any other Purchaser, represents and warrants to and covenants with the Company as follows:
(i) Investment Intent . The Purchaser is acquiring the Shares for the Purchaser’s own account. The Purchaser is acquiring the Shares for investment purposes only and not with a view to or for distributing or reselling the Shares or any part thereof or interest therein in violation of securities laws, however, each Purchaser has the right at all times to sell or otherwise dispose of all or any part of the Shares pursuant to an effective registration statement under the Securities Act and in compliance with applicable state securities laws or under an exemption from such registration.
15
(ii) Status . The Purchaser is an “accredited investor” as defined in Rule 501(a) under the Securities Act.
(iii) Experience of the Purchaser . The Purchaser has such knowledge, sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Shares, and has so evaluated the merits and risks of such investment.
(iv) Ability of the Purchaser to Bear Risk of Investment . The Purchaser is able to bear the economic risk of an investment in the Shares and, at the present time, is able to afford a complete loss of such investment.
(v) Access to Information . The Purchaser acknowledges that it has been afforded (i) the opportunity to ask such questions as Purchaser has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions of the issuance of the Shares and the merits and risks of investing in the Shares; (ii) access to publicly available information about the Company and the Company’s financial condition, results of operations, business, properties, management and prospects sufficient to enable the Purchaser to evaluate the investment; and (iii) the opportunity to obtain such additional publicly available information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment decision with respect to the investment and to verify the accuracy and completeness of the information contained herein.
(vi) Reliance . The Purchaser understands and acknowledges that (i) the Shares are being issued to the Purchaser without registration under the Securities Act and applicable state securities laws in a private placement that is exempt from the registration provisions of the Securities Act and applicable state securities laws; and (ii) the availability of such exemption depends in part on, and the Company will rely upon the accuracy and truthfulness of, the foregoing Purchaser representations and the Purchaser hereby consents to such reliance.
(c) Legends . The Purchaser understands that the certificates evidencing the Shares will bear the following or similar legends for as long as required by the Securities Act and applicable state securities laws:
“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.
16
THE SHARES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OR THE SECURITIES LAWS OF ANY STATE AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND SUCH LAWS. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SECURITIES AND EXCHANGE COMMISSION, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON OR ENDORSED THE MERITS OF THE OFFER AND SALE OF THE SHARES OR THE ACCURACY OR ADEQUACY OF THIS AGREEMENT. ANY REPRESENTATION TO THE CONTRARY IS UNLAWFUL.”
(d) Foreign Investors . If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code of 1986, as amended), the Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares or any use of this Agreement, including (i) the legal requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares. The Purchaser’s subscription and payment for and continued beneficial ownership of the Shares will not violate in any material respect any applicable securities or other laws of the Purchaser’s jurisdiction.
(e) No “Bad Actor” Disqualification . Each Purchaser severally and not jointly, represents and warrants to the Company that neither (i) such Purchaser, nor (ii) any person or entity that is a beneficial owner of such Purchaser’s securities for purposes of Rule 506(d) under the Securities Act, is subject to any Disqualification Event, except for Disqualification Events both (x) covered by Rule 506(d)(2)(i), (ii) or (iii) or (d)(3) under the Securities Act and (y) disclosed in writing in reasonable detail to the Company.
ARTICLE III
OTHER AGREEMENTS OF THE PARTIES
3.1 Transfer Restrictions .
(a) The Shares may only be disposed of pursuant to an effective registration statement under the Securities Act and applicable state securities laws, or pursuant to an available exemption from or in a transaction not subject to the registration requirements of the Securities Act and applicable state securities laws. In connection with any transfer of the Securities other than pursuant to an effective registration statement, the Company may require the transferor thereof to provide to the Company an opinion of counsel selected by the transferor, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not require registration of such transferred securities under the Securities Act and applicable state securities laws, provided that no such opinion shall be required for any transfer of Shares to an Affiliate (as defined in the Investor Rights Agreement).
17
(b) Purchasers agree to the imprinting, so long as is required under the Securities Act and the rules and regulations thereunder, of an appropriate restrictive legend on the certificates evidencing the Shares.
3.2 Joint Venture . After Closing, the parties will use their reasonable best efforts to consummate as promptly as reasonably practicable the proposed JV.
3.3 Post-Closing Covenants .
(a) Within ninety (90) days following the Closing Date or within such longer period as may be approved by the Board, including the approval of at least one of the Investor Directors (as defined in the Investors’ Rights Agreement), the Company will review with the Board of Directors, including at least one of the Investors Director (as defined in the Investors’ Rights Agreement), the trademarks held by it and each Subsidiary and ensure that each trademark is assigned to the appropriate legal entity as well as attend to any other clean-up matters as may be reasonably requested by the Board of Directors, including the Investor Director.
(b) Within one hundred eighty (180) days following the Closing Date or within such longer period as may be approved by the Board, including the approval of at least one of the Investor Directors, The Company shall complete the audit of its financial statements for the years ended December 31, 2013 and 2014 with an audit firm acceptable to the Board, including at least one of the Investor Directors.
ARTICLE IV
INDEMNIFICATION
4.1 Survival . The representations and warranties of the Company and the Purchasers contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and Closing for a period of three (3) years.
4.2 Indemnity by the Company . The Company shall indemnify the Purchasers and hold the Purchasers and their respective members, managers, directors, officers, employees and agents (collectively, the “Purchaser Parties” ) harmless against and in respect of any and all damages, losses, diminution in value claims, penalties, liabilities, costs and expenses (including, without limitation, all fines, interest, reasonable and actual legal fees and expenses and amounts paid in settlement), that arise from or relate or are attributable to (and without giving effect to any tax benefit to the indemnified party) (a) any misrepresentation by the Company or breach of any representation or warranty by the Company in this Agreement; or (b) any breach of any covenant or agreement on the part of the Company in this Agreement or the Investor Rights Agreement. Notwithstanding anything in this Agreement to the contrary, in no event shall the Company be liable for any punitive, consequential or special damages of any kind or nature arising from this Agreement, regardless of the form of action through which such damages are sought including any claim for indemnity under this Section 4.2.
18
4.3 Notice to Indemnitor; Right of Parties to Defend . Promptly after the assertion of any claim by a third party or occurrence of any event which may give rise to a claim for indemnification from an indemnifying party (the “Indemnitor” ) under this Article IV, an indemnified party (the “Indemnitee”) shall notify the Indemnitor in writing of such claim. The Indemnitor shall have the right to assume the control and defense of any such action (including, but without limitation, tax audits), provided that the Indemnitee may participate in the defense of such action subject to the Indemnitor’s reasonable direction and at Indemnitee’s sole cost and expense. The party contesting any such claim shall be furnished all reasonable assistance in connection therewith by the other party and be given full access to all information relevant thereto. In no event shall any such claim be settled without the Indemnitor’s consent.
ARTICLE V
MISCELLANEOUS
5.1 Fees and Expenses . Each party to this Agreement shall pay the fees and expenses of its or its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiations, preparation, execution, delivery and performance of this Agreement; provided , however , that the Company shall pay the Purchasers’ counsel fees incurred in connection with this Agreement in an amount not to exceed Twenty Thousand Dollars ($20,000.00) in the aggregate.
5.2 Entire Agreement; Amendments . This Agreement, together with the Other Agreements and the exhibits and schedules hereto and thereto, contains the entire understanding of the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and schedules.
5.3 Notices . All notices required or permitted hereunder shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified; (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, if not, then on the next business day; (c) five (5) days after having been sent by certified mail, return receipt requested, postage prepaid; or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt. All communications shall be sent to the parties at the address as set forth on the signature page hereof or at such other address or electronic mail address as the applicable party may designate by ten (10) days advance written notice to the other parties hereto:
19
For purposes hereof, any notice shall be addressed as follows:
If to the Company, to: | Celsius Holdings, Inc. |
Attention: CEO | |
2424 North Federal Highway | |
Boca Raton, FL 33341 | |
Telephone Number: 561-276-2239 | |
Fax Number: 561-276-2268 | |
Email: jfieldly@celsius.com |
With a copy (which shall not constitute notice) to:
Dale S. Bergman, Esquire | |
Gutierrez Bergman Boulris, PLLC | |
100 Almeria Avenue, Suite 340 | |
Coral Gables, FL 33134 | |
Telephone Number: 305-358-5100 | |
Fax Number: 888-281-1829 | |
Email: dale.bergman@gbbpl.com |
If to the Purchasers, to: | Their street addresses, telephone numbers, fax numbers and e-mail addresses, as set forth on their respective Purchaser Counterpart Signature pages to this Agreement |
With a copy (which shall not constitute notice) to:
J. Patrick Loofbourrow | |
Cooley LLP | |
International Finance Center, Tower 2, Level 35 | |
8 Century Avenue, Pudong | |
Shanghai 200120, China | |
Telephone: +86 21 6030 0608 | |
US Mobile: 619-840-4824 | |
Email: loof@cooley.com |
or such other address as may be designated in writing hereafter, in the same manner, by the Company or any Purchaser.
5.4 Amendments; Waivers . No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of an amendment, by all the parties; or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of either party to exercise any right hereunder in any manner impair the exercise of any such right accruing to it thereafter.
5.5 Headings . The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect any of the provisions hereof.
20
5.6 Successors and Assigns . This Agreement shall be binding upon and inure to the benefit of the parties and their successors and permitted assigns. Neither party may assign this Agreement nor any of the rights or obligations hereunder without the written consent of the other party, which consent shall not unreasonably withheld.
5.7 No Third-Party Beneficiaries . This Agreement is intended for the benefit of the parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person.
5.8 Governing Law . This Agreement shall be governed by and construed and enforced in accordance with the internal laws of the State of New York without regard to the principles of conflicts of law thereof. Any unresolved controversy or claim arising out of or relating to this Agreement, except as otherwise provided in this Agreement, shall be submitted to arbitration by one arbitrator mutually agreed upon by the parties, and if no agreement can be reached within thirty (30) days after names of potential arbitrators have been proposed by the American Arbitration Association (the “AAA” ), then by one arbitrator having reasonable experience in corporate finance transactions of the type provided for in this Agreement and who is chosen by the AAA. The arbitration shall take place in New York, in accordance with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding and may be entered in any court having jurisdiction thereof. There shall be limited discovery prior to the arbitration hearing as follows: (a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party witnesses, and (c) such other depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance with the New York Code of Civil Procedure, the arbitrator shall be required to provide in writing to the parties the basis for the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting the official transcript of such proceedings.
5.9 Attorneys’ Fees . In any suit, action or proceeding brought with respect to interpretation or enforcement of this Agreement, the prevailing party shall be entitled to recover from the non-prevailing party, attorneys’ fees and costs at both the trial and appellate levels.
5.10 Public Announcement; Confidentiality . Except as may be required by law, no party shall issue any press release or otherwise publicly disclose this Agreement or the transactions contemplated hereby or any dealings between or among the parties in connection with the subject matter hereof without the prior approval of the other parties, which shall not be unreasonably withheld. In the event that any such press release or other public disclosure shall be required by applicable law, the party required to issue such release or disclosure shall consult in good faith with the other parties hereto with respect to the form and substance of such release or disclosure prior to the public dissemination thereof.
5.11 Execution . This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile or electronic transmission, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) the same with the same force and effect as if such facsimile signature page were an original thereof.
21
6.12 Severability . In case any one or more of the provisions of this Agreement shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Agreement shall not in any way be affecting or impaired thereby and the parties will attempt to agree upon a valid and enforceable provision that shall be a reasonable substitute therefore, and upon so agreeing, shall incorporate such substitute provision in this Agreement.
6.13. No Commitment for Additional Financing . The Company acknowledges and agrees that no Purchaser has made any representation, undertaking, commitment or agreement to provide or assist the Company in obtaining any financing, investment or other assistance, other than the purchase of the Shares as set forth herein and subject to the conditions set forth herein. In addition, the Company acknowledges and agrees that (i) no statements, whether written or oral, made by any Purchaser or its representatives on or after the date of this Agreement shall create an obligation, commitment or agreement to provide or assist the Company in obtaining any financing or investment, (ii) the Company shall not rely on any such statement by any Purchaser or its representatives, and (iii) an obligation, commitment or agreement to provide or assist the Company in obtaining any financing or investment may only be created by a written agreement, signed by such Purchaser and the Company, setting forth the terms and conditions of such financing or investment and stating that the parties intend for such writing to be a binding obligation or agreement. Each Purchaser shall have the right, in its sole and absolute discretion, to refuse or decline to participate in any other financing of or investment in the Company, and shall have no obligation to assist or cooperate with the Company in obtaining any financing, investment or other assistance.
(Signatures appear on following pages )
22
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
THE COMPANY: | ||
CELSIUS HOLDINGS, INC. | ||
By: | /s/ Gerry David | |
Name: | Gerry David | |
Title: | CEO |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
CHARMNEW LIMITEDS: | ||
By: | /s/ Pau Yee Wan, Ezra | |
Name: | Pau Yee Wan, Ezra | |
Title: | Director |
Address: 7/F, Cheung Kong Center | |
2 Queen’s Road Central, Hong Kong | |
Attn: Ms. Ezra Pau/Ms. Eirene Yeung | |
Phone #: +852 21288888 | |
Fax #: +852 21288001 | |
Email: ezra.pau@ckh.com.hk | |
/ eirene.yeung@ckh.com.hk |
GRIEG INTERNATIONAL LIMITED | ||
By: | /s/ Chau Hoi Shuen, Solina Holly | |
Name: | Chau Hoi Shuen, Solina Holly | |
Title: | Director |
Address: 29th Floor, Harbour Centre, | |
25 Harbour Road, Wanchai, Hong Kong | |
Attention: Jason Wong | |
Phone #: +852 21863873 | |
Fax #: +852 37411011 | |
Email: jason.wong@horizons.com.hk | |
raymond.ng@horizons.com.hk | |
chris.lai@horizons.com.hk |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
NU HORIZONS INVESTMENT GROUP, LLC | ||
By: | /s/ Tim Leissner | |
Name: | Tim Leissner | |
Title: | Director |
Address: Rush Communications | |
512 Seventh Avenue, 43rd Floor | |
New York, NY 10018 | |
Phone Number: +852 9742 9229 | |
Email: tim_leissner@yahoo.com | |
Attention: Tim Leissner |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
XYXY HOLDINGS LTD. | ||
By: | /s/ Tong Xiaomeng | |
Name: | Tong Xiaomeng | |
Title: | Director |
Address: Flat B, 45/F, Block 8, Phase 2, | |
Residence Bel-Air, Pokfulam, Hong Kong | |
Phone Number: +85292683074 | |
Email: stong@boyucapital.com | |
Attention: Xiaomeng Tong |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
SINO ELECT INVESTMENTS LIMITED | ||
By: | /s/ [ILLEGIBLE] | |
Name: | [ILLEGIBLE] | |
Title: | Director |
Address: Kum Hing Court,28 Tomlinson | |
Road 10-32, Singapore 247854 | |
Phone Number: +65 97843406 | |
Email: awy.julianto@gmail.com | |
Attention: Awy Julianto |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
OSCAR TIME LIMITED | ||
By: | /s/ Chau Hoi Shuen Solina Holly | |
Name: | Chau Hoi Shuen Solina Holly | |
Title: | Director |
Address: 29th Floor, Harbour Centre, | |
25 Harbour Road, Wanchai, | |
Hong Kong | |
Email: jason.wong@horizons.com.hk / raymond.ng@horizons.com.hk | |
Attention: Jason Wong / Raymond Ng |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
BEYOND MERITS LIMITED | ||
By: | /s/ Jason Wong | |
Name: | Jason Wong | |
Title: | Director |
Address: 29th Floor, Harbour Centre, | |
25 Harbour Road, Wanchai, | |
Hong Kong | |
Email: jason.wong@horizons.com.hk / | |
raymond.ng@horizons.com.hk | |
Attention: Jason Wong / Raymond Ng |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
HELLO WARRIOR FAMILY TRUST DTD 2/27/09 | ||
DocuSigned by: | ||
By: | /s/ Brigette Lau | |
Name: | Brigette Lau | |
Title: | Trustee |
Address: | |
c/o ICONIQ Capital | |
394 Pacific Ave 2nd Floor | |
San Francisco, CA 94111 | |
Phone Number: 415-967-7483 | |
Fax Number: 415-321-3960 | |
Email: fundadmin@iconiqcapital.com | |
Attention: Grace Nam |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
HUGO BARRA | ||
By: | /s/ Hugo Barra | |
Name: | Hugo Barra |
Address: | |
601 4th St | |
San Francisco, CA 94107 | |
Phone Number: 617-592-7676 | |
Email: hbarra@gmail.com |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
HELVETICO LIMITED | ||
By: | /s/ Lou Montilla | |
Name: | Lou Montilla | |
Title: | Director |
Address: Flat A | |
31 Parkside | |
Wimbledon | |
SW19 5NB | |
UK | |
Email: lou.montilla@yahoo.com.au | |
Attention: Lou Montilla |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
LUKE NOLAN | ||
By: | /s/ Luke Nolan | |
Name: | Luke Nolan |
Address: Flat 1901, Block 6, 9 Maoming | |
South Road, Huangpu District, Shanghai, | |
China | |
Phone Number: +44 7771 685 068 (UK) | |
+86 135 1215 7147 (China) | |
Email: luke@overseasstudentliving.com | |
Attention: Luke Nolan |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
WINNIE YU | ||
By: | /s/ Winnie Yu | |
Name: | ||
Title: |
Address: No. 3, Broadcast Drive, | |
Kowloon, Hong Kong SAR | |
Phone Number: +852 91039103 | |
Email: yt@9103.hk | |
Attention: Winnie Yu |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
SHOUBIN CHEN | ||
By: | /s/ Shoubin Chen | |
Name: | Shoubin Chen |
Address: Flat F 25/F, Tower 3, Island | |
Place, Tanner Road, | |
North Point, Hong Kong | |
Phone Number: +852 5578-1830 | |
Email: johnc@horizons.com.hk | |
Attention: Shoubin Chen |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
Jumbo Eagle Investments limited | ||
By: | /s/ Ip Man Kit | |
Name: | Ip Man Kit | |
Title: | Director |
Address: 6/f Shun Feng International | |
Centre, 182 Queens Road East, | |
WanChai, Hong Kong | |
Phone Number: +852 69018136 | |
Email: tommy.hbc@gmail.com | |
Attention: IP MAN KIT |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
ICQ INVESTMENTS 26, LLP | ||
By: | /s/ Kevin Foster | |
Name: | Kevin Foster | |
Title: | Authorized Signatory |
Address: 394 Pacific Ave, 2nd Floor, | |
San Francisco, CA 94111 | |
Phone Number: (415)967-7757 | |
Email: kevin@iconiqcapital.com | |
Attention: Kevin Foster |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.
PURCHASERS: | ||
RISEJOY SERVICES LIMITED | ||
By: | /s/ Wang Rui | |
Name: | Wang Rui | |
Title: | Director |
Address: | |
19th Floor, Tower B Fang Heng International Building | |
No. 6 Futong Ease Avenue, | |
Chaoyang District, | |
Beijing 100102, China | |
Email: lilywangrui @ 126.com |
COMMON STOCK PURCHASE AGREEMENT
SCHEDULE 1.2 PURCHASERS NAMES AND ALLOCATIONS
Reference Document: Project Mercury – Common Stock Purchase Agreement - Schedule 1.2 Purchasers Names and Allocations
Celsius, Inc. • 2424 North Federal Highway • Suite 208 • Boca Raton, Florida 33431
Office: 561.276.2239 • Fax: 561.276.2268 • www.celsius.com
SCHEDULE 1.2
PURCHASERS NAMES AND ALLOCATIONS
UNDER COMMON STOCK PURCHASE AGREEMENT
Purchaser | Purchase Price |
Number
of Shares of
Celsius Common Stock to be Purchased |
Contact Information | |||
CHARMNEW LIMITED | $3,570,000.04 | 4,011,236 |
Address: 7/F, Cheung Kong Center
2 Queens’s Road Central |
|||
Hong Kong | ||||||
Attn: Ms, Ezra Pau/Ms. Eirene Yeung | ||||||
Phone #: +852 212 88888 | ||||||
Fax #: +852 212 88001 | ||||||
Email: ezra.pau@ckh.com.hk | ||||||
Eirene.yeung@ckh.com.hk | ||||||
GRIEG INTERNATIONAL LIMITED | $2,380,000.62 | 2,674,158 |
Address: 29th Floor, Harbour Centre, 25 Harbour Road, Wanchai, Hong Kong |
|||
Phone Number: +852 21863873 | ||||||
Fax Number: +852 37411011 | ||||||
Email: jason.wong@horizons.com.hk / | ||||||
raymond.ng@horizons.com.hk | ||||||
chris.lai@horizons.com.hk | ||||||
Attention: Jason Wong | ||||||
NU HORIZONS INVESTMENT GROUP, LLC | $3,000,000.43 | 3,370,787 |
Address: Rush Communications
512 Seventh Avenue, 43rd Floor New York, NY 10018 |
|||
Phone Number: +852 9742 9229 | ||||||
Email: tim_leissner@yahoo.com
Attention: Tim Leissner |
||||||
XYXY HOLDINGS LTD. | $500,000.22 | 561,798 | Address: Flat B, 45/F, Block 8, Phase 2, Residence Bel-Air, Pokfulam, Hong Kong | |||
Phone Number: +85292683074 | ||||||
Email: stong@boyucapital.com | ||||||
Attention: Xiaomeng Tong |
1 |
Purchaser | Purchase Price |
Number of Shares
of
Celsius Common Stock to be Purchased |
Contact Information | |||
SINO ELECT INVESTMENTS LIMITED | $199,999.91 | 224,719 |
Address: Kum Hing Court,28 Tomlinson Road 10-32, Singapore 247854 Phone Number: +65 97843406 Email: awy.julianto@gmail.com Attention: Awy Julianto |
|||
OSCAR TIME LIMITED | $209,999.95 | 235,955 |
Address: 29th Floor, Harbour Centre, 25 Harbour Road, Wanchai, Hong Kong Email: jason.wong@horizons.com.hk / raymond.ng@horizons.com.hk Attention: Jason Wong / Raymond Ng |
|||
BEYOND MERITS LIMITED | $89,999.47 | 101,123 |
Address: 29th Floor, Harbour Centre, 25 Harbour Road, Wanchai, Hong Kong Email: jason.wong@horizons.com.hk / raymond.ng@horizons.com.hk Attention: Jason Wong / Raymond Ng |
|||
HELLO WARRIOR FAMILY TRUST DTD 2/27/09 | $99,999.51 | 112,359 |
c/o ICONIQ Capital 394 Pacific Ave 2nd Floor San Francisco, CA 94111 Phone Number: 415-967-7483 Fax Number: 415-321-3960 Email: fundadmin@iconiqcapital.com Attention: Grace Nam |
|||
HUGO BARRA | $10,000.04 | 11,236 |
601 4th Street San Francisco, CA 94107 Phone Number: 617-592-7676 Email: hbarra@gmail.com |
|||
HELVETICO LIMITED | $10,000.04 | 11,236 |
Address: Flat A 31 Parkside Wimbledon SW19 5NB UK Email: lou.montilla@yahoo.com.au Attention: Lou Montilla |
|||
LUKE NOLAN | $10,000.04 | 11,236 |
Address: Flat 1901, Block 6, 9 Maoming South Road, Huangpu District, Shanghai, China Phone Number: +44 7771 685 068 (UK) +86 135 1215 7147 (China) Email: luke@overseasstudentliving.com |
2 |
Purchaser | Purchase Price |
Number
of Shares of
Celsius Common Stock to be Purchased |
Contact Information | |||
WINNIE YU | $10,000.04 | 11,236 |
Address: No. 3, Broadcast Drive, Kowloon, Hong Kong SAR Phone Number: +852 91039103 Email: yt@9103.hk Attention: Winnie Yu |
|||
SHOUBIN CHEN | $10,000.04 | 11,236 |
Address: Flat F 25/F, Tower 3, Island Place, Tanner Road, North Point, Hong Kong Phone Number: +852 5578-1830 Email: johnc@horizons.com.hk Attention: Shoubin Chen |
|||
JUMBO EAGLE INVESTMENTS LIMITED | $99,999.51 | 112,359 |
Address: 6/f Shun Feng International Centre, 182 Queens Road East, WanChai, Hong Kong Phone Number: +852 69018136 Email: tommy.hbc@gmail.com Attention: IP MAN KIT |
|||
ICQ INVESTMENTS 26, LP | $999,999.55 | 1,123,595 |
Address: 394 Pacific Ave, 2nd Floor, San Francisco, CA 94111 Phone Number: (415)967-7757 Email: kevin@iconiqcapital.com Attention: Kevin Foster |
|||
RISEJOY SERVICES LIMITED | $300,000.31 | 337,079 |
Address: 19th Floor, Tower B Fang Heng International Building No.6 Futong East Avenue, Chaoyang District, Beijing 100102, China Phone Number: +8613601003336 Fax: +861063720333 Email: lilywangrui@126.com Attention: Rui Wang |
|||
Total | $11,499,999.72 | 12,921,348 |
3 |
EXHIBIT A
FORM INDEMNIFICATION AGREEMENT FOR THE MEMBER OF THE BOARD OF DIRECTORS DESIGNATED BY THE PURCHASERS
Reference Document: Doc#69867_v2_Project Mercury – Indemnification Agreement
Celsius, Inc. • 2424 North Federal Highway • Suite 208 • Boca Raton, Florida 33431
Office: 561.276.2239 • Fax: 561.276.2268 • www.celsius.com
INDEMNIFICATION AGREEMENT
This Indemnification Agreement (this “ Agreement ”) is made as of April [____], 2015 by and between Celsius Holdings, Inc., a Nevada corporation (the “ Company ”) and [the Horizons Designee] (the “ Indemnitee ”).
RECITALS
The Company and Indemnitee recognize the increasing difficulty in obtaining liability insurance for directors, officers and key employees, the significant increases in the cost of such insurance and the general reductions in the coverage of such insurance. The Company and Indemnitee further recognize the substantial increase in corporate litigation in general, subjecting directors, officers and key employees to expensive litigation risks at the same time as the availability and coverage of liability insurance have been severely limited. The Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, and to indemnify its directors, officers and key employees so as to provide them with the maximum protection permitted by law.
AGREEMENT
In consideration for mutual promises made in this Agreement, and for other good and valuable consideration, receipt of which is hereby acknowledged, the Company and Indemnitee hereby agree as follows:
1. Indemnification .
(a) Third Party Proceedings . The Company shall indemnify Indemnitee if Indemnitee is or was a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by, or in the right of, the Company) by reason of the fact that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, by reason of any action or inaction on the part of Indemnitee while an officer or director or by reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee in connection with such action, suit or proceeding if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, and, with respect to any criminal action or proceeding, had no reasonable cause to believe Indemnitee’s conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that Indemnitee did not act in good faith and in a manner which Indemnitee reasonably believed to be in or not opposed to the best interests of the Company, or, with respect to any criminal action or proceeding, that Indemnitee had reasonable cause to believe that Indemnitee’s conduct was unlawful.
(b) Proceedings By or in the Right of the Company . The Company shall indemnify Indemnitee if Indemnitee was or is a party or is threatened to be made a party to any threatened, pending or completed action or proceeding by, or in the right of, the Company or any subsidiary of the Company to procure a judgment in its favor by reason of the fact that Indemnitee is or was a director, officer, employee or agent of the Company, or any subsidiary of the Company, by reason of any action or inaction on the part of Indemnitee while an officer or director or by reason of the fact that Indemnitee is or was serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys’ fees) and, to the fullest extent permitted by law, amounts paid in settlement, in each case to the extent actually and reasonably incurred by Indemnitee in connection with the defense or settlement of such action or suit if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company and its stockholders, except that no indemnification shall be made in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudicated by court order or judgment to be liable to the Company in the performance of Indemnitee’s duty to the Company and its stockholders unless and only to the extent that the court in which such action or proceeding is or was pending shall determine upon application that, in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.
(c) Mandatory Payment of Expenses . To the extent that Indemnitee has been successful on the merits or otherwise in defense of any action, suit or proceeding referred to in Section 1(a) or Section 1(b) or the defense of any claim, issue or matter therein, Indemnitee shall be indemnified against expenses (including attorneys’ fees) actually and reasonably incurred by Indemnitee in connection therewith. If Indemnitee is not wholly successful in such proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all expenses actually and reasonably incurred by him or on his behalf in connection with each successfully resolved claim, issue or matter. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.
(d) Primacy of Indemnification . The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and/or insurance provided by Charmnew Limited and Grieg International Limited (“ Horizons ”) and/or certain of its Affiliates, as defined below (collectively, the “ Fund Indemnitors ”). The Company hereby agrees (i) that it is the indemnitor of first resort (i.e., its obligations to Indemnitee are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all expenses (including attorneys’ fees), judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement and the Articles of Incorporation, as amended from time to time (the “ Articles of Incorporation ”) and/or Bylaws of the Company, as amended from time to time (the “ Bylaws ”) (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Fund Indemnitors, and (iii) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company. The Company and Indemnitee agree that the Fund Indemnitors are express third party beneficiaries of the terms of this Section 1 (d). “ Affiliates ” shall mean, with respect to Horizons, any other person or entity who, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with Horizons, including without limitation any general partner, managing member, officer or director of such person or entity or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such person or entity, and Charmnew Limited and Grieg International Limited and their respective beneficial owners shall all be deemed Affiliates of one another.
- 2 -
(e) Indemnification of Appointing Stockholder . If Horizons or any of its Affiliates (collectively, the “ Appointing Stockholder ”) is, or is threatened to be made, a party to or a participant in any Proceeding, and the Appointing Stockholder’s involvement in the Proceeding (A) arises primarily out of, or relates to, any action taken by the Company that was approved by the Company’s Board, and (B) arises out of facts or circumstances that are the same or substantially similar to the facts and circumstances that form the basis of claims that have been, could have been or could be brought against the Indemnitee in a Proceeding, regardless of whether the legal basis of the claims against the Indemnitee and the Appointing Stockholder are the same or similar, then the Appointing Stockholder shall be entitled to all of the indemnification rights and remedies under this Agreement pursuant to this Agreement as if the Appointing Stockholder were the Indemnitee.
2. No Employment Rights . Nothing contained in this Agreement is intended to create in Indemnitee any right to employment.
3. Expenses; Indemnification Procedure .
(a) Advancement of Expenses . The Company shall advance all expenses incurred by Indemnitee in connection with the investigation, defense, settlement or appeal of any civil or criminal action, suit or proceeding referred to in Section 1(a), Section 1 (b) or Section 1 (e) hereof (including amounts actually paid in settlement of any such action, suit or proceeding). Indemnitee hereby undertakes to repay such amounts advanced only if, and to the extent that, it shall ultimately be determined that Indemnitee is not entitled to be indemnified by the Company as authorized hereby.
(b) Notice/Cooperation by Indemnitee . Indemnitee shall give the Company notice in writing as soon as practicable of any claim made against Indemnitee for which indemnification will or could be sought under this Agreement. Notice to the Company shall be directed to the Chief Executive Officer of the Company and shall be given in accordance with the provisions of Section 12(d) below. In addition. Indemnitee shall give the Company such information and cooperation as it may reasonably require and as shall be within Indemnitee’s power.
- 3 -
(c) Procedure . Any indemnification and advances provided for in Section 1 and this Section 3 shall be made no later than twenty (20) days after receipt of the written request of Indemnitee. If a claim under this Agreement, under any statute, or under any provision of the Company’s Articles of Incorporation or Bylaws providing for indemnification, is not paid in full by the Company within twenty (20) days after a written request for payment thereof has first been received by the Company, Indemnitee may, but need not, at any time thereafter bring an action against the Company to recover the unpaid amount of the claim and, subject to Section 11 of this Agreement, Indemnitee shall also be entitled to be paid for the expenses (including attorneys’ fees) of bringing such action. It shall be a defense to any such action (other than an action brought to enforce a claim for expenses incurred in connection with any action, suit or proceeding in advance of its final disposition) that Indemnitee has not met the standards of conduct which make it permissible under applicable law for the Company to indemnify Indemnitee for the amount claimed, but the burden of proving such defense shall be on the Company and Indemnitee shall be entitled to receive interim payments of expenses pursuant to Section 3(a) unless and until such defense may be finally adjudicated by court order or judgment from which no further right of appeal exists. It is the parties’ intention that if the Company contests Indemnitee’s right to indemnification, the question of Indemnitee’s right to indemnification shall be for the court to decide, and neither the failure of the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its stockholders) to have made a determination that indemnification of Indemnitee is proper in the circumstances because Indemnitee has met the applicable standard of conduct required by applicable law, nor an actual determination by the Company (including its Board of Directors, any committee or subgroup of the Board of Directors, independent legal counsel, or its stockholders) that Indemnitee has not met such applicable standard of conduct, shall create a presumption that Indemnitee has or has not met the applicable standard of conduct.
(d) Notice to Insurers . If, at the time of the receipt of a notice of a claim pursuant to Section 3(b) hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.
(e) Selection of Counsel . In the event the Company shall be obligated under Section 3(a) hereof to pay the expenses of any proceeding against Indemnitee, the Company, if appropriate, shall be entitled to assume the defense of such proceeding, with counsel approved by Indemnitee, upon the delivery to Indemnitee of written notice of its election so to do. After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees of counsel subsequently incurred by Indemnitee with respect to the same proceeding, provided that (i) Indemnitee shall have the right to employ counsel in any such proceeding at Indemnitee’s expense; and (ii) if (A) the employment of counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of any such defense or (C) the Company shall not, in fact, have employed counsel to assume the defense of such proceeding, then the fees and expenses of Indemnitee’s counsel shall be at the expense of the Company.
4. Additional Indemnification Rights; Nonexclusivity .
(a) Scope . Notwithstanding any other provision of this Agreement, the Company hereby agrees to indemnify the Indemnitee to the fullest extent permitted by law, notwithstanding that such indemnification is not specifically authorized by the other provisions of this Agreement, the Company’s Articles of Incorporation, the Company’s Bylaws or by statute. In the event of any change, after the date of this Agreement, in any applicable law, statute, or rule which expands the right of a Nevada corporation to indemnify a member of its board of directors or an officer, such changes shall be deemed to be within the purview of Indemnitee’s rights and the Company’s obligations under this Agreement. In the event of any change in any applicable law, statute or rule which narrows the right of a Nevada corporation to indemnify a member of its board of directors or an officer, such changes, to the extent not otherwise required by such law, statute or rule to be applied to this Agreement shall have no effect on this Agreement or the parties’ rights and obligations hereunder.
- 4 -
(b) Nonexclusivity . The indemnification provided by this Agreement shall not be deemed exclusive of any rights to which Indemnitee may be entitled under the Company’s Articles of Incorporation, its Bylaws, any agreement, any vote of stockholders or disinterested members of the Company’s Board of Directors, by applicable law, statute, or rule or otherwise, both as to action in Indemnitee’s official capacity and as to action in another capacity while holding such office. The Indemnitee’s rights hereunder shall continue after the Indemnitee has ceased acting as a director, officer, employee or agent of the Company, or any subsidiary of the Company, and shall inure to the benefit of the heirs, executors and administrators of the Indemnitee. The indemnification provided under this Agreement shall continue as to Indemnitee for any action taken or not taken while serving in an indemnified capacity even though he or she may have ceased to serve in any such capacity at the time of any action, suit or other covered proceeding.
5. Partial Indemnification . If Indemnitee is entitled under any provision of this Agreement to indemnification by the Company for some or a portion of the expenses, judgments, fines or penalties actually or reasonably incurred in the investigation, defense, appeal or settlement of any civil or criminal action, suit or proceeding, but not, however, for the total amount thereof, the Company shall nevertheless indemnify Indemnitee for the portion of such expenses, judgments, fines or penalties to which Indemnitee is entitled.
6. Mutual Acknowledgment . Both the Company and Indemnitee acknowledge that in certain instances, Federal law or public policy may override applicable state law and prohibit the Company from indemnifying its directors and officers under this Agreement or otherwise. For example, the Company and Indemnitee acknowledge that the Securities and Exchange Commission (the “ SEC ”) has taken the position that indemnification is not permissible for liabilities arising under certain federal securities laws, and federal legislation prohibits indemnification for certain ERISA violations. Indemnitee understands and acknowledges that the Company has undertaken or may be required in the future to undertake with the SEC to submit the question of indemnification to a court in certain circumstances for a determination of the Company’s right under public policy to indemnify Indemnitee.
7. Officer and Director Liability Insurance . The Company shall obtain and maintain a policy or policies of insurance with reputable insurance companies providing the officers and directors of the Company with coverage for losses from wrongful acts, or to ensure the Company’s performance of its indemnification obligations under this Agreement. In all policies of director and officer liability insurance, Indemnitee shall be named as an insured in such a manner as to provide Indemnitee the same rights and benefits as are accorded to the most favorably insured of the Company’s directors, if Indemnitee is a director; or of the Company’s officers, if Indemnitee is not a director of the Company but is an officer; or of the Company’s key employees, if Indemnitee is not an officer or director but is a key employee.
- 5 -
8. Severability . Nothing in this Agreement is intended to require or shall be construed as requiring the Company to do or fail to do any act in violation of applicable law. The Company’s inability, pursuant to court order, to perform its obligations under this Agreement shall not constitute a breach of this Agreement. The provisions of this Agreement shall be severable as provided in this Section 8. If this Agreement or any portion hereof shall be invalidated on any ground by any court of competent jurisdiction, then the Company shall nevertheless indemnify Indemnitee to the full extent permitted by any applicable portion of this Agreement that shall not have been invalidated, and the balance of this Agreement not so invalidated shall be enforceable in accordance with its terms.
9. Exceptions . Any other provision herein to the contrary notwithstanding, the Company shall not be obligated pursuant to the terms of this Agreement:
(a) Claims Initiated by Indemnitee . To indemnify or advance expenses to Indemnitee with respect to proceedings or claims initiated or brought voluntarily by Indemnitee and not by way of defense, except with respect to proceedings brought to establish or enforce a right to indemnification under this Agreement or under any other applicable law, statute or rule, but such indemnification or advancement of expenses may be provided by the Company in specific cases if the Board of Directors finds it to be appropriate;
(b) Lack of Good Faith . To indemnify Indemnitee for any expenses incurred by Indemnitee with respect to any proceeding instituted by Indemnitee to enforce or interpret this Agreement, if a court of competent jurisdiction finally (and without further appeal) determines that each of the material assertions made by Indemnitee in such proceeding was not made in good faith or was frivolous;
(c) Insured Claims . To indemnify Indemnitee for expenses or liabilities of any type whatsoever (including, but not limited to, judgments, fines, ERISA excise taxes or penalties, and amounts paid in settlement) to the extent such expenses or liabilities have been paid directly to Indemnitee by an insurance carrier under a policy of officers’ and directors’ liability insurance maintained by the Company; or
(d) Claims under Section 16(b) . To indemnify Indemnitee for expenses or the payment of profits arising from the purchase and sale by Indemnitee of securities in violation of Section 16(b) of the Securities Exchange Act of 1934, as amended, or any similar successor statute.
10. Construction of Certain Phrases .
(a) For purposes of this Agreement, references to the “ Company ” shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors, officers and employees or agents, so that if Indemnitee is or was a director, officer, employee or agent of such constituent corporation, or is or was serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, Indemnitee shall stand in the same position under the provisions of this Agreement with respect to the resulting or surviving corporation as Indemnitee would have with respect to such constituent corporation if its separate existence had continued.
- 6 -
(b) For purposes of this Agreement, references to “ other enterprises ” shall include employee benefit plans; references to “ fines ” shall include any excise taxes assessed on Indemnitee with respect to an employee benefit plan; and references to “ serving at the request of the Company ” shall include any service as a director, officer, employee or agent of the Company which imposes duties on, or involves services by, such director, officer, employee or agent with respect to an employee benefit plan, its participants, or beneficiaries; and if Indemnitee acted in good faith and in a manner Indemnitee reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan, Indemnitee shall be deemed to have acted in a manner “ not opposed to the best interests of the Company ” as referred to in this Agreement.
11. Attorneys’ Fees . In the event that any action is instituted by Indemnitee under this Agreement to enforce or interpret any of the terms hereof, Indemnitee shall be entitled to be paid all court costs and expenses, including reasonable attorneys’ fees, incurred by Indemnitee with respect to such action, unless as a part of such action, the court of competent jurisdiction determines that each of the material assertions made by Indemnitee as a basis for such action were not made in good faith or were frivolous. In the event of an action instituted by or in the name of the Company under this Agreement or to enforce or interpret any of the terms of this Agreement, Indemnitee shall be entitled to be paid all court costs and expenses, including attorneys’ fees, incurred by Indemnitee in defense of such action (including with respect to Indemnitee’s counterclaims and cross-claims made in such action), unless as a part of such action the court finally (without further appeal) determines that each of Indemnitee’s material defenses to such action were made in bad faith or were frivolous.
12. Miscellaneous .
(a) Governing Law . This Agreement and all acts and transactions pursuant hereto and the rights and obligations of the parties hereto shall be governed, construed and interpreted in accordance with the laws of the State of Nevada, without giving effect to principles of conflict of law.
(b) Entire Agreement; Enforcement of Rights . This Agreement sets forth the entire agreement and understanding of the parties relating to the subject matter herein and merges all prior discussions between them. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement, shall be effective unless in writing signed by the parties to this Agreement. The failure by either party to enforce any rights under this Agreement shall not be construed as a waiver of any rights of such party.
(c) Construction . This Agreement is the result of negotiations between and has been reviewed by each of the parties hereto and their respective counsel, if any; accordingly, this Agreement shall be deemed to be the product of all of the parties hereto, and no ambiguity shall be construed in favor of or against any one of the parties hereto.
(d) Notices . Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall be deemed sufficient when delivered personally, sent by telegram or facsimile or three business days after being deposited in the U.S. mail, as certified or registered mail, with postage prepaid, and addressed to the party to be notified at such party’s address as set forth below or as subsequently modified by written notice.
- 7 -
(e) Counterparts . This Agreement may be executed in two or more counterparts, each of which shall be deemed an original and all of which together shall constitute one instrument.
(f) Successors and Assigns . This Agreement shall be binding upon the Company and its successors and assigns, and inure to the benefit of Indemnitee and Indemnitee’s heirs, legal representatives and assigns.
(g) Subrogation . In the event of payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all documents required and shall do all acts that may be necessary to secure such rights and to enable the Company to effectively bring suit to enforce such rights.
(h) Consent to Jurisdiction . The Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only a state or federal court of competent jurisdiction in Palm Beach County, Florida (the “ Florida Court ”), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Florida Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action or proceeding in the Florida Court and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Florida Court has been brought in an improper or inconvenient forum.
(Signature Page Follows)
- 8 -
IN WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement as of the day and year set forth on the first page of this Agreement.
CELSIUS HOLDINGS, INC. | ||
By: | ||
Name: | ||
Title: |
Address: | [Address] | |
[Address] |
AGREED TO AND ACCEPTED: | |
[Horizons Ventures Designee(s)] | |
Address: |
SIGNATURE PAGE TO CELSIUS HOLDINGS, INC.
INDEMNIFICATION AGREEMENT
EXHIBIT B
REFERENCE INVESTORS’ RIGHTS AGREEMENT
INVESTOR RIGHTS AGREEMENT
ATTACH CURRENT INVESTORS RIGHTS AGREEMENT
Celsius, Inc. • 2424 North Federal Highway • Suite 208 • Boca Raton, Florida 33431
Office: 561.276.2239 • Fax: 561.276.2268 • www.celsius.com
INVESTORS’ RIGHTS AGREEMENT
INVESTORS’ RIGHTS AGREEMENT
THIS INVESTORS’ RIGHTS AGREEMENT (this “Agreement” ), is made as of the ___ day of April, 2015, by and among Celsius Holdings, Inc., a Nevada corporation (the “Company” ), each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor,” and each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder.”
RECITALS
WHEREAS, the Company and the Investors are parties to the Common Stock Purchase Agreement of even date herewith (the “Purchase Agreement” ); and
WHEREAS, in order to induce the Company to enter into the Purchase Agreement and to induce the Investors to invest funds in the Company pursuant to the Purchase Agreement, the Investors and the Company hereby agree that this Agreement shall govern the rights of the Investors to cause the Company to register shares of Common Stock issuable to the Investors, to receive certain information from the Company, and to participate in future equity offerings by the Company, and shall govern certain other matters as set forth in this Agreement.
AGREEMENT
NOW, THEREFORE, the parties hereby agree as follows:
1. Definitions . For purposes of this Agreement, in addition to capitalized terms otherwise defined herein:
1.1 “Affiliate” means, with respect to any specified Person, any other Person who, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with such Person, including without limitation any general partner, managing member, officer or director of such Person or any venture capital fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management company with, such Person. For the avoidance of doubt, Channnew Limited and Grieg International Limited (together, “Horizons” ) and their respective beneficial owners shall all be deemed Affiliates of one another.
1.2 “Common Stock” means shares of the Company’s common stock, par value $0,001 per share.
1.3 “Change of Control” means the existence, occurrence, public announcement or entering into an agreement contemplating of any of the following: (a) the sale, conveyance or disposition of all or substantially all of the assets of the Company to any Person; (b) the sale, conveyance or disposition of all or substantially all of the assets of any Company subsidiary to a Person other than the Company or another Company subsidiary; (c) the effectuation of a transaction or series of transactions in which more than fifty percent (50%) of the equity or voting power of the Company is disposed of; (d) the effectuation of a transaction or series of transactions in which any of the equity or voting power of any Company subsidiary is disposed to a Person other than the Company or another Company subsidiary; (e) the consolidation, merger or other business combination of the Company with or into any other entity, immediately following which the prior stockholders of the Company fail to own, directly or indirectly, at least fifty percent (50%) of the surviving entity; (f) the consolidation, merger or other business combination of any Company subsidiary with or into any other entity other than the Company or another Company subsidiary: (g) a transaction or series of transactions in which any Person or group (other than pursuant to an agreement between current affiliates of the Company) acquires more than fifty percent (50%) of the equity or voting power of the Company; and (h) a transaction or series of transactions in which any Person or group (other than the Company or a Company subsidiary) acquires any of the voting equity of a Company subsidiary.
1.4 “Damages” means any loss, damage, claim or liability (joint or several) to which a party hereto may become subject under the Securities Act, the Exchange Act, or other federal or state law, insofar as such loss, damage, claim or liability (or any action in respect thereof) arises out of or is based upon: (i) any untrue statement or alleged untrue statement of a material fact contained in any registration statement of the Company, including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; (ii) an omission or alleged omission to state therein a material fact required to be stated therein, or necessary to make the statements therein not misleading: or (iii) any violation or alleged violation by the indemnifying party (or any of its agents or Affiliates) of the Securities Act, the Exchange Act, any state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any state securities law.
1.5 “Derivative Securities” means any securities or rights convertible into, or exercisable or exchangeable for (in each case, directly or indirectly), Common Stock, including options and warrants.
1.6 “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.
1.7 “Excluded Registration” means (i) a registration relating to the sale of securities to employees of the Company or a subsidiary pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included in a registration statement covering the sale of the Registrable Securities; or (iv) a registration in which the only Common Stock being registered is Common Stock issuable upon conversion of debt securities that are also being registered.
1.8 “Form S-1” means such form under the Securities Act as in effect on the date hereof or any successor registration form under the Securities Act subsequently adopted by the SEC.
2 |
1.9 “Form S-3” means such form under the Securities Act as in effect on the date hereof or any registration form under the Securities Act subsequently adopted by the SEC that permits incorporation of substantial information by reference to other documents filed by the Company with the SEC.
1.10 “GAAP” means generally accepted accounting principles in the United States.
1.11 “Holder” means any holder of Registrable Securities who is a party to this Agreement.
1.12 “Immediate Family Member” means a child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including, adoptive relationships, of a natural person referred to herein.
1.13 “Initiating Holders” means, collectively, Holders who properly initiate a registration request under this Agreement.
1.14 “Offering” means the Company’s first underwritten public offering of its Common Stock under the Securities Act after the date hereof.
1.15 “Investor Directors” means the directors of the Company that the Investors are entitled to elect pursuant to Section 5.11 hereof and designated as such by the Investors.
1.16 “Key Employee” means any executive-level employee (including, division director and vice president-level positions) as well as any employee who, either alone or in concert with others, develops, invents, programs, or designs any Company Intellectual Property (as defined in the Purchase Agreement).
1.17 “Major Investor” means any Investor that, individually, or together with such Investor’s Affiliates, holds at least 112,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization effected after the date hereof).
1.18 “New Securities” means, collectively, equity securities of the Company, whether or not currently authorized, as well as rights, options, or warrants to purchase such equity securities, or securities of any type whatsoever that are, or may become, convertible or exchangeable into or exercisable for such equity securities.
1.19 “Person” means any individual, corporation, partnership, trust, limited liability company, association or other entity.
3 |
1.20 “Registrable Securities” means (i) the Common Stock initially issued to the Investors pursuant to the Purchase Agreement; (ii) the Common Stock issued upon conversion of the convertible notes acquired by the Investors pursuant to that certain Secondary Convertible Promissory Note Purchase Agreement dated April __, 2015; (iii) the shares of Common Stock held by CD Financial, LLC or its Affiliates (“CDF” ); (iv) any Common Stock, or any Common Stock issued or issuable (directly or indirectly) upon conversion and/or exercise of any other securities of the Company, held by the Investors or CDF; and (v) any Common Stock issued as (or issuable upon the conversion or exercise of any warrant right, or other security that is issued as) a dividend or other distribution with respect to, or in exchange for or in replacement of, the shares referenced in clauses (i), (ii) , (iii) and (iv) above; excluding in all cases, however, any Registrable Securities sold by a Person in a transaction in which the applicable rights under this Agreement are not assigned pursuant to Section 6.1 , and excluding for purposes of Section 2 any shares for which registration rights have terminated pursuant to Section 2.13 of this Agreement.
1.21 “Registrable Securities then outstanding” means the number of shares determined by adding the number of shares of outstanding Common Stock that are Registrable Securities and the number of shares of Common Stock issuable (directly or indirectly) pursuant to then exercisable and/or convertible securities that are Registrable Securities.
1.22 “Restricted Securities” means the securities of the Company required to be notated with the legend set forth in Subsection 2.12(b) hereof.
1.23 “SEC” means the Securities and Exchange Commission.
1.24 “SEC Rule 144” means Rule 144 promulgated by the SEC under the Securities Act.
1.25 “SEC Rule 145” means Rule 145 promulgated by the SEC under the Securities Act.
1.26 “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.
1.27 “Selling Expenses” means all underwriting discounts, selling commissions, and stock transfer taxes applicable to the sale of Registrable Securities, and fees and disbursements of counsel for any Holder, except for the fees and disbursements of the Selling Holder Counsel borne and paid by the Company as provided in Section 2.6 .
2. Registration Rights . The Company covenants and agrees as follows:
2.1 Demand Registration .
(a) Form S-1 Demand . If at any time after the date of this Agreement, the Company receives a request from Holders of at least twenty-five percent (25%) of the Registrable Securities then outstanding that the Company file a Form S-1 registration statement with respect to at least twenty-five percent (25%) of the Registrable Securities then outstanding (or a lesser percent if the anticipated aggregate offering price, net of Selling Expenses, would exceed $10 million), then the Company shall (x) within ten (10) days after the date such request is given, give notice thereof (the “Demand Notice” ) to all Holders other than the Initiating Holders; and (y) as soon as practicable, and in any event within sixty (60) days after the date such request is given by the Initiating Holders, file a Form S-1 registration statement under the Securities Act covering all Registrable Securities that the Initiating Holders requested to be registered and any additional Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection 2.1(c) and Section 2.3 .
4 |
(b) Form S-3 Demand . If at any time when it is eligible to use a Form S-3 registration statement, the Company receives a request from Holders of at least ten percent (10%) of the Registrable Securities then outstanding that the Company file a Form S-3 registration statement with respect to outstanding Registrable Securities of such Holders having an anticipated aggregate offering price, net of Selling Expenses, of at least $5 million, then the Company shall (i) within ten (10) days after the date such request is given, give a Demand Notice to all Holders other than the Initiating Holders; and (ii) as soon as practicable, and in any event within forty-five (45) days after the date such request is given by the Initiating Holders, or ninety (90) days after the date such request is given, if made within sixty (60) days after the Company’s fiscal year end, file a Form S-3 registration statement under the Securities Act covering all Registrable Securities requested to be included in such registration by any other Holders, as specified by notice given by each such Holder to the Company within twenty (20) days of the date the Demand Notice is given, and in each case, subject to the limitations of Subsection 2.1(c) and Section 2.3 .
(c) Notwithstanding the foregoing obligations, if the Company furnishes to Holders requesting a registration pursuant to this Section 2.1 a certificate signed by the Company’s chief executive officer stating that in the good faith judgment of the Company’s Board of Directors it would be materially detrimental to the Company and its stockholders for such registration statement to either become effective or remain effective for as long as such registration statement otherwise would be required to remain effective, because such action would (i) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving the Company; (ii) require premature disclosure of material information that the Company has a bona fide business purpose for preserving as confidential; or (iii) render the Company unable to comply with requirements under the Securities Act or Exchange Act, then the Company shall have the right to defer taking action with respect to such filing for a period of not more than one hundred twenty (120) days after the request of the Initiating Holders is given; provided , however , that the Company may not invoke this right more than once in any twelve (12) month period; and provided further that the Company shall not register any securities for its own account or that of any other stockholder during such one hundred twenty (120) day period other than an Excluded Registration.
(d) The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(a) : (i) during the period that is sixty (60) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is one hundred eighty (180) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; (ii) after the Company has effected two registrations pursuant to Subsection 2.1(a) ; or (iii) if the Initiating Holders propose to dispose of shares of Registrable Securities that may be immediately registered on Form S-3 pursuant to a request made pursuant to Subsection 2.1(b) . The Company shall not be obligated to effect, or to take any action to effect, any registration pursuant to Subsection 2.1(b) during the period that is thirty (30) days before the Company’s good faith estimate of the date of filing of, and ending on a date that is ninety (90) days after the effective date of, a Company-initiated registration, provided that the Company is actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective. A registration shall not be counted as “effected” for purposes of this Subsection 2.1(d) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders withdraw their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6 , in which case such withdrawn registration statement shall be counted as “effected” for purposes of this Subsection 2.1(d) .
5 |
2.2 Company Registration . If the Company proposes to register (including, for this purpose, a registration effected by the Company for stockholders other than the Holders) any of its securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded Registration), the Company shall, at such time, promptly give each Holder notice of such registration. Upon the request of each Holder given within twenty (20) days after such notice is given by the Company, the Company shall, subject to the provisions of Section 2.3 , cause to be registered all of the Registrable Securities that each such Holder has requested to be included in such registration. The Company shall have the right to terminate or withdraw any registration initiated by it under this Section 2.2 before the effective date of such registration, whether or not any Holder has elected to include Registrable Securities in such registration. The expenses (other than Selling Expenses) of such withdrawn registration shall be borne by the Company in accordance with Section 2.6 .
2.3 Underwriting Requirements .
(a) If, pursuant to Section 2.1 , the Initiating Holders intend to distribute the Registrable Securities covered by their request by means of an underwriting, they shall so advise the Company as a part of their request made pursuant to Section 2.1 , and the Company shall include such information in the Demand Notice. The underwriter(s) will be selected by the Initiating Holders, subject only to the reasonable approval of the Company. In such event, the right of any Holder to include such Holder’s Registrable Securities in such registration shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company as provided in Subsection 2.4(e)) enter into an underwriting agreement in customary form with the underwriter(s) selected for such underwriting. Notwithstanding any other provision of this Section 2.3 , if the underwriter(s) advise(s) the Initiating Holders in writing that marketing factors require a limitation on the number of shares to be underwritten, then the Initiating Holders shall so advise all Holders of Registrable Securities that otherwise would be underwritten pursuant hereto, and the number of Registrable Securities that may be included in the underwriting shall be allocated among such Holders of Registrable Securities, including the Initiating Holders, in proportion (as nearly as practicable) to the number of Registrable Securities owned by each Holder or in such other proportion as shall mutually be agreed to by all such selling Holders; provided , however , that the number of Registrable Securities held by the Holders to be included in such underwriting shall not be reduced unless all other securities are first entirely excluded from the underwriting.
6 |
(b) In connection with any offering involving an underwriting of shares of the Company’s capital stock pursuant to Section 2.2 , the Company shall not be required to include any of the Holders’ Registrable Securities in such underwriting unless the Holders accept the terms of the underwriting as agreed upon between the Company and its underwriters, and then only in such quantity as the underwriters in their sole discretion determine will not jeopardize the success of the offering by the Company. If the total number of securities, including Registrable Securities, requested by stockholders to be included in such offering exceeds the number of securities to be sold (other than by the Company) that the underwriters in their reasonable discretion determine is compatible with the success of the offering, then the Company shall be required to include in the offering only that number of such securities, including Registrable Securities, which the underwriters and the Company in their sole discretion determine will not jeopardize the success of the offering. If the underwriters determine that less than all of the Registrable Securities requested to be registered can be included in such offering, then the Registrable Securities that are included in such offering shall be allocated among the selling Holders in proportion (as nearly as practicable to) the number of Registrable Securities owned by each selling Holder or in such other proportions as shall mutually be agreed to by all such selling Holders. Notwithstanding the foregoing, in no event shall (i) the number of Registrable Securities included in the offering be reduced unless all other securities (other than securities to be sold by the Company) are first entirely excluded from the offering, or (ii) the number of Registrable Securities included in the offering be reduced below thirty percent (30%) of the total number of securities included in such offering. For purposes of the provision in this Subsection 2.3(b) concerning apportionment, for any selling Holder that is a partnership, limited liability company, or corporation, the partners, members, retired partners, retired members, stockholders, and Affiliates of such Holder, or the estates and Immediate Family Members of any such partners, retired partners, members, and retired members and any trusts for the benefit of any of the foregoing Persons, shall be deemed to be a single “selling Holder,” and any pro rata reduction with respect to such “selling Holder” shall be based upon the aggregate number of Registrable Securities owned by all Persons included in such “selling Holder,” as defined in this sentence.
(c) For purposes of Section 2.1 , a registration shall not be counted as “effected” if, as a result of an exercise of the underwriter’s cutback provisions in Subsection 2.3(a) , fewer than fifty percent (50%) of the total number of Registrable Securities that Holders have requested to be included in such registration statement are actually included.
2.4 Obligations of the Company . Whenever required under this Section 2 to effect the registration of any Registrable Securities, the Company shall, as expeditiously as reasonably possible:
(a) prepare and file with the SEC a registration statement with respect to such Registrable Securities and use its commercially reasonable efforts to cause such registration statement to become effective and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement effective for a period of up to one hundred twenty (120) days or, if earlier, until the distribution contemplated in the registration statement has been completed; provided , however , that (i) such one hundred twenty (120) day period shall be extended for a period of time equal to the period the Holder refrains, at the request of an underwriter of Common Stock (or other securities) of the Company, from selling any securities included in such registration, and (ii) in the case of any registration of Registrable Securities on Form S-3 that are intended to be offered on a continuous or delayed basis, subject to compliance with applicable SEC rules, such one hundred twenty (120) day period shall be extended for up to thirty (30) days, if necessary, to keep the registration statement effective until all such Registrable Securities are sold:
7 |
(b) prepare and file with the SEC such amendments and supplements to such registration statement, and the prospectus used in connection with such registration statement, as may be necessary to comply with the Securities Act in order to enable the disposition of all securities covered by such registration statement;
(c) furnish to the selling Holders such numbers of copies of a prospectus, including a preliminary prospectus, as required by the Securities Act, and such other documents as the Holders may reasonably request in order to facilitate their disposition of their Registrable Securities;
(d) use its commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities or blue-sky laws of such jurisdictions as shall be reasonably requested by the selling Holders; provided that the Company shall not be required to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act;
(e) in the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and customary form, with the underwriter(s) of such offering;
(f) use its commercially reasonable efforts to cause all such Registrable Securities covered by such registration statement to be listed on a national securities exchange or trading system and each securities exchange and trading system (if any) on which similar securities issued by the Company are then listed;
(g) provide a transfer agent and registrar for all Registrable Securities registered pursuant to this Agreement and provide a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration;
(h) promptly make available for inspection by the selling Holders, any underwriter(s) participating in any disposition pursuant to such registration statement, and any attorney or accountant or other agent retained by any such underwriter or selected by the selling Holders, all financial and other records, pertinent corporate documents, and properties of the Company, and cause the Company’s officers, directors, employees, and independent accountants to supply all information reasonably requested by any such seller, underwriter, attorney, accountant, or agent, in each case, as necessary or advisable to verify the accuracy of the information in such registration statement and to conduct appropriate due diligence in connection therewith;
8 |
(i) notify each selling Holder, promptly after the Company receives notice thereof, of the time when such registration statement has been declared effective or a supplement to any prospectus forming a part of such registration statement has been filed; and
(j) after such registration statement becomes effective, notify each selling Holder of any request by the SEC that the Company amend or supplement such registration statement or prospectus.
In addition, the Company shall ensure that, at all times after any registration statement covering a public offering of securities of the Company under the Securities Act shall have become effective, its insider trading policy shall provide that the Company’s directors may implement a trading program under Rule 10b5-l of the Exchange Act.
2.5 Furnish Information . It shall be a condition precedent to the obligations of the Company to take any action pursuant to this Section 2 with respect to the Registrable Securities of any selling Holder that such Holder shall furnish to the Company such information regarding itself, the Registrable Securities held by it, and the intended method of disposition of such securities as is reasonably required to effect the registration of such Holder’s Registrable Securities.
2.6 Expenses of Registration . All expenses (other than Selling Expenses) incurred in connection with registrations, filings, or qualifications pursuant to Section 2, including all registration, filing, and qualification fees; printers’ and accounting fees; fees and disbursements of counsel for the Company; and the reasonable fees and disbursements of one counsel for the selling Holders up to a maximum of twenty thousand dollars ($20,000) (“Selling Holder Counsel” ), shall be borne and paid by the Company; provided , however , that the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.1 if the registration request is subsequently withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered (in which case all selling Holders shall bear such expenses pro rata based upon the number of Registrable Securities that were to be included in the withdrawn registration), unless the Holders of a majority of the Registrable Securities agree to forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b) , as the case may be; provided further that if, at the time of such withdrawal, the Holders shall have learned of a material adverse change in the condition, business, or prospects of the Company from that known to the Holders at the time of their request and have withdrawn the request with reasonable promptness after learning of such information then the Holders shall not be required to pay any of such expenses and shall not forfeit their right to one registration pursuant to Subsections 2.1(a) or 2.1(b) . All Selling Expenses relating to Registrable Securities registered pursuant to this Section 2 shall be borne and paid by the Holders pro rata on the basis of the number of Registrable Securities registered on their behalf.
2.7 Delay of Registration . No Holder shall have any right to obtain or seek an injunction restraining or otherwise delaying any registration pursuant to this Agreement as the result of any controversy that might arise with respect to the interpretation or implementation of this Section 2 .
9 |
2.8 Indemnification . If any Registrable Securities are included in a registration statement under this Section 2 :
(a) To the extent permitted by law, the Company will indemnify and hold harmless each selling Holder, and the partners, members, officers, directors, and stockholders of each such Holder; legal counsel and accountants for each such Holder; any underwriter (as defined in the Securities Act) for each such Holder; and each Person, if any, who controls such Holder or underwriter within the meaning of the Securities Act or the Exchange Act, against any Damages, and the Company will pay to each such Holder, underwriter, controlling Person, or other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided , however , that the indemnity agreement contained in this Subsection 2.8(a) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Company, which consent shall not be unreasonably withheld, nor shall the Company be liable for any Damages to the extent that they arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of any such Holder, underwriter, controlling Person, or other aforementioned Person expressly for use in connection with such registration.
(b) To the extent permitted by law, each selling Holder, severally and not jointly, will indemnify and hold harmless the Company, and each of its directors, each of its officers who has signed the registration statement, each Person (if any), who controls the Company within the meaning of the Securities Act, legal counsel and accountants for the Company, any underwriter (as defined in the Securities Act), any other Holder selling securities in such registration statement, and any controlling Person of any such underwriter or other Holder, against any Damages, in each case only to the extent that such Damages arise out of or are based upon actions or omissions made in reliance upon and in conformity with written information furnished by or on behalf of such selling Holder expressly for use in connection with such registration; and each such selling Holder will pay to the Company and each other aforementioned Person any legal or other expenses reasonably incurred thereby in connection with investigating or defending any claim or proceeding from which Damages may result, as such expenses are incurred; provided , however , that the indemnity agreement contained in this Subsection 2.8(b) shall not apply to amounts paid in settlement of any such claim or proceeding if such settlement is effected without the consent of the Holder, which consent shall not be unreasonably withheld; and provided further that in no event shall the aggregate amounts payable by any Holder by way of indemnity or contribution under Subsections 2.8(b) and 2.8(d) exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of fraud or willful misconduct by such Holder.
10 |
(c) Promptly after receipt by an indemnified party under this Section 2.8 of notice of the commencement of any action (including any governmental action) for which a party may be entitled to indemnification hereunder, such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.8 , give the indemnifying party notice of the commencement thereof. The indemnifying party shall have the right to participate in such action and, to the extent the indemnifying party so desires, participate jointly with any other indemnifying party to which notice has been given, and to assume the defense thereof with counsel mutually satisfactory to the parties; provided , however , that an indemnified party (together with all other indemnified parties that may be represented without conflict by one counsel) shall have the right to retain one separate counsel, with the fees and expenses to be paid by the indemnifying party, if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential differing interests between such indemnified party and any other party represented by such counsel in such action.
(d) To provide for just and equitable contribution to joint liability under the Securities Act in any case in which either: (i) any party otherwise entitled to indemnification hereunder makes a claim for indemnification pursuant to this Section 2.8 but it is judicially determined (by the entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case, notwithstanding the fact that this Section 2.8 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any party hereto for which indemnification is provided under this Section 2.8 , then, and in each such case, such parties will contribute to the aggregate losses, claims, damages, liabilities, or expenses to which they may be subject (after contribution from others) in such proportion as is appropriate to reflect the relative fault of each of the indemnifying party and the indemnified party in connection with the statements, omissions, or other actions that resulted in such loss, claim, damage, liability, or expense, as well as to reflect any other relevant equitable considerations. The relative fault of the indemnifying party and of the indemnified party shall be determined by reference to, among other things, whether the untrue or allegedly untrue statement of a material fact, or the omission or alleged omission of a material fact, relates to information supplied by the indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information, and opportunity to correct or prevent such statement or omission; provided , however , that, in any such case (x) no Holder will be required to contribute any amount in excess of the public offering price of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement, and (y) no Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation; and provided further that in no event shall a Holder’s liability pursuant to this Subsection 2.8(d) , when combined with the amounts paid or payable by such Holder pursuant to Subsection 2.8(b) , exceed the proceeds from the offering received by such Holder (net of any Selling Expenses paid by such Holder), except in the case of willful misconduct or fraud by such Holder.
(e) Unless otherwise superseded by an underwriting agreement entered into in connection with the underwritten public offering, the obligations of the Company and Holders under this Section 2.8 shall survive the completion of any offering of Registrable Securities in a registration under this Section 2 , and otherwise shall survive the termination of this Agreement.
11 |
2.9 Reports Under Exchange Act . With a view to making available to the Holders the benefits of SEC Rule 144 and any other rule or regulation of the SEC that may at any time permit a Holder to sell securities of the Company to the public without registration or pursuant to a registration on Form S-3, the Company shall:
(a) use its reasonable best efforts to make and keep available adequate current public information, as those terms are understood and defined in SEC Rule 144, at all times after the effective date of the first registration statement filed by the Company and declared effective by the SEC under the Securities Act or filing with the SEC and effectiveness of a Form 10 registration statement under the Exchange Act, following the date of this Agreement;
(b) use commercially reasonable efforts to file with the SEC in a timely manner all reports and other documents required of the Company under the Securities Act and the Exchange Act (at any time after the Company has become subject to such reporting requirements); and
(c) use its reasonable best efforts to furnish to any Holder, so long as the Holder owns any Registrable Securities, forthwith upon request (i) to the extent accurate, a written statement by the Company that it has complied with the reporting requirements of SEC Rule 144 pursuant to Subsection 2.9(a) above, the Securities Act, and the Exchange Act (at any time after the Company has become subject to such reporting requirements), or that it qualifies as a registrant whose securities may be resold pursuant to Form S-3 (at any time after the Company so qualifies); and (ii) such other information as may be reasonably requested in availing any Holder of any rule or regulation of the SEC that permits the selling of any such securities without registration (at any time after the Company has become subject to the reporting requirements under the Exchange Act) or pursuant to Form S-3 (at any time after the Company so qualifies to use such form).
2.10 Limitations on Subsequent Registration Rights . From and after the date of this Agreement, the Company shall not, without the prior written consent of the Holders of at least sixty-six and two-thirds (66 2/3) of the Registrable Securities then outstanding enter into any agreement with any holder or prospective holder of any securities of the Company that (i) would provide to such holder the right to include securities in any registration on other than either a pro rata basis with respect to the Registrable Securities or on a subordinate basis after all Holders have had the opportunity to include in the registration and offering all shares of Registrable Securities that they wish to so include; or (ii) allow such holder or prospective holder to initiate a demand for registration of any securities held by such holder or prospective holder.
12 |
2.11 “Market Stand-off’ Agreement . Each Holder hereby agrees that it will not, if requested by the managing underwriter in connection with the Offering, without the prior written consent of the managing underwriter, during the period commencing on the date of the final prospectus relating to the registration by the Company for its own behalf in connection with the Offering of shares of its Common Stock on a registration statement on Form S-1, and ending on the date specified by the Company and the managing underwriter (such period not to exceed one hundred eighty (180) days, or such other period as may be requested by the Company or an underwriter to accommodate regulatory restrictions on (1) the publication or other distribution of research reports, and (2) analyst recommendations and opinions, including, but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto), (i) lend; offer; pledge; sell; contract to sell; sell any option or contract to purchase; purchase any option or contract to sell; grant any option, right, or warrant to purchase; or otherwise transfer or dispose of, directly or indirectly, any shares of Common Stock or any securities convertible into or exercisable or exchangeable (directly or indirectly) for Common Stock held immediately before the effective date of the registration statement for such offering or (ii) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of such securities, whether any such transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or other securities, in cash, or otherwise. The foregoing provisions of this Section 2.11 shall not apply to the sale of any shares to an underwriter pursuant to an underwriting agreement, or the transfer of any shares to any trust for the direct or indirect benefit of the Holder or the immediate family of the Holder, provided that the trustee of the trust agrees to be bound in writing by the restrictions set forth herein, and provided further that any such transfer shall not involve a disposition for value, and shall be applicable to the Holders only if all officers and directors are subject to the same restrictions and the Company uses commercially reasonable efforts to obtain a similar agreement from all stockholders individually owning more than one percent (1%) of the Company’s outstanding Common Stock. The underwriters in connection with such registration are intended third-party beneficiaries of this Section 2.11 and shall have the right, power and authority to enforce the provisions hereof as though they were a party hereto. Each Holder further agrees to execute such agreements as may be reasonably requested by the underwriters in connection with such registration that are consistent with this Section 2.11 or that are necessary to give further effect thereto.
2.12 Restrictions on Transfer .
(a) The Registrable Securities shall not be sold, pledged, or otherwise transferred, and the Company shall not recognize and shall issue stop-transfer instructions to its transfer agent with respect to any such sale, pledge, or transfer, except upon the conditions specified in this Agreement, which conditions are intended to ensure compliance with the provisions of the Securities Act. A transferring Holder will cause any proposed purchaser, pledgee, or transferee of the Registrable Securities held by such Holder to agree to take and hold such securities subject to the provisions and upon the conditions specified in this Agreement.
(b) Each certificate, instrument, or book entry representing (i) the Registrable Securities, and any other securities issued in respect of Registrable Securities, upon any stock split, stock dividend, recapitalization, merger, consolidation, or similar event, shall (unless otherwise permitted by the provisions of Subsection 2.12(c)) be notated with a legend substantially in the following form:
THE SECURITIES REPRESENTED HEREBY HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933. SUCH SHARES MAY NOT BE SOLD, PLEDGED, OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR A VALID EXEMPTION FROM THE REGISTRATION AND PROSPECTUS DELIVERY REQUIREMENTS OF SAID ACT.
13 |
THE SECURITIES REPRESENTED HEREBY MAY BE TRANSFERRED ONLY IN ACCORDANCE WITH THE TERMS OF AN AGREEMENT BETWEEN THE COMPANY AND THE STOCKHOLDER, A COPY OF WHICH IS ON FILE WITH THE SECRETARY OF THE COMPANY.
The Holders consent to the Company making a notation in its records and giving instructions to any transfer agent of the Restricted Securities in order to implement the restrictions on transfer set forth in this Section 2.12 .
(c) The holder of such Restricted Securities, by acceptance of ownership thereof, agrees to comply in all respects with the provisions of this Section 2.12 . Before any proposed sale, pledge, or transfer of any Restricted Securities, unless there is in effect a registration statement under the Securities Act covering the proposed transaction, the Holder thereof shall give notice to the Company of such Holder’s intention to effect such sale, pledge, or transfer. Each such notice shall describe the manner and circumstances of the proposed sale, pledge, or transfer in sufficient detail. Each certificate, instrument, or book entry representing the Restricted Securities transferred as above provided shall be notated with, except if such transfer is made pursuant to SEC Rule 144, the appropriate restrictive legend set forth in Subsection 2.12(b) , except that such certificate instrument, or book entry shall not be notated with such restrictive legend if, in the opinion of counsel for such Holder and the Company, such legend is not required in order to establish compliance with any provisions of the Securities Act.
2.13 Termination of Registration Rights . The right of any Holder to request registration or inclusion of Registrable Securities in any registration pursuant to Sections 2.1 or 2.2 shall terminate upon the fifth (5 th ) anniversary of the date of this Agreement. Moreover, the registration rights hereunder shall not be exercisable, if at the time thereof, the Registrable Securities may be publicly sold under SEC Rule 144 without restriction.
3. Information Rights .
3.1 Delivery of Financial Statements . Upon request of any Major Investor or CDF, the Company shall deliver to such Major Investor or CDF, as the case may be, the following provided that such information is (i) not publicly available and (ii) reasonably necessary to protect or otherwise manage such Major Investor’s or CDF’s, as the case may be, interest in the Company as determined in good faith by such Major Investor or CDF, as the case may be:
(a) as soon as practicable, but in any event within ninety (90) days after the end of each fiscal year of the Company (i) a balance sheet as of the end of such year, (ii) statements of income and of cash flows for such year, and a comparison between (x) the actual amounts as of and for such fiscal year and (y) the comparable amounts for the prior year and as included in the Budget (as defined in Subsection 3.1(d)) for such year, with an explanation of any material differences between such amounts and a schedule as to the sources and applications of funds for such year, and (iii) a statement of stockholders’ equity as of the end of such year;
14 |
(b) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, unaudited statements of income and cash flows for such fiscal quarter, and an unaudited balance sheet and a statement of stockholders’ equity as of the end of such fiscal quarter, all prepared in accordance with GAAP (except that such financial statements may (i) be subject to normal year- end audit adjustments; and (ii) not contain all notes thereto that may be required in accordance with GAAP);
(c) as soon as practicable, but in any event within forty-five (45) days after the end of each of the first three (3) quarters of each fiscal year of the Company, a statement showing the number of shares of each class and series of capital stock and securities convertible into or exercisable for shares of capital stock outstanding at the end of the period, the Common Stock issuable upon conversion or exercise of any outstanding securities convertible or exercisable for Common Stock and the exchange ratio or exercise price applicable thereto, and the number of shares of issued stock options and stock options not yet issued but reserved for issuance, if any, all in sufficient detail as to permit such Major Investor or CDF, as the case may be, to calculate their respective percentage equity ownership in the Company, and certified by the chief financial officer or chief executive officer of the Company as being true, complete, and correct;
(d) as soon as practicable, but in any event thirty (30) days before the end of each fiscal year, a budget and business plan for the next fiscal year (collectively, the “Budget”), approved by the Board of Directors and prepared on a monthly basis, including balance sheets, income statements, and statements of cash flow for such months and, promptly after prepared, any other budgets or revised budgets prepared by the Company;
(e) copies of all materials sent to the Company’s stockholders at the same time as such materials are delivered to such stockholders and copies of all OTC Pink basic disclosure documents prepared by the Company and all related financial statements and officer certifications when filed with OTC Markets, Inc., provided that such disclosure documents and financial information when filed with OTC Markets, Inc. shall satisfy the information requirements of Sections 3.1 (a), (b) and (c); and
(f) such other publicly available information relating to the financial condition, business, prospects, or corporate affairs of the Company as any such Major Investor or CDF may from time to time reasonably request; provided , however , that the Company shall not be obligated under this Section 3.1 to provide information (i) that the Company reasonably determines in good faith to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in a form acceptable to the Company); or (ii) the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.
If, for any period, the Company has any subsidiary whose accounts are consolidated with those of the Company, then in respect of such period the financial statements delivered pursuant to the foregoing Sections shall be the consolidated and consolidating financial statements of the Company and all such consolidated subsidiaries.
15 |
Notwithstanding anything else in this Section 3.1 to the contrary, the Company may cease providing the information set forth in this Section 3.1 during the period starting with the date thirty (30) days before the Company’s good-faith estimate of the date of filing of a registration statement if it reasonably concludes it must do so to comply with the SEC rules applicable to such registration statement and related offering; provided that the Company’s covenants under this Section 3.1 shall be reinstated at such time as the Company is no longer actively employing its commercially reasonable efforts to cause such registration statement to become effective. The Company agrees that it will not provide any material non-public information to any such Major Investor or CDF in response to a request for information pursuant to this Section 3.1 without first obtaining the consent from such Investor or CDF, as the case may be.
3.2 Inspection . The Company shall permit each Major Investor or CDF, at such Major Investor’s or CDF’s expense, to visit and inspect the Company’s properties; examine its books of account and records; and discuss the Company’s affairs, finances, and accounts with its officers, during normal business hours of the Company as may be reasonably requested by such Major Investor or CDF but only if reasonably necessary to protect or otherwise manage such Major Investor’s or CDF’s, as the case may be, interest in the Company; provided , however , that the Company shall not be obligated pursuant to this Section 3.2 to provide access to any information that it reasonably and in good faith considers to be a trade secret or confidential information (unless covered by an enforceable confidentiality agreement, in form acceptable to the Company) or the disclosure of which would adversely affect the attorney-client privilege between the Company and its counsel.
3.3 Termination of Information Rights; Limitation on Assignment: Waiver . The covenants set forth in Section 3.1 and Section 3.2 shall terminate and be of no further force or effect upon the earliest to occur: (i) immediately before the consummation of any Offering, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, whichever event occurs first, or (iii) when the Investors or their Affiliates cease to hold at least fifty percent (50%) of the Common Stock originally issued pursuant to the Purchase Agreement (subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like) (the “Original Shares”). The rights of a Major Investor in this Section 3 may not be assigned to any Person who holds less than 112,000 shares of Registrable Securities (as adjusted for any stock split, stock dividend, combination, or other recapitalization effected after the date hereof). Any information and inspection rights under this Section 3 may be waived with respect to any particular Major Investor or all Major Investors with the written consent of the Holders of at least sixty-six and two-thirds (66 2/3) of the Registrable Securities then outstanding
3.4 Confidentiality . Each Investor and CDF, as the case may be, agrees that such Investor or CDF, as applicable, will keep confidential and will not disclose, divulge, or use for any purpose (other than to monitor its investment in the Company) any confidential information obtained from the Company pursuant to the terms of this Agreement or otherwise (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or becomes known to the public in general (other than as a result of a breach of this Section 3.4 by such Investor or CDF, as applicable), (b) is or has been independently developed or conceived by the Investor or CDF, as applicable, without use of the Company’s confidential information, or (c) is or has been made known or disclosed to the Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided , however , that an Investor or CDF, as applicable, may disclose confidential information (i) to its attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any prospective purchaser of any Registrable Securities from such Investor or CDF, as applicable, if such prospective purchaser agrees to be bound by the provisions of this Section 3.4 ; (iii) to any existing or prospective Affiliate, partner, member, stockholder, beneficial owner, director, officer or wholly owned subsidiary of such Investor or CDF, as applicable, in the ordinary course of business, provided that such Investor or CDF, as the case may be, informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such information; or (iv) as may otherwise be required by law, provided that the Investor or CDF, as the case may be, promptly notifies the Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. Moreover, the Investors and CDF acknowledge that the Company’s Common Stock is publicly traded on the OTC Pink Market and accordingly must comply with applicable securities laws.
16 |
4. Rights to Future Stock Issuances .
4.1 Right of First Offer . Subject to the terms and conditions of this Section 4.1 and applicable securities laws, if the Company proposes to offer or sell any New Securities, the Company shall first offer such New Securities to each Major Investor and CDF. Each Major Investor and CDF shall be entitled to apportion the right of first offer hereby granted to it. in such proportions as it deems appropriate, among (i) itself, (ii) its Affiliates and (iii) its beneficial interest holders, such as limited partners, members or any other Person having “beneficial ownership,” as such term is defined in Rule 13d-3 promulgated under the Exchange Act, of such Major Investor or CDF, as the case may be (“Beneficial Owners”); provided that each such Affiliate or Beneficial Owner agrees to enter into this Agreement.
(a) The Company shall give notice (the “Offer Notice”) to each Major Investor and CDF, stating (i) its bona fide intention to offer such New Securities, (ii) the number of such New Securities to be offered, and (iii) the price and terms, if any, upon which it proposes to offer such New Securities.
(b) By notification to the Company within twenty (20) days after the Offer Notice is given, each Major Investor or CDF, as the case may be, may elect to purchase or otherwise acquire, at the price and on the terms specified in the Offer Notice, up to that portion of such New Securities which equals the proportion that the Common Stock then held by such Major Investor or CDF, as the case may be (including all shares of Common Stock then issuable upon conversion or exercise of any Derivative Securities then held by such Major Investor or CDF, as applicable, bears to the Common Stock of the Company then outstanding (including all shares of Common Stock then issuable upon conversion or exercise of any then outstanding Derivative Securities). At the expiration of such twenty (20) day period, the Company shall promptly notify each Major Investor and CDF, in each case that elects to purchase or acquire all the shares available to it (each, a “Fully Exercising Investor” ) of any other Major Investor’s (or CDF’, as the case may be) failure to do likewise. During the ten (10) day period commencing after the Company has given such notice, each Fully Exercising Investor may, by giving notice to the Company, elect to purchase or acquire, in addition to the number of shares specified above, up to that portion of the New Securities for which Major Investors and CDF, as applicable, were entitled to subscribe but that were not subscribed for by such Major Investors or CDF which is equal to the proportion that the Common Stock issued and held, and issuable upon conversion or exercise of any other Derivative Securities then held, by such Fully Exercising Investor bears to the Common Stock issued and held, and any other Common Stock then issuable upon conversion or exercise of all Derivative Securities then held, by all Fully Exercising Investors who wish to purchase such unsubscribed shares. The closing of any sale pursuant to this Subsection 4.1(b) shall occur within the later of thirty (30) days of the date that the Offer Notice is given and the date of initial sale of New Securities pursuant to Subsection 4.1(c) .
17 |
(c) If all New Securities referred to in the Offer Notice are not elected to be purchased or acquired as provided in Subsection 4.1(b) , the Company may, during the thirty (30) day period following the expiration of the periods provided in Subsection 4.1(b) , offer and sell the remaining unsubscribed portion of such New Securities to any Person or Persons at a price not less than, and upon terms no more favorable to the offeree than, those specified in the Offer Notice. If the Company does not enter into an agreement for the sale of the New Securities within such period, or if such agreement is not consummated within thirty (30) days of the execution thereof, the right provided hereunder shall be deemed to be revived and such New Securities shall not be offered unless first reoffered to the Major nvestors and CDF in accordance with this Section 4.1 .
(d) The right of first offer in this Section 4.1 shall not be applicable to:
(i) shares of Common Stock or Derivative Securities issued by reason of a dividend, stock split, split-up or other distribution on shares of Common Stock;
(ii) shares of Common Stock or Derivative Securities issued to employees or directors of, or consultants or advisors to, the Company or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board of Directors;
(iii) shares of Common Stock actually issued upon the exercise of Derivative Securities outstanding as of the date hereof, in each case provided such issuance is pursuant to the terms of such Derivative Security;
(iv) shares of Common Stock or Derivative Securities issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing transaction approved by the Board of Directors;
(v) shares of Common Stock or Derivative Securities issued in connection with sponsored research, collaboration, technology license, development, OEM, marketing or other similar agreements or strategic partnerships approved by the Board of Directors;
(vi) shares of Common Stock issued pursuant to a registration statement; or
18 |
(vii) shares of Common Stock or Derivative Securities which the holders of at least sixty-six and two-thirds (66 2/3) of the Registrable Securities then outstanding agree shall not be subject to the right of first refusal in this Section 4.1 .
4.2 Termination. The covenants set forth in Section 4.1 shall terminate and be of no further force or effect (i) immediately before the consummation of the Offering, or (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, whichever event occurs first.
5. Additional Covenants .
5.1 Insurance . The Company shall use its commercially reasonable efforts to obtain, within ninety (90) days of the date hereof, from financially sound and reputable insurers Directors and Officers liability insurance and term “key-person” insurance in an amount and on terms and conditions satisfactory to the Board of Directors, including at least one (1) Investor Director, and will use commercially reasonable efforts to cause such insurance policy to be maintained until such time as the Board of Directors determines that such insurance should be discontinued. Notwithstanding any other provision of this Section 5.1 to the contrary, for so long as at least one (1) Investor Director is serving on the Board of Directors, the Company shall not cease to maintain a Directors and Officers liability insurance policy in an amount of at least two million dollars ($2,000,000) unless approved by at least one (1) Investor Director, and the Company shall annually, within one hundred twenty (120) days after the end of each fiscal year of the Company, deliver to the Investor Directors a certification that such a Directors and Officers liability insurance policy remains in effect.
5.2 Employee Agreements . The Company will cause (i) each person now or hereafter employed by it or by any subsidiary (or engaged by the Company or any subsidiary as a consultant/independent contractor) with access to confidential information and/or trade secrets to enter into a nondisclosure and proprietary rights assignment agreement; and (ii) each Key Employee to enter into a one (1) year noncompetition and nonsolicitation agreement, each of the foregoing agreements substantially in the form approved by the Board of Directors, including at least one (1) Investor Director. In addition, the Company shall not amend, modify, terminate, waive, or otherwise alter, in whole or in part, any of the above-referenced agreements or any restricted stock agreement between the Company and any employee, without the consent of at least one (1) Investor Director.
5.3 Employee Stock . Unless otherwise approved by the Board of Directors, including at least one (1) Investor Director, all future employees and consultants of the Company who purchase, receive options to purchase, or receive awards of shares of the Company’s capital stock after the date hereof shall be required to execute restricted stock or option agreements, as applicable, providing for (i) vesting of shares over a three (3) or four (4) year period, with the first twenty-five percent (25%) of such shares vesting following twelve (12) months of continued employment or service, and the remaining shares vesting in equal monthly installments thereafter, and (ii) a market stand-off provision substantially similar to that in Section 2.11 . In addition, unless otherwise approved by the Board of Directors, including the Director, the Company shall retain a “right of first refusal” on employee transfers until the Company’s Offering or other earlier registration of its Common Stock pursuant to a registration statement and shall have the right to repurchase unvested shares at cost upon termination of employment of a holder of restricted stock.
19 |
5.4 Matters Requiring Investor Director Approval . So long as the Investors are entitled to elect an Investor Director, the Company hereby covenants and agrees with each of the Investors that it shall not, without approval of the Board of Directors, which approval must include the affirmative vote of at least one (1) Investor Director:
(a) liquidate, dissolve or wind-up the business and affairs of the Company, effect any Change of Control or consent to any of the foregoing;
(b) amend, alter or repeal any provision of the Articles of Incorporation or Bylaws of the Company in a manner that adversely affects the powers, preferences or rights of the Investors hereunder or under the Purchase Agreement;
(c) purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Company other than (i) redemptions of or dividends or distributions on the Series C Preferred Stock or Series D Preferred Stock as expressly authorized in the Certificate of Designation for the Series C Preferred Stock or the Certificate of Designation for the Series D Preferred Stock, as applicable provided , however , the Company has adequate cash flow for payment of such redemption or distribution and such redemption or distribution is not effected earlier than eighteen (18) months following the date of this Agreement (and for the avoidance of doubt, for purposes of this proviso, a distribution does not include a dividend), (ii) dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock, and (iii) repurchases of stock from former employees, officers, directors, consultants or other persons who performed services for the Company or any subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market value thereof;
(d) create, or authorize the creation of, or issue, or authorize the issuance of any debt security, or permit any subsidiary to take any such action with respect to any debt security, if the aggregate indebtedness of the Company and its subsidiaries for borrowed money following such action would exceed $1,000,000, other than up to $4,500,000 of indebtedness under the line of credit note payable to CDF;
(e) increase or decrease the authorized number of directors constituting the Board of Directors;
(f) (i) enter into or materially amend any exclusive distribution agreement for the Company’s products for any material territory unless approved by the Board of Directors, which approval shall not require (other than with respect to any territories contemplated by the proposed JV (as defined in the Purchase Agreement)) the affirmative vote of either Investor Director, or (ii) enter into or materially amend any distribution or other commercialization agreement for the Company’s products for any territory contemplated by the proposed JV. Notwithstanding the foregoing, the affirmative vote of either Investor Director shall not be required for any territory if the proposed JV is not consummated in accordance with the Purchase Agreement by mutual agreement of the parties to the proposed JV;
20 |
(g) make, or permit any subsidiary to make, any loan or advance to, or own any stock or other securities of, any subsidiary or other corporation, partnership, or other entity unless it is wholly owned by the Company;
(h) make, or permit any subsidiary to make, any loan or advance to any Person, including, without limitation, any employee or director of the Company or any subsidiary, except advances and similar expenditures in the ordinary course of business or under the terms of an employee stock or option plan approved by the Board of Directors;
(i) guarantee, directly or indirectly, or permit any subsidiary to guarantee, directly or indirectly, any indebtedness except for indebtedness of the Company or any subsidiary;
(j) otherwise enter into or be a party to any transaction with any director, officer, or employee of the Company or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such Person, including without limitation any “management bonus” or similar plan providing payments to employees in connection with a Change of Control, except for transactions contemplated by this Agreement, the Purchase Agreement, and the Secondary Convertible Promissory Note Purchase Agreement dated as of April ____ , 2015; or transactions made in the ordinary course of business and pursuant to reasonable requirements of the Company’s business and upon fair and reasonable terms that are approved by a majority of the Board of Directors;
(k) hire, terminate, or change the compensation of the executive officers, including approving any option grants or stock awards to executive officers unless approved by the Board of Directors, which approval shall not require the affirmative vote of either Investor Director;
(l) materially change the fundamental direction of the principal business of the Company away from functional beverages;
(m) sell, assign, license, pledge, or encumber material technology or intellectual property, other than licenses granted in the ordinary course of business; or
(n) enter into any corporate strategic relationship involving the payment, contribution, or assignment by the Company or to the Company of money or assets greater than $1,000,000.
5.5 Board Matters . Unless otherwise determined by the vote of a majority of the directors then in office, the Board of Directors shall meet at least quarterly in accordance with an agreed-upon schedule. The Company shall reimburse the nonemployee directors for all reasonable out-of-pocket travel expenses incurred (consistent with the Company’s travel policy) in connection with attending meetings of the Board of Directors. Further, each director shall be entitled to compensation for his services as a director to the Company in the amount of $3,000 per calendar quarter.
21 |
5.6 Successor Indemnification . If the Company or any of its successors or assignees consolidates with or merges into any other Person and is not the continuing or surviving corporation or entity of such consolidation or merger, then to the extent necessary, proper provision shall be made so that the successors and assignees of the Company assume the obligations of the Company with respect to indemnification of members of the Board of Directors as in effect immediately before such transaction, whether such obligations are contained in the Company’s Bylaws, its Articles of Incorporation, or elsewhere, as the case may be.
5.7 Indemnification Matters . The Company hereby acknowledges that any director nominated to serve on the Board of Directors by the Investors (each a “Fund Director”) may have certain rights to indemnification, advancement of expenses and/or insurance provided by one or more of the Investors and certain of their affiliates (collectively, the “Fund Indemnitors”). The Company hereby agrees (a) that it is the indemnitor of first resort (i.e., its obligations to any such Fund Director are primary and any obligation of the Fund Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by such Fund Director are secondary), (b) that it shall be required to advance the full amount of expenses incurred by such Fund Director and shall be liable for the full amount of all expenses, judgments, penalties, fines and amounts paid in settlement by or on behalf of any such Fund Director to the extent legally permitted and as required by the Company’s Articles of Incorporation or Bylaws of the Company (or any agreement between the Company and such Fund Director), without regard to any rights such Fund Director may have against the Fund Indemnitors, and, (c) that it irrevocably waives, relinquishes and releases the Fund Indemnitors from any and all claims against the Fund Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof. The Company further agrees that no advancement or payment by the Fund Indemnitors on behalf of any such Fund Director with respect to any claim for which such Fund Director has sought indemnification from the Company shall affect the foregoing and the Fund Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of such Fund Director against the Company.
5.8 Right to Conduct Activities . The Company hereby agrees and acknowledges that each of the Investors (together with its Affiliates) is a professional investment fund, and as such invests in numerous portfolio companies, some of which may be deemed competitive with the Company’s business (as currently conducted or as currently propose to be conducted). The Company hereby agrees that, to the extent permitted under applicable law, such Investor shall not be liable to the Company for any claim arising out of, or based upon, (i) the investment by such Investor or its Affiliates in any entity competitive with the Company, or (ii) actions taken by any partner, officer or other representative of such Investor or its Affiliates to assist any such competitive company, whether or not such action was taken as a member of the board of directors of such competitive company or otherwise, and whether or not such action has a detrimental effect on the Company; provided, however, that the foregoing shall not relieve (x) any of the Investors from liability associated with the unauthorized disclosure of the Company’s confidential information obtained pursuant to this Agreement or otherwise, or (y) any director or officer of the Company from any liability associated with his or her fiduciary duties to the Company.
22 |
5.9 FCPA . The Company represents that it shall not (and shall not permit any of its subsidiaries or affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute any item of value to, directly or indirectly, to any third party, including any Non-U.S. Official (as (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) cease all of its or their respective activities, as well as remediate any actions taken by the Company, its subsidiaries or affiliates, or any of their respective directors, officers, managers, employees, independent contractors, representatives or agents in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company further represents that it shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive information and/or certifications concerning its compliance with applicable anti- corruption laws. The Company shall promptly notify each Investor if the Company becomes aware of any enforcement or other legal action related to a violation or alleged violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company shall, and shall cause any direct or indirect subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA. The Company shall use its best efforts to cause any direct or indirect subsidiary, whether now in existence or formed in the future, to comply in all material respects with all applicable laws.
5.10 Certain Affirmative Covenants of the Company . The Company shall, and shall cause each Company’s subsidiaries to: (i) maintain its corporate existence in good standing; (ii) comply with all governmental requirements and laws applicable to the operation of its business, except for any instances of noncompliance that would not reasonably be expected to have, individually or in the aggregate, a material adverse effect on the consolidated business, properties, assets, operations, results of operations, financial condition, credit worthiness or prospects of the Company and the Company’s subsidiaries taken as a whole (“Material Adverse Effect”); (iii) comply with all agreements, documents and instruments binding on it or affecting its properties or business, including, without limitation, all material contracts, except for instances of noncompliance that would not reasonably be expected to have, individually or in the aggregate, a Material Adverse Effect;
5.11 Board Composition . For so long as the Investors or their Affiliates continue to hold at least fifty percent (50%) of the shares of Common Stock originally issued pursuant to the Purchase Agreement (subject to appropriate adjustment for all stock splits, dividends, combinations, recapitalizations and the like), each Investor and Key Holder agrees to vote, or cause to be voted, all shares of Common Stock and other Derivative Securities owned by such Investor or Key Holder, as the case may be, or over which such Investor or Key Holder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that at each annual or special meeting of shareholders at which an election of directors is held or pursuant to any written consent of the shareholders, the following person(s) shall be elected to the Board of Directors:
23 |
(a) (i) three (3) persons who shall be designated by the Investors and shall be reasonably satisfactory to the Board of Directors, one of whom shall be designated by the holders of the Original Shares, which individual shall initially be Tim Leissner, and one of whom shall be designated by Horizons (such two directors are referred to herein as “Investor Directors”) and a third person who shall also be designated by Horizons but who shall not be designated as an Investor Director hereunder (the “Additional Investor Director”), and (ii) four (4) persons who shall be designated by CDF (the “CDF Directors”), one of whom shall initially be the current Chief Executive Officer of the Company. For the avoidance of doubt, the Additional Investor Director shall not be counted as an Investor Director for any purpose hereunder, including for purposes of determining whether any approval has been obtained from an Investor Director under this Agreement (including without limitation Section 5.4) .
(b) Failure to Designate a Board Member . In the absence of any designation from the Persons or groups with the right to designate a director as specified in Subsection 5.11(a) above, the director previously designated by them and then serving shall be reelected if still eligible to serve as provided herein.
(c) Removal of Board Members . Each Investor and Key Holder also agrees to vote, or cause to be voted, all shares of Common Stock and other Derivative Securities owned by such Investor or Key Holder, as the case may be, or over which such Investor or Key Holder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that:
(i) no director elected pursuant to Subsection 5.11(a) of this Agreement may be removed from office other than for cause as determined under applicable laws unless (i) such removal is directed or approved by the affirmative vote of the Person, or of the holders of at least a majority of the shares of stock, entitled under Subsection 5.11(a) to designate that director; or (ii) the Person(s) originally entitled to designate or approve such director pursuant to Subsection 5.11(a) is no longer so entitled to designate or approve such director;
(ii) any vacancies created by the resignation, removal or death of a director elected pursuant to Subsections 5.11(a) shall be filled pursuant to the provisions of this Section 5.11 ; and
(iii) upon the request of any party entitled to designate a director as provided in Subsection 5.11(a) to remove such director, such director shall be removed.
(d) Cooperation . All Investors and Key Holders agree to execute any written consents required to perform the obligations of this Agreement, and the Company agrees at the request of any party entitled to designate directors to call a special meeting of stockholders for the purpose of electing directors.
(e) No Liability for Election of Recommended Directors . No Investor, nor any Affiliate of any Investor, shall have any liability as a result of designating a person for election as a director for any act or omission by such designated person in his or her capacity as a director of the Company, nor shall any Investor or Key Holder have any liability as a result of voting for any such designee in accordance with the provisions of this Agreement.
24 |
(f) Size of the Board . Each Investor and Key Holder agrees to vote, or cause to be voted, all shares of Common Stock and other Derivative Securities owned by such Investor or Key Holder, as the case may be, or over which such Investor or Key Holder has voting control, from time to time and at all times, in whatever manner as shall be necessary to ensure that the size of the Board of Directors shall be set and remain at seven (7) directors except only with the approval of the Board, including the approval of at least one (1) Investor Director and at least one CDF Director.
5.12 Termination of Covenants . The covenants set forth in this Section 5 , except for Sections 5.7 and 5.8 , shall terminate and be of no further force or effect upon the earliest to occur: (i) immediately before the consummation of the Offering, (ii) when the Company first becomes subject to the periodic reporting requirements of Section 12(g) or 15(d) of the Exchange Act, whichever event occurs first, or (iii) when the Investors or their Affiliates cease to hold at least fifty percent (50%) of the Original Shares.
6. Miscellaneous .
6.1 Successors and Assigns . The rights under this Agreement may be assigned (but only with all related obligations) by a Holder to a transferee of Registrable Securities that (i) is an Affiliate of a Holder; (ii) is a Holder’s Immediate Family Member or trust for the benefit of an individual Holder or one or more of such Holder’s Immediate Family Members; or (iii) after such transfer, holds at least ten thousand (10,000) shares of Registrable Securities (subject to appropriate adjustment for stock splits, stock dividends, combinations, and other recapitalizations); provided , however , that (x) the Company is, within a reasonable time after such transfer, furnished with written notice of the name and address of such transferee and the Registrable Securities with respect to which such rights are being transferred; and (y) such transferee agrees in a written instrument delivered to the Company to be bound by and subject to the terms and conditions of this Agreement, including the provisions of Section 2.11 . For the purposes of determining the number of shares of Registrable Securities held by a transferee, the holdings of a transferee (1) that is an Affiliate or stockholder of a Holder; (2) who is a Holder’s Immediate Family Member; or (3) that is a trust for the benefit of an individual Holder or such Holder’s Immediate Family Member shall be aggregated together and with those of the transferring Holder; provided further that all transferees who would not qualify individually for assignment of rights shall have a single attorney-in-fact for the purpose of exercising any rights, receiving notices, or taking any action under this Agreement. The terms and conditions of this Agreement inure to the benefit of and are binding upon the respective successors and permitted assignees of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and permitted assignees any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided herein.
6.2 Governing Law . This Agreement shall be governed by the internal law of the State of New York.
25 |
6.3 Counterparts . This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.
6.4 Titles and Subtitles . The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting this Agreement.
6.5 Notices . All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given upon the earlier of actual receipt or (i) personal delivery to the party to be notified; (ii) when sent, if sent by electronic mail or facsimile during the recipient’s normal business hours, and if not sent during normal business hours, then on the recipient’s next business day; (iii) five (5) days after having been sent by certified mail, return receipt requested, postage prepaid; or (iv) one (1) business day after the business day of deposit with a nationally recognized overnight courier, freight prepaid, specifying next-day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their addresses as set forth on Schedule A hereto, or to the principal office of the Company and to the attention of the Chief Executive Officer, in the case of the Company, or to such email address, facsimile number, or address as subsequently modified by written notice given in accordance with this Section 6.5 . If notice is given to the Company, a copy, which shall not constitute notice, shall also be given to Gutierrez Bergman Boulris, PLLC, 100 Almeria Avenue, Suite 340, Coral Gables, Florida 33134 and if notice is given to the Holders, a copy, which shall not constitute notice, shall also be given to Cooley LLP, attention Patrick Loofbourrow, IFC – Tower 2, Level 35, Unit 3510, 8 Century Avenue Pudong New Area, Shanghai, 200120, China.
6.6 Amendments and Waivers . Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance, and either retroactively or prospectively) only with the written consent of the Company, the Key Holders and the holders of at least sixty-six and two-thirds (66 2/3) of the Registrable Securities then outstanding, including the holders of a majority of the Original Shares; provided that the Company may in its sole discretion waive compliance with Subsection 2.12(c) (and the Company’s failure to object promptly in writing after notification of a proposed assignment allegedly in violation of Subsection 2.12(c) shall be deemed to be a waiver); and provided further that any provision hereof may be waived (either generally or in a particular instance, and either retroactively or prospectively) by any waiving party on such party’s own behalf, without the consent of any other party. Notwithstanding the foregoing, this Agreement may not be amended or terminated and the observance of any term hereof may not be waived with respect to any Investor without the written consent of such Investor, unless such amendment, termination, or waiver applies to all Investors in the same fashion (it being agreed that a waiver of the provisions of Section 4 with respect to a particular transaction shall be deemed to apply to all Investors in the same fashion if such waiver does so by its terms, notwithstanding the fact that certain Investors may nonetheless, by agreement with the Company, purchase securities in such transaction). Any amendment to Section 5.11 shall require the prior written consent of Horizons. The Company shall give prompt notice of any amendment or termination hereof or waiver hereunder to any party hereto that did not consent in writing to such amendment, termination, or waiver. Any amendment, termination, or waiver effected in accordance with this Section 6.6 shall be binding on all parties hereto, regardless of whether any such party has consented thereto. No waivers of or exceptions to any term, condition, or provision of this Agreement, in any one or more instances, shall be deemed to be or construed as a further or continuing waiver of any such term, condition, or provision.
26 |
6.7 Severability . In case any one or more of the provisions contained in this Agreement is for any reason held to be invalid, illegal or unenforceable in any respect, such invalidity, illegality, or unenforceability shall not affect any other provision of this Agreement, and such invalid, illegal, or unenforceable provision shall be reformed and construed so that it will be valid, legal, and enforceable to the maximum extent permitted by law.
6.8 Aggregation of Stock . All shares of Registrable Securities held or acquired by Affiliates shall be aggregated together for the purpose of determining the availability of any rights under this Agreement and such Affiliated persons may apportion such rights as among themselves in any manner they deem appropriate.
6.9 Entire Agreement . This Agreement (including any Schedules and Exhibits hereto) constitutes the full and entire understanding and agreement among the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties is expressly canceled.
6.10 Arbitration . Any unresolved controversy or claim arising out of or relating to this Agreement, except as otherwise provided in this Agreement, shall be submitted to arbitration by one arbitrator mutually agreed upon by the parties, and if no agreement can be reached within thirty (30) days after names of potential arbitrators have been proposed by the American Arbitration Association (the “AAA” ), then by one arbitrator having reasonable experience in corporate finance transactions of the type provided for in this Agreement and who is chosen by the AAA. The arbitration shall take place in New York, in accordance with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding and may be entered in any court having jurisdiction thereof. There shall be limited discovery prior to the arbitration hearing as follows: (a) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated, (b) depositions of all party witnesses, and (c) such other depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance with the New York Code of Civil Procedure, the arbitrator shall be required to provide in writing to the parties the basis for the award or order of such arbitrator and a court reporter shall record all hearings, with such record constituting the official transcript of such proceedings. Notwithstanding anything in this Agreement to the contrary, in no event shall a party hereto be liable for punitive, consequential or special damages of any kind or nature in any action arising from this Agreement, regardless of the form of action through which such damages are sought.
27 |
6.11 Delays or Omissions . No delay or omission to exercise any right, power, or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power, or remedy of such nonbreaching or nondefaulting party, nor shall it be construed to be a waiver of or acquiescence to any such breach or default, or to any similar breach or default thereafter occurring, nor shall any waiver of any single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. All remedies, whether under this Agreement or by law or otherwise afforded to any party, shall be cumulative and not alternative.
6.12 Acknowledgment . The Company acknowledges that the Investors are in the business of venture capital investing and therefore review the business plans and related proprietary information of many enterprises, including enterprises which may have products or services which compete directly or indirectly with those of the Company. Nothing in this Agreement shall preclude or in any way restrict the Investors from investing or participating in any particular enterprise whether or not such enterprise has products or services which compete with those of the Company.
[Remainder of Page Intentionally Left Blank]
28 |
IN WITNESS WHEREOF, the parties have executed this Investors’ Rights Agreements as of the date first written above
CELSIUS HOLDINGS, INC. | ||
By: | ||
Name: | ||
Title: |
[ Signature Page to Celsius Holdings, Inc.
Investors’ Rights Agreement]
IN WITNESS WHEREOF, the parties have executed this Investors’ Rights Agreement as of the date first written above.
INVESTORS: | ||
CHARMNEW LIMITED | ||
By: | ||
Name: | ||
Title: |
Address: 7/F, Cheung Kong Center | |
2 Queen’s Road Central | |
Hong Kong | |
Attn. : Ms. Ezra Pau/Ms. Eirene Yeung | |
Phone #: +852 21288888 | |
Fax #: +852 21288001 | |
Email: ezra.pau@ckh.com.hk | |
eirene.yeung@ckh.com.hk |
GRIEG INTERNATIONAL LIMITED | ||
By: | ||
Name: | ||
Title: |
Address: 29th Floor, Harbour Centre, | |
25 Harbour Road, Wanchai, | |
Hong Kong | |
Attention: Jason Wong | |
Phone #: +852 21863873 | |
Fax #: +852 37411011 | |
Email: jason.wong@horizons.com.hk | |
raymond.ng@horizons.com.hk | |
chris.lai@horizons.com.hk |
[ Signature Page to Celsius Holdings, Inc.
Investors’ Rights Agreement]
IN WITNESS WHEREOF, the parties have executed this Investors’ Rights Agreement as of the date first written above.
INVESTORS: | ||
Name: | ||
By: | ||
Name: | ||
Title: |
[ Signature Page to Celsius Holdings, Inc.
Investors’ Rights Agreement]
IN WITNESS WHEREOF, the parties have executed this Investors’ Rights Agreement as of the date first written above.
KEY HOLDERS: | ||
CD Financial LLC | ||
By: | ||
Name: | ||
Title: | ||
CDS Ventures of South Florida LLC | ||
By: | ||
Name: | ||
Title: |
[ Signature Page to Celsius Holdings, Inc.
Investors’ Rights Agreement]
IN WITNESS WHEREOF, the parties have executed this Investors’ Rights Agreement as of the date first written above.
KEY HOLDERS: | ||
Name: | ||
By: | ||
Name: | ||
Title: |
[ Signature Page to Celsius Holdings, Inc.
Investors’ Rights Agreement]
SCHEDULE A
Investors
Charmnew Limited
Address:
7/F, Cheung Kong Center,
2 Queen’s Road Central, Hong Kong
Phone Number: +852 21288888
Fax Number: +852 21288001
Email: ezra.pau@ckh.com.hk / eirene.yeung@ckh.com.hk
Attention: Ms. Ezra Pau/Ms. Eirene Yeung
Grieg International Limited
Address: 29th Floor, Harbour Centre,
25 Harbour Road,
Wanchai, Hong Kong
Phone Number: +852 21863873
Fax Number: +852 37411011
Email: jason.wong@horizons.com.hk / raymond.ng@horizons.com.hk
chris.lai@horizons.com.hk
Attention: Jason Wong
[Others to be updated]
SCHEDULE B
Key Holders
CD Financial LLC
Address
Phone Number
Fax Number
Email]
CDS Ventures of South Florida LLC
Address
Phone Number
Fax Number
Email]
EXHIBIT C
Form of Certificate from the Secretary certifying the Articles of Incorporation and bylaws of the Company, the resolutions adopted by the directors and stockholders of the Company in connection with this Agreement and the transactions contemplated herby, and the incumbency of certain officers of the Company.
Celsius, Inc. • 2424 North Federal Highway • Suite 208 • Boca Raton, Florida 33431
Office: 561.276.2239 • Fax: 561.276.2268 • www.celsius.com
CELSIUS HOLDINGS, INC.
OFFICER’S CERTIFICATE
The undersigned hereby certifies that he is the duly elected, qualified and acting Secretary of Celsius Holdings, Inc., a Nevada corporation (the “Company”), and that as such he is authorized to execute and deliver this certificate in the name and on behalf of the Company, and further certifies in his official capacity, in the name and on behalf of the Company, the items set forth below.
1. | Attached hereto as Exhibit A is a true, correct and complete copy of resolutions duly adopted at a meeting of the Board of Directors of the Company held on April 16, 2015, and a true, correct and complete copy of resolutions adopted by the written consent of the holders of capital stock having a majority of the issued and outstanding voting rights of the Company. The resolutions contained in Exhibit A have not in any way been amended, modified, revoked or rescinded, have been in full force and effect since their adoption to and including the date hereof and are now in full force and effect. |
2. | Attached hereto as Exhibit B is a true, correct and complete copy of the Articles of Incorporation of the Company, together with any and all amendments thereto, and no action has been taken to further amend, modify or repeal such Articles of Incorporation, the same being in full force and effect in the attached form as of the date hereof |
3. | Attached hereto as Exhibit C is a true, correct and complete copy of the Bylaws of the Company and any and all amendments thereto, and no action has been taken to further amend, modify or repeal such Bylaws, the same being in full force and effect in the attached form as of the date hereof. |
4. | Each person listed below has been duly elected or appointed to the position(s) indicated opposite his name and is duly authorized to sign the Agreement and any related documents on behalf of the Company, and the signature appearing opposite such person’s name below is such person’s genuine signature. |
Name | Position | Signature | |||
Gerry David | President and CEO |
IN WITNESS WHEREOF , the undersigned has executed this certificate as of April 16, 2015.
John Fieldly, Secretary |
Celsius Holdings, Inc.
Officer’s Certificate
Page 2 of 4
EXHIBIT A
Resolutions
Celsius Holdings, Inc.
Officer’s Certificate
Page 3 of 4
EXHIBIT B
Articles of Incorporation
Celsius Holdings, Inc.
Officer’s Certificate
Page 4 of 4
EXHIBIT C
Bylaws
EXHIBIT D
GUTIERREZ BERGMAN BOULRIS PLLC, COUNSEL FOR THE COMPANY, AN OPINION, dated AS OF THE CLOSING, IN SUBSTANTIALLY THE FORM OF AGREEMENT
Celcius, Inc. • 2424 North Federal Highway
• Suite 208 • Boca Raton, Florida 33431
Office: 561.276.2239 • Fax: 561.276.2268 • www.celcius.com
ATTORNEYS AT LAW
April 20, 2015
Investors listed on Schedule 1.2 to
the Purchase Agreement
Re: | Common Stock Purchase Agreement dated April 20, 2015 (the “Purchase Agreement”) by and among Celsius Holdings, Inc. and the investors listed on Schedule 1.2 to the Purchase Agreement (the “Purchasers”) |
Ladies and Gentlemen:
We are counsel to Celsius Holdings, Inc., a Nevada corporation (the “Company”) and its wholly-owned subsidiaries, Celsius Inc., a Nevada corporation, Celsius Products Holdings, Inc., a Florida corporation and Celsius Netshipments, Inc., a Florida corporation (individually, a “Subsidiary” and collectively, the “Subsidiaries”). We deliver this opinion pursuant to Section 1.4(l) of the Purchase Agreement. Capitalized terms not otherwise defined herein shall have the meanings set forth in the Purchase Agreement.
A. | Basis Of Opinion . |
In connection with this opinion, we have examined such documents and obtained such factual information as we believe necessary to give the opinions set forth herein, including the following:
1. | the Purchase Agreement, as executed by the Company and the Purchasers; |
2. | the Investors’ Rights Agreement, as executed by the Company, the Purchasers and the other shareholders of the Company who are party thereto; |
3. | the Secondary Convertible Promissory Note Purchase Agreement, as executed by CDS Ventures of South Florida, LLC, certain of the Purchasers and the Company; |
4. | the Indemnification Agreements, as executed by the Company and the directors designated by the Purchasers; |
5. | the Amendment to Loan and Security Agreement, as executed by the Company and CD Financial, LLC; |
Guti érrez Bergman Boulris, PLLC
100 Almeria Ave, Suite 340 | Coral Gables, FL 33134
Office: (305) 358-5100 | Fax: (888) 281-1829
April 20, 2015
Page 2 of 7
6. | the Amended and Restated Promissory Note, as executed by the Company in favor of CD Financial, LLC; |
7. | the certificate of the President and Chief Executive Officer of the Company, executed and delivered pursuant to Section 1.4(c) of the Purchase Agreement; |
8. | the certificate of the Secretary of the Company executed and delivered pursuant to Section 1.4(h) of the Purchase Agreement including the exhibits thereto; |
9. | a certificate of the Secretary of State of the state of incorporation of the Company and each Subsidiary, attesting to the incorporation and good standing of the Company and each Subsidiary, as the case may be, in such state; and |
10. | such other documents and matters of law as we have considered necessary or appropriate for the expression of the opinions contained herein. |
For the purpose of this opinion, the documents in Items 1 through 6 above are referred to collectively as the “Transaction Documents” and all the documents and information referred to above, inclusively, are collectively referred to herein as the “Documents.”
B. | Assumptions. |
In rendering the following opinions, we have also relied, with your permission and without investigation, as to factual matters which affect our opinions, on the statements, representations and warranties contained in the Documents.
We have made no investigations of the facts or law underlying the foregoing assumptions, and you have not requested us to do so, but we wish to advise you that nothing has come to our attention which would provide us with actual knowledge that we are not justified in making such assumptions.
Guti érrez Bergman Boulris, PLLC
100 Almeria Ave, Suite 340 | Coral Gables, FL 33134
Office: (305) 358-5100 | Fax: (888) 281-1829
April 20, 2015
Page 3 of 7
In rendering the opinions set forth herein, we have relied, without investigation, on each of the following assumptions: (a) the legal capacity of each natural person to take all actions required of each such person in connection with the transaction contemplated by the Purchase Agreement (the “Transaction”); (b) the legal existence of each party to the Documents other than the Company and the Subsidiaries; (c) the power of each party to the Documents other than the Company and the Subsidiaries, to execute, deliver and perform all Documents executed and delivered by such party and to do each other act done or to be done by such party; (d) the authorization, execution and delivery by each party, other than the Company and the Subsidiaries, of each Document executed and delivered or to be executed and delivered by such party; (e) the legality, validity, binding effect and enforceability as to each party, other than the Company and the Subsidiaries, of each Document executed and delivered by such party or to be executed and delivered and of each other act done or to be done by such party; (f) there have been no undisclosed modifications of any provision of any Document reviewed by us in connection with the rendering of this opinion letter and no undisclosed prior waiver of any right or remedy contained in the Transaction Documents; (g) the genuineness of each signature, the completeness of each document submitted to us, the authenticity of each document reviewed by us as an original, the conformity to the original of each document reviewed by us as a copy and the authenticity of the original of each document received by us as a copy; (h) the truthfulness of each statement as to all factual matters otherwise not known to us to be untruthful contained in any document encompassed within the diligence review undertaken by us; (i) each certificate or other document issued by a public authority is accurate, complete and authentic as of the date of the opinion, and all official public records (including their proper indexing and filing) are accurate and complete; (j) each recipient of this opinion letter has acted in good faith, without notice of any defense against enforcement of rights created by, or adverse claim to any property or security interest transferred or created as part of, the Transaction, and has complied with all laws applicable to it that affect the Transaction; (k) the Transaction and the conduct of the parties to the Transaction comply with any requirement of good faith, fair dealing and conscionability; (1) routine procedural matters such as service of process or qualification to do business in the relevant jurisdiction(s) will be satisfied by the parties seeking to enforce the Transaction Documents; (m) agreements (other than the Transaction Documents as to which opinions are being given) and judgments, decrees and orders reviewed in connection with rendering the opinions will be enforced as written; (n) no action, discretionary or otherwise, will be taken by or on behalf of the Company in the future that might result in a violation of law or otherwise constitute a breach or default under the Purchase Agreement (or any other document related thereto) or under any applicable court order; (o) there are no agreements or understandings among the parties, written or oral, and there is no usage of trade or course of prior dealing among the parties that would, in either case, define, supplement, modify or qualify the terms of the Transaction Documents or the rights of the parties thereunder; and (p) with respect to the Transaction and the Transaction Documents, including the inducement of the parties to enter into and perform their respective obligations thereunder, there has been no mutual mistake of fact or undue influence and there exists no fraud or duress.
C. | Opinions . |
Based on the foregoing, and subject to the qualifications set forth below, it is our opinion that:
1. The Company and each Subsidiary is an entity duly formed and validly existing under the laws of the state of its formation and is in good standing under such laws. The Company and each Subsidiary has requisite corporate power to own, lease and operate their respective properties and to conduct their respective businesses as presently conducted.
2. The Company has the requisite corporate power and authority to execute, deliver and perform all of its obligations under the Transaction Documents to which it is a party, including, without limitation, the issuance of the Common Stock and the Note Conversion Shares in accordance with the terms thereof. The execution and delivery of the Transaction Documents by the Company, and the consummation of the transactions contemplated therein (including, without limitation, the issuance of the Common Stock and the Note Conversion Shares) have been duly authorized by the Board of Directors of the Company, and except as contemplated by the Purchase Agreement, no further consent or authorization of the Company, its Board of Directors or shareholders, is required therefor. The Transaction Documents have been duly executed and delivered by the Company. The Transaction Documents constitute valid and binding agreements or obligations of the Company, enforceable against the Company, in accordance with their respective terms.
Guti érrez Bergman Boulris, PLLC
100 Almeria Ave, Suite 340 | Coral Gables, FL 33134
Office: (305) 358-5100 | Fax: (888) 281-1829
April 20, 2015
Page 4 of 7
3. The execution, delivery and performance of the Transaction Documents by the Company and the consummation by the Company of the transactions contemplated thereby, including, without limitation, the issuance of the Common Stock and the Note Conversion Shares, and the compliance by the Company with the terms thereof (a) do not and will not result in a violation of, or constitute a default (or an event which, with the giving of notice or lapse of time or both, constitutes or would constitute a default) under, or give rise to any right of termination, cancellation or acceleration under, (i) the articles or certificate of incorporation or bylaws of the Company, (ii) any other agreement, note, lease, mortgage, deed or other instrument to which the Company is a party or by which the Company is bound or (iii) any applicable statute, law, rule or regulation or any order, writ, injunction or decree of the United States, the State of Nevada, the State of New York or the State of Florida, applicable to the Company and (b) do not and will not result in or require the creation of any lien, security interest or other charge or encumbrance (other than pursuant to the Transactions Documents) upon or with respect to any of its respective properties.
4. When so issued, the Common Stock and the Note Conversion Shares will be duly authorized and validly issued, fully paid and non-assessable, and all of the foregoing will be free of any all liens and charges and preemptive or similar rights contained in the Company’s Articles of Incorporation or Bylaws or any agreement, note, lease, publicly filed mortgage deed or other instrument to which the Company is a party or by which the Company is bound. The Common Stock and the Note Conversion Shares have been duly and validly authorized and reserved for issuance by all proper corporate action.
5. Assuming the accuracy of the representations and warranties made by each of the Purchasers in the Purchase Agreement, the offer and sale of the Common Stock and the Note Conversion Shares in accordance with the Transaction Documents constitute transactions exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act” ).
6. No authorization, approval, consent, filing or other order of any federal or state governmental body, regulatory agency, self-regulatory organization or stock exchange or market, or the shareholders of the Company, or any court or to our knowledge, any third party, is required to be obtained by the Company to enter into and perform its obligations under the Transaction Documents, or for the issuance and sale of the Common Stock and the Note Conversion Shares in accordance with the Transaction Documents or for the exercise of any rights and remedies under any Transaction Documents, other than filings which may be required under federal and state securities laws.
Guti érrez Bergman Boulris, PLLC
100 Almeria Ave, Suite 340 | Coral Gables, FL 33134
Office: (305) 358-5100 | Fax: (888) 281-1829
April 20, 2015
Page 5 of 7
7. To our knowledge, no action, suit, proceeding, inquiry or investigation before or by any court, public board or body or any governmental agency or self-regulatory organization is pending or threatened against the Company or any of its properties or assets.
8. Neither the Company nor any Subsidiary is an “investment company” or any entity controlled by an “investment company,” as such term is defined in the Investment Company Act of 1940, as amended.
D. | Comments, Assumptions, Limitations, Qualifications and Exceptions . |
The opinions expressed in Section C above are based upon and subject to, the further comments, assumptions, limitations, qualifications and exceptions set forth below:
1. As used herein, the phrases “known to us,” “to our knowledge” or similar phrases refers only to the actual knowledge of attorneys within our firm who have given substantive attention to the Company, and does not (a) include constructive notice of matters or information, or (b) except for our conversations with certain officers and directors and our review of the Documents, imply that we have undertaken any independent investigation with any persons outside of our firm. Furthermore, such reference means only that we do not know of any fact or circumstance contradicting the statement that follows, and does not imply that we know the statement to be correct.
2. No opinion is expressed as to the enforceability of the obligations of the Company under the Transaction Documents to the extent that enforceability of the rights, obligations and agreements and remedies thereunder are subject to, affected or limited by: (a) rights of the United States of America under the Federal Tax Lien Act of 1966; (b) applicable liquidation, conservatorship, bankruptcy, insolvency, moratorium, fraudulent conveyance, reorganization or similar debtor relief laws from time to time in effect under state and federal law; (c) general principles of equity (whether considered in a proceeding in equity or at law); (d) the exercise of the discretionary powers of any court or other authority before which may be brought any proceeding seeking equitable remedies, including, without limitations, specific performance and injunctive relief; (e) public policy or other applicable limitations on indemnification or contribution under the federal securities laws; or (f) other applicable laws and court decisions that may limit or render unenforceable certain rights and remedies of Purchasers provided in the documents about which we opine, but that do not, in our judgment, make such documents inadequate for the ultimate practical realization of the benefits intended to be provided thereby, though they may result in delays (and we express no opinion as to the economic consequences, if any, of any such delays).
3. We are licensed to practice law in the States of Florida and New York. Accordingly, the opinions expressed herein are specifically limited to the laws of the States of Florida and New York, the Nevada General Corporation Law, and the federal laws of the United States of America.
Guti érrez Bergman Boulris, PLLC
100 Almeria Ave, Suite 340 | Coral Gables, FL 33134
Office: (305) 358-5100 | Fax: (888) 281-1829
April 20, 2015
Page 6 of 7
4. No opinion is expressed herein with respect to any provision of the Transaction Documents that: (a) purports to excuse a party from liability for the party’s own acts; (b) purports to make void any act done in contravention thereof; (c) purports to authorize a party to act in the party’s sole discretion or purports to provide that determination by a party is conclusive; (d) requires waivers or amendments to be made only in writing; (e) purports to effect waivers of constitutional, statutory or equitable rights or the effect of applicable laws, waivers of any statute of limitations or waivers of broadly or vaguely stated rights, of unknown future defenses or of rights to damages; (f) imposes or permits: (i) the appointment of a receiver, (ii) penalties, (iii) indemnification for gross negligence, willful misconduct or other wrongdoing,(iv) confessions of judgment, or (v) rights of self-help, or forfeiture: (g) purports to limit or alter laws requiring mitigation of damages; (h) concerns choice of forum, consent or submission to the personal or subject matter jurisdiction of courts, venue of actions or means of service of process, waivers of rights to jury trials, and agreements regarding arbitration; (i) purports to reconstitute the terms thereof as necessary to avoid a claim or defense of usury; (j) purports to require a party thereto to pay or reimburse attorneys’ fees incurred by another party, or to indemnify another party therefor, which provisions may be limited by applicable statutes and decisions relating to the collection and award of attorneys’ fees; (k) relates to the evidentiary standards or other standards by which the Transaction Documents are to be construed, including, but not limited to, provisions that attempt to change or waive rules of evidence or fix the method or quantum of proof to be applied in litigation or similar proceedings; (1) prohibits or unreasonably restricts: (i) competition, (ii) the solicitation or acceptance of customers, business relationships or employees, (iii) the use or disclosure of information, or (iv) activities in restraint of trade; (m) enumerates that remedies are not exclusive or that a party has the right to pursue multiple remedies without regard to other remedies elected or that all remedies are cumulative; (n) constitutes severability provisions; (o) permits the exercise, under certain circumstances, of rights without notice or without providing opportunity to cure failures to perform; (p) purports to create rights to setoff otherwise than in accordance with applicable law; (q) contains a blanket prohibition on assignments or a specific prohibition on assignment of payments due or to come due; or (r) purports to entitle any party to specific performance of any provision thereof.
5. Although we have acted as counsel to the Company in connection with certain other matters, our engagement is limited to certain matters about which we have been consulted. Consequently, there may exist matters of a legal nature involving the Company in connection with which we have not been consulted and have not represented the Company.
6. The opinions set forth herein are based in part upon the federal and state authorities as they are currently compiled and reported on by customary reporting services. It is possible that legislation affecting the opinions expressed herein may have been enacted into law that are not reflected in such reporting services. We are not currently aware of the passage of any such legislation. However, it is not possible for us to know with certainty as of the date of this letter whether any such legislation may have been passed into law.
7. This opinion letter is limited to the matters stated herein and no opinions may be implied or inferred beyond the matters expressly stated herein.
Guti érrez Bergman Boulris, PLLC
100 Almeria Ave, Suite 340 | Coral Gables, FL 33134
Office: (305) 358-5100 | Fax: (888) 281-1829
April 20, 2015
Page 7 of 7
8. The opinions expressed herein are as of the date hereof and we assume no obligation to update or supplement such opinions to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur.
This opinion letter has been issued solely for the benefit of the Purchasers, and no other party shall be entitled to rely hereon without the express written consent of this firm. Without our prior written consent in each instance, this opinion letter may not be quoted in whole or in part or otherwise referred to in any document or report and may not be furnished to any person or entity.
Very truly yours, | |
Gutiérrez Bergman Boulris, P.L.L.C. |
Guti érrez Bergman Boulris, PLLC
100 Almeria Ave, Suite 340 | Coral Gables, FL 33134
Office: (305) 358-5100 | Fax: (888) 281-1829
SCHEDULE 2.1c
SUBSIDIARY OR SUBSIDIARIES
Celsius Holdings, Inc. (incorporated under the laws of the State of Nevada)
(All companies, listed below, are 100% owned by Celsius Holdings, Inc.)
Celsius Inc. (sub of Celsius Holdings, Inc.) (incorporated under the laws of the State of Nevada)
Celsius Products Holding, Inc. (sub of Celsius Holdings, Inc.) - not active currently (incorporated under the laws of the State of Florida)
Celsius Netshipments (sub of Celsius Holdings) (incorporated under the laws of the State of Florida)
SCHEDULE 2.1c (i)
As of April 15 th 2015
75,000,000 shares of Common Stock Authorized, $0,001 par value per share (post authorized increase)
2,500,000 shares of Preferred Stock Authorized, $0,001 par value per share
20,459,032 shares of Common Stock Outstanding as of 3/31/2015
2,200 shares of Preferred Stock Outstanding as of 3/31/2015
Each Series C Share of Series C Preferred Valued at $1,000 is convertible into Common Stock at $0.52, each preferred share accrues interest at 6% payable in additional preferred shares. As of 12/31/14 accrued interest totals $180,403 available to be converted to additional Series C Preferred shares.
As of 3/31/15 a $1,500,000 Convertible Note is outstanding and is available to be converted at $0.30 per share or 5,000,000 shares of Common Stock and accrues interest at 6% payable quarterly.
As of 3/31/15 the company has 4,192,194 options outstanding; in addition upon execution of this agreement, the Company will issue a total of 406,500 options to D3M. The options base strike price will be based on the 10 day average upon execution of this agreement, 1/3 of the options or 135,500 shares will be issued at the base strike price plus 20%, 1/3 options or 135,500 shares will be issued at the at base price plus 40%, and 1/3 options or 135,500 shares will be issued at the base price plus 60%.
Celsius, Inc. • 2424 North Federal Highway • Suite 208 • Boca Raton, Florida 33431
Office: 561.276.2239 • Fax: 561.276.2268 • www.celsius.com
SCHEDULE 2.1c (iv)
OUTSTANDING INVESTOR RIGHTS AGREEMENTS
1) | Reference is made to that certain Registration Rights Agreement, dated as of August 8, 2008 between Celsius Holdings, Inc. and CDS Ventures of South Florida, LLC. |
2) | Reference is made to that certain Registration Rights Agreement, dated as of December 12, 2008 between Celsius Holdings, Inc. and CDS Ventures of South Florida, LLC. |
*The aforementioned Registration Rights Agreements are terminated at Closing.
SCHEDULE 2.1 (c )(v)
All agreements related to the Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock and any convertible securities, including convertible note agreements
Series A Preferred Stock:
Stock Purchase Agreement: file (Series A Conv Preferred Stock Purchase Agreement)
Certificate of Designation: file (Series A Conv Preferred Stock Designation)
Registration Rights Agreement: file (Series A Conv Preferred Stock Registration Rights Agreement) Amendment: file (Series A Conv Preferred Stock Amendment, dated December 12 2008)
Conversion Documents: file (Series A Conv Preferred Stock Conversion March 10 2010)
Series B Preferred Stock:
Stock Purchase Agreement: file (Series B Conv Preferred Stock Purchase Agreement)
Certificate of Designation: file (Series B Conv Preferred Stock Designation)
Registration Rights Agreement: file (Series B Conv Preferred Stock Registration Rights Agreement)
Conversion Documents: file (Series B Conv Preferred Stock Conversion 12.23.09)
Series C Preferred Stock:
Stock Purchase Agreement: file (Series C Conv Preferred Stock Purchase Agreement)
Certificate of Designation: file (Series C Conv Preferred Stock Designation)
Series D Preferred Stock:
Certificate of Designation: file (Series D Conv Preferred Stock Designation)
Celsius, Inc. • 2424 North Federal Highway • Suite 208 • Boca Raton, Florida 33431
Office: 561.276.2239 • Fax: 561.276.2268 • www.celsius.com
2.1 (c) (v) – Convertible notes and related agreements
SCHEDULE 2.1 (m) (i)(ii)
Employment Agreements
Outstanding Employment Agreements and Other Agreements
Gerry David CEO
John Fieldly CFO
Sandy Telsaint Controller
Mike Hopf VP International Sales
Pending Marketing Agreement with D3M for $350,000 plus 406,500 option in relation to a marketing contractor consulting agreement
Pending dividends associated with the Preferred C Shares are issued quarterly and are eligible to be converted into additional Preferred C Shares.
Schedule 2.1(m)(iii)
Sales representatives, distributors, or other third parties selling the Company’s products International - 3/31/15
· | People’s Choice - Exclusive Sweden, Norway, Finland, Denmark, Switzerland |
o | Negotiating addition of Estonia, Latvia, Lithuania |
· | Latco Beverages - Exclusive Brazil, Argentina, Paraguay, Uruguay |
· | UAE International Investments LCC (UII) - Exclusive UAE, Kuwait, Qatar, Saudi Arabia, Oman, Bahrain, Lebanon |
o | Negotiating Turkey, Cyprus, Iraq |
· | McGovern Capital LLC - as of 12/8/14: |
· | Exclusive Antigua, Aruba, Bahamas, Barbados, Cayman Islands, China, Colombia, Costa Rica, Curacao, Dominican Republic, Jamaica, Japan, Mexico, Panama, Puerto Rico, St. Lucia, St. Maarten, Trinidad, United Kingdom, Venezuela |
· | Trigger Territories (first right of refusal) - Canada, Chile, Croatia, Ecuador, India, Indonesia, Ireland, Israel, Kazakhstan, Malaysia, Peru, Russia, Serbia, South Africa, South Korea, Vietnam |
· | Triangle Cedarberry LTD (Premier Distributors LTD) - Exclusive Bermuda |
· | Peacefield Investments - Exclusive Nigeria (terminating) |
· | Bevaso GmbH (Marcus Mayenschein, our EU consultant) - non exclusive representative agreement paid only on revenues from strategic partners introduced by the representative. |
o | Territory - EU (Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, France, Germany, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain |
Celsius, Inc. • 2424 North Federal Highway • Suite 208 • Boca Raton, Florida 33431
Office: 561.276.2239 • Fax: 561.276.2268 • www.celsius.com
Domestic – Distribution Agreements Listed Below
NAME | LOCATION | REGION COVER | COMMENTS | |||
American Fitness Wholesalers Distribution | Tempe, AZ | Tempe, AZ, NV | ||||
Creative Drinks | Ceres, CA | CA | Contract on File | |||
Haralambos | City of Industry, CA | CA | Contract on File - Exclusive to Los Angeles/Santa Barbara | |||
Kimball Distributing (KDI) | Grand Prairie, TX | Metro Dallas | Contract on File | |||
Kingdom Nutrition | Hutto, TX | Houston | ||||
Reliant Foodservice | Temecula, CA | Temecula, CA | ||||
Seacoast Distributors | San Diego, CA | CA | ||||
Statewide Distributors | Poway, CA | CA | Contract on File | |||
TNT Distributing | Murfreesboro, TN | TN | Fitness Distributor | |||
Polar Distributors - HQ | Worcester, MA | New England Territory w/sub distributors below | Contract on File - Exclusive to New England Territory | |||
Bellavance | Nashua, NH | |||||
Federal Distributors | Lewiston, ME | |||||
National Distributors | So. Portland, ME | |||||
New Hampshire Distributors | Concord, NH | |||||
Northeast Beverage | West Greenwich, Rl | |||||
Polar | North Haven, CT | |||||
Polar | Worcester, MA | |||||
Polar | Portsmouth, NH | |||||
Polar | Avon, MA | |||||
Maine Distributors inc. | Bangor, ME | |||||
Island Food Products | Vineyard Haven, MA | |||||
B & E Juice | Bridgeport, CT | |||||
AFW Mass | Worcester, MA | Fitness | ||||
Blast Brand Management, Inc | Tamarac, FL | So Florida | ||||
Europa | Charlotte, NC | National - Gym/Health Clubs/Nutrition | ||||
House of Beers Wholesale, LLC | Omaha, NE | Omaha | ||||
Lone Star - FL DC | Pompano Beach, FL | National - Gym/Health Clubs/Nutrition | Contract on File | |||
Lone Star - NY Sales Office | Franklin Square | National - Gym/Health Clubs | Contract on File | |||
NYB Distribution | Jericho, NY | Long Island NY, Manhattan NY, NewJersey | ||||
Pointe Dairy Services | Troy, Mi | Detroit | ||||
Powershack | Biloxi, MS | Mississippi | ||||
ZT Wholesale | Milwaukee, Wl | Milwaukee | Contract on File | |||
Emergent Health Corp. (MLM GROUP) | Boca Raton, FL | Contract on File | ||||
C&S Wholesale Grocers | Seacaucus, NJ | Winn Dixie/BiLo | ||||
McLane (Wholesale) | Temple, TX | Race Trac C-Stores/Gate C-Stores | Contract on File | |||
UNFI - Select Nutrition (Wholesale) | Providence, Rl | PA, CA | Contract on File | |||
Natures Best | Los Angeles, CA | Sprouts | KeHe in process of purchasing NB | |||
Unified Grocers | Sacramento, CA | Raleys |
Celsius, Inc. • 2424 North Federal Highway • Suite 208 • Boca Raton, Florida 33431
Office: 561.276.2239 • Fax: 561.276.2268 • www.celsius.com
SCHEDULE 2.1 (n)(i)
Affiliates
As of the date of this agreement, there are no agreements, understandings or between Company and any of its officers, directors, any members of their immediate families, or any Affiliated of the foregoing, other than what has been described in the notes to the Financial Statements and debt per 2.1(n)(ii).
SCHEDULE 2.1 (o)
Registration Rights Agreements
OUTSTANDING INVESTOR RIGHTS AGREEMETNS
1) | Reference is made to that certain Registration Rights Agreement, dated as of August 8, 2008 between Celsius Holdings, Inc. and CDS Ventures of South Florida, LLC. |
2) | Reference is made to that certain Registration Rights Agreement, dated as of December 12, 2008 between Celsius Holdings, Inc. and CDS Ventures of South Florida, LLC. |
*The aforementioned Registration Rights Agreements are terminated at Closing.
Celsius, Inc. • 2424 North Federal Highway • Suite 208 • Boca Raton, Florida 33431
Office: 561.276.2239 • Fax: 561.276.2268 • www.celsius.com
Exhibit 10.12
DISTRIBUTION AGREEMENT
Distributor Information: | Effective Date: March 19, 2015 |
Name: | People’s Choice AB, company registration number: 556705-5784 | |
Address: | Box 5121 | |
City, State, Zip: | 402 23 Gothenburg Sweden | |
Telephone: | 011-46-31-762-83-80 | |
Facsimile: | 011-46-31-762-83-81 | |
E-Mail: | andreas@celsiussverige.se |
This Distribution Agreement (“Agreement”) is made and entered into as of March 19, 2015 , (“Effective Date”), by and between Celsius Holdings, Inc., a Nevada corporation with offices at 2424 North Federal Highway, Suite 208, Boca Raton, Florida 33431 USA (“Celsius”), and the above-identified “Distributor.”
WHEREAS, Celsius develops, manufactures and sells Celsius ® beverages.
WHEREAS, Distributor has significant distribution experience and capability with products similar to Celsius ® beverages in the territories set forth on Schedule B to this Agreement (each, a “Territory” and collectively, the “Territories”).
WHEREAS, both Celsius and Distributor have agreed to the terms and conditions under which Distributor shall provide such services.
WHEREAS, Celsius and Distributor were parties’ to a previous distribution agreement (the “Prior Agreement”), wish to enter into this Agreement in order to amend and restate the terms of their relationship in full and hereby agree that this Agreement supersedes the Prior Agreement and is from the Effective Date the only distribution agreement applicable between the parties.
NOW, THEREFORE, for and in consideration of the mutual promises set forth herein and other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties do hereby agree as follows
1. | Appointment and Acceptance. |
A. | Subject to the terms and conditions contained herein, Celsius appoints Distributor; and Distributor accepts its appointment as the exclusive distributor of Celsius’ products set forth in Schedule A to this Agreement (the “Products”), in the Territories. |
B. | Beginning on the Effective Date, Celsius shall cooperate with the Distributor in executing any documents as may be reasonably required to register Distributor as an authorized user of the trademark(s) and to confirm the rights of Distributor to Subdistributors. |
C. | Distributor shall have the right to appoint local Sub distributors in each Territory to effect the sale and distribution of the Product(s). Such Sub distributors shall be selected by Distributor and shall be reasonably acceptable to Celsius. Periodically and at least twice per calendar year, Distributor shall provide Celsius with a complete list of all such local Subdistributors. |
D. | It is expressly understood and agreed that Celsius hereby retains all rights not expressly granted hereunder. |
E. | Without Celsius’ written authorization, Distributor shall not sell or distribute inside or outside the Territories any products that are confusingly or substantially similar or competitive thereto and will not knowingly sell the Product(s) to parties that intend to or are likely to resell them. For purposes of this Section 1 (E), products that are “competitive” mean beverages (to include powder) in the fat burning, calorie burning and energy product categories. |
F. | Celsius will not be liable to Distributor or Subdistributor for any third party sales of the Product or other activities within the Territories which have not been authorized by Celsius; provided, however, that Celsius will not sell the Products to any entity it knows, or has reason to know, intends to distribute or sell the Products within the Territory. |
G. | Products sold to Distributor are for export to and consumption within the Territories only. Distributor shall not re-ship to, nor permit the re-shipment of, any Products purchased by Distributors, to any location outside of the Territories without Celsius’ written authorization. |
2. | Term. |
A. | The term of this Agreement shall commence as of the Effective Date and shall continue for a period of ten (10) years (the “Initial Term”). Upon expiration of the Initial Term, this Agreement shall automatically renew for successive one (1) year terms (each, an “Annual Renewal Term”), unless a party provides 60 days written notice of cancellation prior to the to the expiration of the Initial Term and any Annual Renewal Term and provided further that Distributor is not in breach of this Agreement upon the commencement of any Annual Renewal Term. |
B. | Notwithstanding Section 2 (A), by written notice given by Distributor within one hundred eighty (180) days of the expiration of the Initial Term, Distributor may elect to renew this Agreement for a period of ten (10) additional years (the “Fixed Renewal Term”), provided that Distributor is not in breach of this Agreement upon the giving of notice and upon commencement of the Fixed Renewal Term. The Initial Term together with all Annual Renewal Terms or the Fixed Renewal Term shall be referred to in this Agreement as the “Term.” |
3. | Orders, Payment and Delivery. |
A. | It is understood and agreed that all orders for Subdistributors shall be placed by and through Distributor. In the event of any inconsistency between the terms of this Agreement and any such Subdistributor order document, the provisions of this Agreement shall govern. |
B. | It is understood that prices for all Product(s) may be changed (increased or decreased) once annually by Celsius , effective as of January 1 of each calendar year during the Term, provided that Celsius gives at least ninety (90) days’ written notice to Distributor of such change. Any such adjustment of the existent prices may only reflect increases or decreases of the direct manufacturing costs (exclusively understood as “COPACK” (i.e. the direct costs relating to the filling of cans), cans, flavors and “meta-plus” (i.e. the active ingredients in the Products)) in USD-currency for Celsius for the manufacturing of the Product(s). Celsius shall provide reasonable substantiation to Distributor of such increased or decreased manufacturing costs for the Products prior to any price adjustment coming into effect. In case of decreases of the manufacturing costs, the prices for the Products shall be changed. In order for Distributor to gain knowledge about any fluctuation of the manufacturing costs, Celsius will provide information about the manufacturing costs for the Products on an annual basis during the Term. |
C. | All orders placed by Distributor shall include the quantity and name of each Product(s) ordered. Shipments shall be “FOB” Product(s) manufacturer, as designated by Celsius. Title to the Product(s) and the risk of loss shall pass to Distributor upon such “FOB” delivery. The Product(s) shall not be returnable. |
D. | The Distributor shall pay twenty-five (25) percent of each total order price seven (7) days prior to scheduled can production for the ordered Products and twenty-five (25) percent of each total order price seven (7) days prior to the scheduled filling of the cans for the ordered Products. The remaining fifty (50) percent of the total order price will be due net ninety (90) days from the date of pick up of the Products, “FOB” Product manufacturer as provided in Section 3 (C). When Product manufacturer in Germany provides terms to Celsius, similar terms will be passed on to Distributor. Payment shall be made in U.S. dollars by wire transfer in immediately available funds to a bank designated by Celsius, or by irrevocable letter of credit, unless otherwise specified by Celsius. Payment obligations with respect to any Product(s) picked up by Distributor “FOB” Product Manufacturer shall survive the expiration or termination of this Agreement. All payments shall be made without deduction for any exchange or conversion and without deduction for any taxes at any time levied or assessed by any governmental authority, all such taxes to be paid for by Distributor. Cancellation of any order by Distributor shall result in the forfeiture of not less than fifty (50) percent of Distributor’s monies paid at the time of the cancellation. |
E. | All transportation and insurance charges are at the Distributor’s sole cost and expense. Distributor shall be responsible for any duty, tariff, customs clearance, fees, taxes, penalties, or other charges or fees, including their collection on resale. |
4. | Product Quality and Packing. |
Product quality shall be the same irrespective of the goods being produced in the US or in Europe. Manufacturing will be restricted to facilities certified in GMP (Good Manufacturing Practices) in compliance with the FDA (Food and Drug Administration) code of Federal Regulations, including an HAACP plan that dictates allergen control, analytical testing/environmental monitoring, chemical control, cleaning and sanitation, glass and brittle plastic control, internal auditing, pest control, receiving, storage and transport, supplier management, training and waste removal.
The criteria for batch acceptance shall be based upon the confidence interval of 99.5% as a result of quality testing. Product not meeting these criteria will not be accepted as finished Product and not released for shipment.
Celsius will monitor that goods are packed in containers, consistent with standard packing processes for international container shipments, and available for inspection by Distributor’s carrier prior to pickup.
5. | Responsibility of Celsius. |
During the term of this Agreement, Celsius shall be responsible for the production, quality control, packaging and design of the Products. Inasmuch as local requirements may dictate labeling changes, Celsius will provide such changes at the direction of Distributor.
6. | Responsibility of Distributor. |
Distributor shall provide all of the usual and customary services of a distributor, which shall include without limitation the following:
A. | Use of commercially reasonable best efforts to distribute and sell the Products in the Territories and to extend the distribution and sale of the Products in the Territories so as to maximize such distribution, and to meet or exceed the annual volume sales targets agreed to by the parties. The services shall be consistent with and no less than the services performed by Distributor in connection with the sale and distribution of its products or the products of other manufacturers or suppliers. Distributor shall provide Celsius with forecasts of purchases of Products and ship-to-trade on a Territory –by-Territory basis for each calendar quarter and a rolling twelve (12) month period (the “Forecasts”), in form and substance reasonably acceptable to Celsius. The first Forecast shall be due within 30 days from the execution of this Agreement and at least fifteen (15) days prior to the beginning of the quarter for all subsequent quarters. Such Forecasts shall be stated in the aggregate and categorized by SKU. |
A. | Maintain an aggressive direct sales force and trained personnel adequate for the needs of the Territories, maintaining such office, warehouse and distribution facilities as shall be reasonably necessary. |
B. | Regularly monitor and handle the Products at Distributor’s distribution centers (“DC”) and third party warehouses to ensure their proper storage, handling and continued compliance with applicable local and international laws, regulations and rules regarding food transport and storage. |
C. | Manage inventory rotation of the Products on a “code out” (FIFO) basis. |
D. | It is the sole responsibility of Distributor to ensure that it has enough Product(s) on hand to meet its requirements and the requirements of its Subdistributors, including special sales and promotions. |
Replacement of any Products due to damage from improper handling or storage, or obsolescence resulting from improperly managed inventory rotation, Distributor’s failure to re-sell the Products or other circumstances not within the control of Celsius will be the sole obligation of Distributor. Celsius shall bear the reasonable costs of replacing Products that are obsolete due to circumstances within its control.
7. | Annual Marketing Plan. |
Distributor shall provide Celsius with a written annual sales and marketing plan on a Territory by Territory basis, for each calendar year of the Term (the “Annual Marketing Plan”), which shall be reasonably acceptable to Celsius. The initial Annual Marketing Plan shall be due within 30 days of the execution of this Agreement. Thereafter the Annual Marketing Plan shall be due on or before November 1 of each year or partial year of the Term of this Agreement.
8. | Advertising and Promotion. |
Celsius shall provide Distributor with copies of the Products’ promotional and marketing materials used in the United States of America (“U.S.”), which may include logos, layouts, artwork and copy in the sole discretion of Celsius (“Market Materials”). Distributor shall not alter the Marketing Materials in any manner and shall obtain written approval for all copies or reproductions of the Marketing Materials prior to use in any marketing or promotion. Distributor shall provide Celsius with an accurate English translation of any copy or other portion of the Marketing Materials that shall be written or spoken in any language other than English. Distributor will initiate and pay for all advertising, promotion, publicity and other marketing support for its Territory pursuant to the Annual Marketing Plan and shall provide Celsius with reasonable evidence of initiation and payment thereof.
9. | Warranties and Obligations. |
A. | Celsius represents and warrants that it has the right and power to enter into the subject Agreement and that there are no other agreements with any other party in conflict with this Agreement. |
B. | Celsius warrants to Distributor as follows: (i) that title to the Products purchased by Distributor under this Agreement will be free and clear of liens and security interests that would otherwise prevent Distributor’s resale or distribution; (ii) that all the Products will be manufactured and packaged in compliance with applicable U.S. statutes and regulations (including applicable Food and Drug Administration regulations requiring that such Products not be adulterated or misbranded); and (iii) that each of the Products purchased by Distributor under this Agreement will at the time of shipment to Distributor conform to Celsius’ then current specifications. THIS WARRANTY IS IN LIEU OF ANY AND ALL OTHER WARRANTIES, EXPRESS OR IMPLIED, INCLUDING, BUT NOT LIMITED TO, ANY EXPRESS OR IMPLIED WARRANTY WITH RESPECT TO MERCHANTABILITY OR FITNESS OF PRODUCTS FOR A PARTICULAR PURPOSE. |
C. | Distributor’s exclusive remedy and Celsius’ exclusive liability for a breach of any warranty provided in Section 9 (B) for any shipment made by Celsius to Distributor under this Agreement will be limited to the replacement of the nonconforming or defective Products and to bear all reasonable costs related thereto. In case Distributor notifies Celsius about delivered Products being non-conforming or defective, Distributor shall, on Celsius’ request, furnish Celsius with test samples and other reasonable substantiation of the nonconformance or defects. In case Celsius does not agree that the Product(s) in question are non-conforming or defective, Celsius will select an independent reputable laboratory or other investigation company in Europe to analyze the Product(s) in question. The results of such analysis shall be considered final and binding on both parties. In such situation as the Product(s) are deemed defective, Celsius shall compensate Distributor with an amount equal to the full purchase amount of such batch/batches notified by Distributor to be defective and which remain unsold (such compensation to be in the form of deduction from the purchase price to be paid by Distributor on Distributor’s next ordering of Products from Celsius). Celsius will have a reasonable time to replace any nonconforming or defective Products, including a reasonable amount of time for manufacturing and delivery, provided however that such time shall only be deemed reasonable if it, in Distributor’s reasonable opinion, does not materially adversely affect Distributor’s business in and as it relates to distribution, marketing and sale of the Products. |
D. | CONSEQUENTIAL DAMAGES WAIVER. IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER FOR ANY INCIDENTAL OR CONSEQUENTIAL LOSSES OR DAMAGES (INCLUDING, BUT NOT LIMITED TO ECONOMIC LOSS OR LOSS OF PROFITS BY DISTRIBUTOR) SUFFERED OR INCURRED AS A RESULT OF OR IN CONNECTION WITH ANY BREACH OF THIS AGREEMENT OR ANY TORT (INCLUDING, BUT NOT LIMITED TO, STRICT LIABILITY OR NEGLIGENCE) COMMITTED BY A PARTY IN CONNECTION WITH THIS AGREEMENT. |
E. | Distributor covenants to use its best efforts to promote, market, advertise, sell, and distribute the Product(s) in the Territory and that its Subdistributors will use their best efforts to promote, market, advertise, sell, and distribute the Product(s) in their respective territories. The Distributor and its Subdistributors shall be solely responsible for the sale and distribution of the Product(s) and will bear all costs associated therewith. |
F. | Distributor represents and warrants that to the extent necessary, (i) it has a valid certification of approval (or equivalent of the same) in the name of Celsius from the appropriate governmental authorities in the Territory for distribution of the Product(s) and (ii) it will maintain the certification in good standing during the Term of the Agreement. |
G. | Distributor understands that the Product(s) may be perishable if not stored and maintained under temperature-controlled conditions that are standard in the transport industry. Distributor covenants and agrees that it shall not sell any stale Product(s) or Product(s) that may be in any way defective. |
10. | Product Recalls. |
Celsius agrees to take actions reasonably necessary and appropriate, upon request that is reasonable as to time and scope of action to be taken, to effectuate a Product corrective action, including a Product recall; provided, however, that Distributor agrees to cooperate with Celsius in such action, including, without limitation, contacting customers and assisting in the transfer of Celsius, as directed by Celsius, if necessary. Celsius agrees to respond within a reasonable period to any question or request for information received by Distributor from its customers pertaining to the production of Product. Each party agrees to provide to the other party all necessary information in its possession arising out of a recall or corrective action program or similar program. Upon thirty (30) days’ written notice, each party shall, at a time and place mutually agreeable to the parties, have the right to audit and inspect the other’s facilities, or the facilities of any third party Product manufacturer, and/or records relating to such party’s obligations under this Agreement and with respect to the Products. All information that the inspecting party obtains in the course of such inspection or audit shall be treated as Confidential Information, in accordance with Section 14 of this Agreement.
11. | Notices. |
Any notice under this Agreement will be valid and effective only if given by written instrument which is personally delivered or sent by facsimile, international overnight courier, or registered or certified mail, postage prepaid, addressed as follows:
If to Celsius: | Celsius, Inc. | |
2424 Federal Hwy
Suite 208 |
||
Boca Raton, Florida | ||
33431 | ||
Facsimile: 561-2762239
Attn: Gerry David |
With copy to: | Gutierrez Bergman | |
Boulris, P.L.L.C. | ||
100 Almeria Avenue
Suite 340 |
||
Coral Gables, Florida | ||
33134 | ||
Attn: Dale S. Bergman | ||
If to Distributor: | Peoples Choice AB | |
Box 5121, 402 23 | ||
Gothenburg, Sweden | ||
With copy to: | Setterwalls Advokatbyrå | |
Box 11235, 404 25 | ||
Gothenburg, Sweden
Attn: Anders Holmgren |
Any notice, claim, demand, request or other communication given as provided in this Section 11, if given personally or by international courier, will be effective upon delivery; if given by facsimile, will be effective one (1) day after transmission; and, if given by mail, shall be effective ten (10) days after deposit in the mail. Either party may change the address at which it is to be given notice by giving written notice to the other party as provided in this Section 11.
12. | Intellectual Property Rights. |
A. | Celsius shall retain all right, title, and interest in the original Product(s) and, unless otherwise agreed, to any modifications or changes made thereto. Distributor shall not obtain any rights in the Product(s) as a result of its responsibilities hereunder. The parties agree to execute any documents reasonably requested by the other party to effect any of the above provisions. |
B. | Distributor acknowledges Celsius’ exclusive rights in the Product(s) and that the Product(s) is unique and original to Celsius and that Celsius is the owner of such Intellectual Property Rights. Unless otherwise permitted by law, neither Distributor nor any authorized Subdistributor shall, at any time during or after the effective Term of the Agreement, dispute or contest, directly or indirectly, Celsius’ exclusive Intellectual Property Rights in and relating to the Product(s), trademarks, service marks, logos, and copyrights, or the validity thereof. |
C. | Neither Distributor nor any of its Subdistributors shall have any right to duplicate, translate, reverse engineer, or adapt the Product(s) without Celsius’ prior written consent, nor shall they attempt to develop any products that are identical with any of the product(s). |
D. | Trademarks and Trade Names. All trademarks, trade names, trade packaging, logos, marks, artwork, symbols, copyrights and other designations and intellectual property used or adopted by Celsius in connection with the Products, including without limitation the name Celsius ® (the “Trademarks”) will at all times be and remain the property of Celsius, its affiliated companies or third parties with whom Celsius or its affiliated companies have a license. Distributor shall not in any way dispute or impugn the validity of the Trademarks, Celsius’, its affiliated companies or such third parties’ sole ownership of the Trademarks, or such parties’ right to use and control the use of the Trademarks during the term of this Agreement and thereafter; nor will Distributor do or permit to be done any action or thing which will in any way impair the rights of Celsius or such third parties in and to the Trademarks. Distributor’s use of the Trademarks will be exclusively for the benefit of Celsius and/or its affiliates pursuant to a limited, revocable, non-exclusive license created by this Agreement which terminates immediately upon the termination of this Agreement and does not create in it any right, title or interest in the Trademarks. |
1. | Use. Distributor may use the Trademarks only in connection with the services to be provided hereunder and only in the manner and style approved by Celsius in writing. Distributor will not use the Trademarks as part of its company name or in connection with any product other than the Products. Distributor agrees not to alter, deface, remove, cover up, or mutilate any of the Trademarks or any serial number, lot code number or other designation which may be attached or affixed to the Products or any packaging materials. |
2. | Notification. Distributor will: (i) notify Celsius in writing of any infringing uses, applications for registration, or registrations of the Trademarks or marks similar thereto of which it has actual knowledge; (ii) execute any agreed to documentation requested by Celsius relating to the Trademarks; and (iii) comply with all instructions of Celsius with regard to the use and display of the Trademarks. |
3. | Actions. Distributor acknowledges that only Celsius will have authority to institute actions or proceedings to prevent any infringement, imitation, unauthorized use, or misuse of any of the Trademarks and agrees to provide Celsius with reasonable assistance in such proceedings. |
4. | Similar Marks. Distributor agrees not to adopt any trademark, trade name, trade packaging, mark, logo, artwork or symbol which is similar to or likely to be confused with any of the Trademarks. Distributor will not use any other trademark, trade name, trade packaging, mark, logo, artwork, word, symbol, letter or design in combination with any of the Trademarks. |
5. | Literature. Distributor shall provide Celsius with copies (including accurate English translations) of all sales literature, advertising and promotional materials, manuals and related materials (“Sales Literature”) to be used by Distributor in connection with the Products. Distributor shall obtain written approval from Celsius of all Sales Literature prior to publication or use. |
6. | Effect of Termination. Upon termination of this Agreement for any reason, Distributor immediately cease all use of the Trademarks and Sales Literature, provided that, upon further written consent from Celsius, Distributor may continue to use the Trademarks and approved Sales Literature in its promotion and sale of the Products held in inventory. |
7. | Packaging. The Products shall be resold only in their original packaging. Without the prior written approval from Celsius, Distributor shall not, directly or indirectly, re-label, repackage, mark, or assist or permit any other entity to re-label, repackage, or mark the Products except for such repackaging as may be necessary to replace damaged packaging or to re-label to comply with local laws. |
13. | Product(s) Warranty. |
A. | CELSIUS WARRANTS THAT THE PRODUCT(S) ARE MERCHANTABLE AND FIT FOR A PARTICULAR PURPOSE, PROVIDED, HOWEVER, SUCH WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE SHALL NOT EXTEND BEYOND “FOB” DELIVERY AS SET FORTH IN SECTION 3(C) OF THIS AGREEMENT. CELSIUS SHALL NOT BE LIABLE FOR ANY DAMAGES, DIRECT OR INDIRECT, INCLUDING INCIDENTAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF THE SALE, MANUFACTURE, OR USE OF ANY PRODUCT(S) SOLD HEREUNDER. |
B. | Distributor shall be liable for any representations or warranties made by it or its Subdistributors, without the prior written approval of Celsius, in its advertising, brochures, manuals, or by its agents, employees, or representatives, whether in writing or orally with respect to the Product(s). |
14. | Confidentiality. |
A. | Definition of Confidential Information. The term “ Confidential Information ” as collectively referred to herein, shall include all information or material disclosed by each party, either orally or in writing, including, but not limited to: (i) the identity of customers, suppliers, subcontractors and others with whom the party making disclosure (the “Disclosing Party”) does business; (ii) marketing methods and strategies; (iii) contract terms, pricing, margin, cost information and other information regarding the relationship between Disclosing Party and the persons and entities with which Disclosing Party has contracted; (iv) the Disclosing Party’s services, products, specifications, analyses, software, technology, developments, improvements and methods of operation; (v) results of operations, financial condition, projected financial performance, sales and profit performance and financial requirements; (vi) the identity of and compensation paid to employees, consultants and agents; (vii) business plans, models or strategies and the information contained therein; (viii) sources, leads, or methods of obtaining new business; (ix) designs, inventions, patents, patents pending, licenses and sublicenses; (x) data, know-how, formulae, processes, discoveries, inventions and ideas, whether or not patentable, copyrightable or subject to protection as a trademark or trade name; (xi) acquisitions, divestitures, alliances and other business relationships; and (xii) all other trade secret or Confidential Information of, about or concerning the business of the Disclosing Party. Confidential Information also includes any notes, analyses, compilations, studies or other material or documents prepared by the party receiving confidential information (the “Receiving Party”) which contain, reflect or are based, in whole or in part, on the Confidential Information. | |
Notwithstanding the foregoing, Confidential Information shall not include information or material that, through no action or fault of the Receiving Party: (i) is publicly available or becomes publicly available; or (ii) is or becomes available to the Receiving Party from a source other than the Disclosing Party, provided that the source of such information was not bound by a contractual, legal or fiduciary obligation of confidentiality to the Disclosing Party or any other party with respect thereto. |
B. | Confidentiality. Each Party shall not disclose or use any Confidential Information for any purpose outside the scope of this Agreement without prior written permission. |
C. | Protection. Each party agrees to protect the confidentiality of the Confidential Information of the other party in the same manner that it protects the confidentiality of its own proprietary and confidential information of like kind, but in no event shall either party exercise less than reasonable care in protecting such Confidential Information. |
D. | Compelled Disclosure. If the Receiving Party is compelled by law to disclose Confidential Information of the Disclosing Party, it shall provide the Disclosing Party with prior notice of such compelled disclosure (to the extent legally permitted) and reasonable assistance, at the Disclosing Party’s cost, if the Disclosing Party wishes to contest the disclosure. |
E. | Remedies. If the Receiving Party discloses or uses (or threatens to disclose or use) any Confidential Information of the Disclosing Party in violation of this Section 14, the Disclosing Party shall have the right, in addition to any other remedies available to it, to seek preliminary and permanent injunctive relief, without bond, to enjoin such acts, it being specifically acknowledged by the parties that any other available remedies at law are inadequate. |
F. | Publicity. Neither party may issue press releases relating to this Agreement without the other party’s prior written consent. Notwithstanding the foregoing, either party may include the name and logo of the other party in its lists of customers or vendors. |
15. | Compliance with Applicable Law. |
Distributor and its Subdistributors shall be responsible for compliance with applicable laws, regulations and rules related to the export, shipment, import, storage, distribution and sale of the Products in the Territories (including without limitation proper labeling, licensure and the payment of all export and import taxes, duties, tariffs, and all fees related to licenses and permits). Distributor and its Subdistributors shall indemnify, defend and hold Celsius, its affiliates, and their respective directors, officers, employees and agents harmless against all costs, claims, suits, demands, judgments, expenses (including reasonable attorneys’ fees) or damages resulting from or arising out of any breach of this Section 15.
16. | Government Approval. |
A. | Where necessary, Distributor and its Subdistributors shall be required to obtain all governmental approvals required to fulfill its obligations under this Agreement, including those dealing with the sale and distribution of the Product(s) purchased hereunder. Without limiting the generality of the foregoing, Distributor shall, in the name of Celsius, obtain and maintain all licenses and governmental approvals that may be necessary to permit the importation of the Product(s) purchased hereunder and the sale by the Distributor of the Product(s), complying with all registration, banking, exchange, control, and other regulations or approvals that may be required. Distributor shall keep Celsius informed of any laws regulations, governmental orders, or requirements that affect the ordering, packaging, shipment, importation, sale, marketing, or distribution of the Product(s) within the Territory and shall, in all cases, refrain from engaging in any activities or conduct that would cause Celsius to be in violation of the laws of any jurisdiction. |
B. | In addition to the Distributor’s obligations under Section 16 (A), if approval by any governmental entity in the Territory is required before this Agreement is enforceable by Celsius, then such government approval is a condition precedent to the validity of this Agreement. Celsius shall have no obligations under this Agreement until such governmental approval has been obtained and evidence of such approval has been received by Celsius. |
C. | If any governmental entity requires material changes to be made to the terms of this Agreement or the relationship between the parties, either party may terminate this Agreement with mutual consent upon thirty (30) days’ written notice. |
17. | Noncompetition. |
During the term of this Agreement, and for a period of one (1) year thereafter, neither Distributor nor any of its Subdistributors shall serve as distributor or marketing or sales representative in connection with any product in the fat- and calorie burning drinks (including powder), energy drinks categories that is directly competitive with the Products or products that Distributor has co-developed with or is distributing, promoting, or selling on behalf of Celsius without first obtaining Celsius’ written consent.
18. | Termination. |
The following termination rights are in addition to the termination rights that may be provided elsewhere in the Agreement.
A. | Celsius shall have the right to immediately terminate this Agreement by giving written notice to Distributor in the event that Distributor does any of the following: |
1. | Files a petition in bankruptcy or is adjudicated bankrupt or insolvent, or makes an assignment for the benefit of creditors, or an arrangement pursuant to any bankruptcy law, or if Distributor discontinues or dissolves its business, or if a receiver is appointed for Distributor or for Distributor’s business and such receiver is not discharged within sixty (60) days; |
2. | Makes any change in the current management of Distributor, which in the reasonable opinion of Celsius substantially impairs Celsius’ rights under this Agreement, or has or threatens to damage the reputation of Celsius, or the Product(s); |
3. | Engages in any illegal, unfair, or deceptive business practices or unethical conduct whatsoever, regardless of whether related to the Product(s); or |
4. | sells a majority interest in Distributor to a third party. |
B. | In case Celsius files a petition in bankruptcy or is adjudicated bankrupt or insolvent, or makes an assignment for the benefit of creditors, or an arrangement pursuant to any bankruptcy law, or if Celsius discontinues or dissolves its business, or if a receiver is appointed for Celsius or for Celsius business and such receiver is not discharged within sixty (60) days, all rights pertaining to the Products including all the intellectual rights related thereto, shall be automatically and irrevocably transferred to Distributor with full title and ownership for Europe. |
C. | In addition to the aforementioned grounds for termination, either party may terminate this Agreement on sixty (60) days’ written notice to the other party in the event of a material breach of any provision of this Agreement by the other party, provided that, during the sixty-day period, the breaching party fails to cure such breach. |
19. | Post Termination Rights. |
A. | In order that Celsius may optionally repurchase from Distributor at Distributor’s cost, not less than ninety (90) days prior to the expiration of this Agreement or immediately upon termination thereof, Distributor and its Subdistributors shall provide Celsius with a complete schedule of all inventory of Product(s) then on hand (the “Inventory”). |
B. | Upon expiration or termination of this Agreement, all rights granted to Distributor under this Agreement shall immediately terminate and revert to Celsius and Distributor and its Subdistributors shall discontinue all marketing, distribution, and sale of the Product(s), whether under private or other label, except as provided in this Subsection B. Upon expiration or termination of this Agreement, Celsius shall have the option of purchasing any of the existing Inventory of Product(s) then on hand as of the date of expiration or termination of the Agreement at Distributor’s cost. If Celsius does not purchase Distributor’s Inventory, Distributor may distribute and sell the Inventory in accordance with the terms and conditions of this Agreement until the Inventory is depleted. At no time shall Distributor use the Product(s) or Product(s) packaging for any purpose other than that which is contemplated by this Agreement. |
C. | The termination or expiration of this Agreement shall not extinguish any of Distributor’s obligations under this Agreement that by their terms continue after the date of termination or expiration. |
20. | Infringements. |
A. | Distributor agrees to notify Celsius promptly in the event Distributor or its Subdistributor(s) becomes aware of any direct competitors or any infringements of the Product(s) or Celsius’ trademarks, trade dress, or logos. Celsius shall have the right, in its sole discretion, to prosecute lawsuits against third parties for infringement of Celsius’ Intellectual Property Rights. All costs and expenses associated with such lawsuits shall be borne by Celsius, which shall be entitled to any recovery received, whether by adjudication or settlement. |
B. | Distributor and its Subdistributors agree to fully cooperate with Celsius and its representatives in the prosecution of any such suit. Celsius shall reimburse Distributor for the expenses incurred as a result of such cooperation. |
21. | Indemnity. |
A. | Distributor shall indemnify, hold harmless, and defend Celsius and its officers, directors, agents, and employees, from and against any costs arising out of or related to breach of any representations or warranties in this Agreement, or as a result of any of Distributor’s actions or inactions. Distributor shall employ legal counsel to defend such suit or action at Distributor’s expense. Celsius shall have the right to approve such counsel but Celsius may not unreasonably withhold its approval. Upon notice of any suit or action, Celsius shall promptly notify Distributor and Celsius shall cooperate in Distributor’s defense. Celsius shall have the right, at its sole expense, to employ separate legal counsel to participate in the defense. |
B. | Celsius agrees to defend, indemnify, and hold Distributor, and its officers, directors, agents, and employees, harmless against all costs, expenses, and losses (including reasonable attorneys’ fees and costs) incurred as a result of claims of third parties against Distributor based on Celsius’ breach of any representations or warranties contained herein or as a result of any of Celsius’ actions or inactions. |
22. | Force Majeure. |
It is understood and agreed that in the event an act of government, or war conditions, or fire, flood, labor trouble, or other contingencies beyond the control of Celsius or Distributor interfere or prevent the performance by either party of their respective obligations under this agreement, then such nonperformance shall not be considered as grounds for breach of this Agreement and such nonperformance shall be excused while the conditions herein prevail and for sixty (60) days thereafter.
23. | Independent Contractor. |
Distributor’s performance of its duties and obligations under this Agreement and the performance of its Subdistributors are in a capacity as an independent contractor. Nothing contained in this Agreement shall be construed as establishing an employer/employee, a partnership, agency, brokerage, or a joint venture relationship between Distributor, its Subdistributors, and Celsius.
24. | Arbitration. |
The parties agree that any dispute between them arising out of, based on or relating to this Agreement shall be finally resolved exclusively by arbitration conducted in accordance with the International Rules then in effect of the American Arbitration Association. Any arbitration shall be held in Palm Beach county, Florida, USA. The laws of the State of Florida, U.S.A. shall apply to and govern the Agreement, its interpretation and performance. Judgment upon the award rendered shall be final and non-appealable and may be entered in any court having jurisdiction Each party shall pay its own fees and expenses (including without limitation attorneys’ fees and expenses) incurred in connection with the arbitration proceeding. Common expenses of the arbitration proceeding (such as the fees and expenses of the arbitrators and expenses of administration) shall be born by the parties in such amounts or proportions as the arbitrators may determine. Notwithstanding the obligations set forth in this paragraph, Celsius shall be permitted to seek equitable relief from a court having jurisdiction to prevent the unauthorized use or misuse of its Intellectual Property Rights.
25. | Agreement Binding on Successors. |
This Agreement shall be binding on and shall inure to the benefit of the parties hereto, and their heirs, administrators, successors, and assigns.
26. | Waiver. |
No waiver by either party of any default shall be deemed as a waiver of any prior or subsequent default of the same or other provisions of this Agreement.
27. | Severability. |
If any provision of this Agreement is held invalid or unenforceable by a court of competent jurisdiction, such invalidity shall not affect the validity or operation of any other provision and such invalid provision shall be deemed to be severed from the Agreement.
28. | Assignment. |
Celsius may assign this Agreement in whole or in part and shall promptly notify Distributor thereof. Distributor may not assign or otherwise transfer (whether by operation of law or otherwise) this Agreement in whole or in part to any entity without the express prior written consent of Celsius, upon terms determined by Celsius in its sole discretion.
29. | Integration. |
This Agreement constitutes the entire understanding of the parties, and revokes and supersedes all prior agreements between the parties and is intended as a final expression of their Agreement. It shall not be modified or amended except in writing signed by the parties hereto and specifically referring to this Agreement. This Agreement shall take precedence over any other documents that may be in conflict with this Agreement.
IN WITNESS WHEREOF, the parties’ authorized signatories have duly executed this Agreement as of the Effective Date.
CELSIUS HOLDINGS, INC. | ||
By: | /s/ Gerard David | |
Print Name: | Gerard David | |
Title: | CEO | |
Date: | 3-23-15 | |
DISTRIBUTOR | ||
By: |
/s/ Andreas Celik | |
Print Name | Andreas Celik | |
Title: | Managing Partner | |
Date: | 23-3-15 |
SCHEDULE A
TO DISTRIBUTION AGREEMENT BETWEEN
CELSIUS HOLDINGS, INC.
AND
PEOPLES CHOICE AB
DATED FEBRUARY 24, 2015
1. | Product(s) Description |
Product(s)/Name/Trademark | Description | |
CELSIUS® Beverages | Ready to Drink Beverages in cans | |
2. | Initial Order / Dat e | Not Applicable |
Product(s)/Name/Trademark | Quantity | |
SCHEDULE B
TO DISTRIBUTION AGREEMENT BETWEEN
CELSIUS HOLDINGS, INC.
AND
PEOPLES CHOICE AB
DATED FEBRUARY 24, 2015
1. | Product, Territory, Distribution Channel, and Exclusivity |
(A) Product/Trademark | (B) Territories |
(C) Distribution
Channel(s) |
(D) Exclusivity |
(E) Limitations on
Exclusivity |
||||
1. CELSIUS® |
Sweden, Finland,
Norway, Denmark and Switzerland. |
Retail, Wholesale |
Product (A) in
Territories (B) via Channels (C) |
|||||
As regards the territories’ “Estonia”, “Latvia” and “Lithuania”, the Parties’ hereby agree as follows: Celsius undertakes to inform Distributor in writing prior to any decision by Celsius to grant a distribution right (either exclusive or non-exclusive) to any third party for the marketing and distribution of any of the Products within any of these territories or prior to any decision by Celsius to market or distribute any of the Products themselves or through an affiliated party within any of these territories. Distributor shall be entitled to receive the exclusive distribution right for any of these territories provided that Distributor, within 90 days, confirms in writing to Celsius Distributor’s decision to enter such identified territory as exclusive distributor. Such confirmation from Distributor shall also contain an estimation on when the Products are to be launched on such identified new territory. Distributor shall, in addition hereto, within 60 days from such written confirmation provide Celsius with a business plan for the new territory in question, such business plan which shall be in a form reasonable acceptable to Celsius. Any failure on behalf of Distributor of the aforementioned obligations shall result in the right for Celsius to appoint other distributor or establish themselves as distributors on such new identified territory.
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Amendment No. 2 to Form 10 General Form for Registration of Securities Pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 of our report dated March 24, 2016 for the two years in the period ended December 31, 2015, relating to the consolidated financial statements of Celsius Holdings, Inc. and Subsidiaries, which appear in such General Form for Registration of Securities for the registration of Celsius Holdings, Inc. common stock.
/s/ D’Arelli Pruzansky, P.A. | |
D’Arelli Pruzansky, P.A. | |
Certified Public Accountants |
Coconut Creek, Florida
September 19, 2016